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1.1 THE MALARIA PROBLEM
1.1.1. Introduction
Plasmodium falciparum  infections are an important and increasing cause of morbidity and 
mortality in the tropics. Falciparum malaria is endemic in over 90 countries and it causes an 
estimated 300-500 million clinical cases and 1.5-2.7 million deaths per year (WHO 1996). African 
children carry the greatest burden of disease with an estimated 200 million episodes of clinical 
malaria each year. The vast majority of malaria associated deaths world-wide occurs in this group 
(Greenwood et al, 1991; World bank, 1993).
Malaria is caused by an unicellular parasite of the genus Plasmodium. In man four different 
species can cause malaria: P. vivax, P. ovale, P. malariae and P. falciparum. The first three 
cause severe illness, but are rarely fatal. These are the types of malaria which cause distinctive 
intermittent fevers, and a patient’s temperature chart can be a helpful guide for identification of 
the species. In Africa P. falciparum  is the most common malaria parasite whereas P. vivax is 
rarely seen.
Malaria-parasites are transmitted from man to man by a number of species of Anopheles 
mosquitoes which act as intermediate hosts. The Anopheles are active at night and until dawn and 
shelter in shaded, humid places during daytime.
The parasites reproduce asexually in man, and sexually in female mosquitos. Parasites are 
transmitted by the bite of an infectious mosquito, migrate via the bloodstream to the liver, infect 
liver parenchymal cells and from there they infect erythrocytes. The parasites proliferate in 
erythrocytes, and the released progeny invades new red blood cells. It is at this stage that the 
classical symptoms of malaria occur, such as high periodic fever. Some erythrocytic parasites 
differentiate into sexual forms which, in turn, are infective to the mosquito.
1.2 CLINICAL MANIFESTATIONS
1.2.1 Uncomplicated malaria
The classical picture of uncomplicated malaria is one of sudden cold shivers followed by a high 
fever lasting 6 to 8 hours. When the fever diminishes, a symptom free period of one day follows 
after which the fever returns. Anemia and enlargement of the spleen and liver can develop when 
malaria progresses. Except for the, more or less, typical fever pattern, a variety of clinical
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manifestations can be observed that are by no means specific for malaria (Molyneux et a l. 1989). 
Uncomplicated falciparum  malaria infection can progress rapidly and, if not properly treated, can 
lead to life threatening complications.
1.2.2 Severe malaria
The criteria for severe falciparum  malaria have been defined by the WHO (1990). One of them 
being cerebral malaria (CM). CM is defined as Plasmodium falciparum  in the peripheral blood 
and unrousable coma often preceeded by fever for 1 to 3 days and convulsions.
In endemic areas P. falciparum  infections are especially dangerous to non-immune individuals i.e. 
children until the age of five in Africa, and to travellers without malaria experience. Indigenous 
adults are largely protected from severe disease by a form of partial immunity called premunition. 
Such individuals are carriers of the parasite but without minor clinical symptoms. Premunition 
develops slowly in response to repeated infections by the same species of Plasmodium and is lost 
in the absence of continuous exposure to infection (Knell, 1991).
1.3 PATHOGENESIS OF HUMAN CEREBRAL MALARIA
1.3.1 Introduction
The pathogenesis of cerebral malaria (CM) in P. falciparum  infected people is not completely 
understood. There are two theories: In the the obstruction theory it is proposed that sequestration 
of parasitized red blood cells (PBRCs) in the cerebral microcirculation may lead to obstruction of 
blood flow and subsequently anoxia (Warrell et al. 1988; Pongponratn et al. 1991; Berendt et al. 
1994). Alternatively in the inflammation theory it is stated that cerebral pathology might be 
secondary to (an) immunological reaction(s) affecting the integrity of the vascular endothelial 
lining (Grau et al. 1989; Butcher et al. 1990; Clark & Rockett 1994; Eling & Kremsner 1994; 
Grau & Kossodo 1994; Patnaik et al. 1994; Eling & Sauerwein 1995).
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1.3.2. The obstruction theory
A distinctive feature of P. falciparum  infections is selective accumulation of parasitized red blood 
cells (PRBCs) in the microvasculature of several organs, particularly the brains, but also heart, 
lung, kidney and liver (Pongponratn et al. 1991; Aikawa et al. 1992; Eling & Sauerwein 1995). A 
subsequent characteristic is the adherence of erythrocytes infected with mature stage parasites 
(trophozoites/schizonts) to endothelial cells lining the post-capillary venules. Moreover, 
Pongponratn et al. (1991) found a 94% PRBC sequestration rate in cerebral microvessels of 
patients with cerebral malaria while a 13% rate was found in noncerebral falciparum  cases. 
Adherence in the brain microvessels is considered to potentially block blood flow resulting in 
confusion, lethargy, deep coma and death (Warrell 1987; MacPherson et al. 1985; Howard & 
Gilladoga 1989). Adherence of parasitized erythrocytes depends on the presence of a ligand on the 
membrane surface, P. falciparum  erythrocyte major protein 1 (PfEMP1), a polymorphic (Mr 
200.000-350.000) protein, that binds to receptors on the endothelial lining. PRBCs are able to 
bind to a number of adhesion molecules of endothelial cells, particularly of post-capillary venules 
(e.g. CD36, thrombospondin, intercellular adhesion molecule-1 (ICAM-1), vascular adhesion 
molecule-1 (VCAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1)) and to the 
glycosaminoglycans chondroitin sulfate A and heparan sulfate. Moreover, Turner et al. (1994) 
showed co-localization of PRBC sequestration with the expression of ICAM-1, CD36 and E- 
selectin in cerebral vessels from fatal cases of P. falciparum  malaria. Furthermore, Fried & Duffy 
(1996) showed adherence of P. falciparum-infected red blood cells to chondroitin sulfate A in the 
human placenta, and it is suggested that PfEMP1 is responsible for this binding (Rogerson & 
Brown 1997).
Rosette formation of parasitized and unparasitized erythrocytes has been observed (Carlson et a l . 
1990; Ho et al. 1991; Treutiger et al. 1992) and may contibute to obstruction of the vasculature. 
PfEMP1 is considered to be the rosetting ligand (Chen et al. 1998), and heparan sulfate, or a 
heparan sulfate-like molecule, on erythrocytes are the receptor for PfEMP1 binding. However, 
Rowe et al. (1995) and Newbold et al. (1997) showed that rosette formation was associated with 
severe malaria but not specifically with CM.
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1.3.2 The inflammation theory
The inflammation theory suggests that parasite-induced immunopathology plays an important role 
in the pathogenesis of CM (Grau et al. 1986; Curfs et al. 1989). Malaria parasites live and 
multiply in the blood vascular sytem. Therefore, infection can induce an intravascular 
inflammatory reaction. Inflammation is observed in organs that play an important role in the 
surveillance of the blood vascular compartment such as the liver and spleen but also in brains 
(Eling & Sauerwein 1995). Inflammatory reactions as a result of interactions between the parasite 
and host cells may induce changes in the permeability of the endothelial lining and cause 
disturbance of organ function. Moreover, expression of endothelial cell receptors used for binding 
by inflammatory cells is enhanced by tumour necrosis factora (TNFa; Senaldi et al. 1994) a 
cytokine released in increasing amounts during infection.
This permeability hypothesis is supported by monkey malaria data showing the passage of 
labelled albumin across the blood-brain barrier in malaria-infected animals (Maegraith 1973). On 
the one hand this observation was not confirmed in adult Thai patients with CM (Warrell et al. 
1986), whereas on the other hand enhanced capillary permeability to albumin in falciparum  
malaria was observed by Areekul et al. (1984, 1988). In addition, Das et al. (1991) observed 
increased levels of protein and lipid peroxidation products in the cerebrospinal fluid of patients 
with CM.
The pathogenesis of fatal experimental cerebral malaria (ECM) has been studied in detail in 
murine models (Grau et al. 1986; Curfs et al. 1989; Grau et al. 1989a; Grau et al. 1994b). In 
these models, T cells and macrophages play an important role in the immunopathology of ECM. 
No ECM occurs in congenital T-cell deficient mice or in normal mice treated with anti-T-cell 
antibodies after infection with the parasite (Finley et al. 1982; Grau et al. 1986; Curfs et al. 
1989). Furthermore, a timely depletion of macrophages also prevents the development of the 
cerebral syndrome (Grau et al. 1988; Grau et al. 1990; Curfs et al. 1993). Malaria parasites 
activate T cells and mononuclear phagocytes to release cytokines (Eling & Kremsner 1994). Of 
these cytokines, TNFa (tumour necrosis factora) has been considered important in the 
pathogenesis of CM and ECM.
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1.3.2.1 Malaria and TNFa
TNFa concentrations are more elevated in CM patients than in non-cerebral cases (Scuderi et al. 1986; 
Kern et al. 1989). In Malawi and Zaire, serum-TNFa concentrations of children infected with P. 
falciparum were positively correlated with disease severity (Grau et al. 1989b; Kern et al. 1989; 
Kwiatkowski et al. 1990). Furthermore, many of the clinical symptoms found after TNF a  injection in 
tumour patients, i.e. fever, chills, rigor, headache, anorexia and neurological symptoms (Blick et al. 
1987; Selby et al. 1987; Warren et al. 1987; Springs et al. 1988) resemble clinical symptoms observed in 
malaria patients with CM. Moreover, children homozygous for the TNF2 allele, a variant of the promotor 
region of the TNF a  gene which correlates with a high production capacity of TNF a , have a higher risk 
for CM (McGuire et al. 1994). Effective treatment of patients with CM results in a rapid decrease of 
serum-TNFa levels, even before clinical recovery is observed and before fever and parasitemia have 
disappeared (WHO 1990).
In contrast, studies of Kwiatkowski et al. (1990) and Grau et al. (1989b) showed that serum-TNF a  levels
of patients with uncomplicated malaria and patients with CM exhibit considerable overlap which could
argue against a role for TNF a  in human CM. Furthermore, studies in Gambian children with CM
(Kwiatkowski et al. 1993) show that treatment with a murine monoclonal antibody against human
recombinant TNF a  reduces fever but does not prevent mortality. Van Hensbroek et al. (1996a) not only
observed no effect after treatment with these anti-TNF a  antibodies, but treatment was associated with a
significant increase of cases with neurological sequelae. Another important observation made by Kern et
al. (1992) was that the plasma concentration of soluble TNF a  receptors correlated with parasitemia and
disease severity in human malaria. In addition, Kern et al. (1992); Kwiatkowski et al. (1993) and
Molyneux et al. (1993) all described the absence of bioactive TNF a  in sera of P. falciparum patients
despite high concentrations of immunoreactive TNF a. This finding could be explained by the presence of
excess soluble TNF a  receptors in the plasma (Kern et al. 1992; Molyneux et al. 1993; Deloron et al.
1994; Kremsner et al. 1995). This suggests that the risk for severe pathology by excessive release of
TNFa can be controlled by shedding of TNF a  receptors which forms a complex with free TNF a, thereby
blocking its biological e.g. cytolytic activity ( Kremsner et al. 1995). TNF a  can induce production of
nitric oxide (NO) and this molecule has been implicated in malaria-associated pathology, particularly 
in the development of coma
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Table 1: Cerebral malaria.
Plasm odium  species 
Human:
Sequestration 
PRBCs* MQs**
Haem orrhage
s
in the brain
Neurological
sym ptoms
Literature:
P. falciparum 
models:
Hum an ++ ++
++ --
++
++
++
++
Patnaik et al. 1994 
Turner et al. 1994
Monkeys:
P. knowlesi Maccaca
m ulatta
++ ++ N.I. N.I. M ahdi & Ahm ad 1991
P. coatneyi Maccaca
m ulatta
++ -- N.I. -- Aikawa et al.1992
P. falciparum Saimiri sciureus ++ -- N.I. ++ Gysin et al.1992
P. coatneyi Maccaca
fuscata
++ -- -- -- Kawai et al. 1993
P. fragile Maccaca
m ulatta
++ N.I. N.I. + /-  & Fujioka et al. 1994
Rodents:
P. berghei ANKA 
P. berghei NK65
C57L mice
Golden
ham sters
-- ++ 
-- ++
++
++
++
++
Rest 1982 
Rest 1982
P. berghei NK65 WM Rats N.I. N.I. ++ ++ Kamiyama et al. 1987
P. berghei K173 C57B1 mice -- ++ ++ ++ Polder et al. 1983 
Curfs et al. 1989
P. berghei ANKA CBA mice -- ++ ++ ++ Grau et al. 1986
P. chabaudi-chabaudi 
+ P. berghei ANKA
Mice (N.I.) ++ ++ N.I. N.I. Dennison et al. 1993
P. yoelii 17XL Swiss mice ++ -- -- N.I. Kaul et al. 1994
& : + /-  monkeys became stuporous 
N.I.: not indicated
* : PRBCs = Parasitized Red Blood Cells 
** : MQs = M ononuclear cells
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accompanying CM (Clark et al. 1992). It is hypothesized that NO released by 
vascular endothelial cells after stimulation with TN Fa diffuses into the brain, where 
it disrupts the regulation of glutamate-induced neuronal NO, resulting in alteration of 
neurotransmission and, consequently, coma. Grau & de Kossodo (1994) have 
proposed that NO may mediate early changes in CM, such as neurotransmission 
disturbances, when the neurological syndrome is still reversible, but that NO is 
unlikely to be involved in the actual process causing neurovascular damage at the 
advanced stages of the development of CM. However, that treatment with NO 
inhibitors do not block development of CM in the P. berghei ANKA model, not even 
upon direct intracranial administration of the NO inhibitor N-Methyl-L-Arginine 
(Senaldi et al. 1992; Asensio et al. 1993; Kremsner et al. 1993).
1.4 EXPERIM ENTAL CEREBRAL MALARIA
1.4.1 Experimental models
Because of the limited availability of human specimens for the analysis of the 
pathogenesis of CM a number of animal models were developed (table 1). None of 
these models reflect exactly the human situation, although, they can mirror certain 
aspects.
Several monkey CM models are available (table 1). Although sequestration of PRBC 
(P. falciparum ) in cerebral microvessels, like in the human situation, is observed in 
most of the monkeys only 50% of the microvessels exhibit this sequestration (Gysin 
et al. 1992) whereas 94% of cerebral vessels in human falciparum  CM cases showed 
sequestration (Riganti et al. 1990). Furthermore, neither haemorrhages nor 
adherence of monocytes/macrophages in the microvasculature of the brains of these 
P. falciparum  infected monkeys was described. Therefore, the P. falciparum/Saimiri 
sciureus monkey model is considered to be more suitable to study the obstruction 
theory. In other monkey models, however, the proportion of cerebral microvessels 
with sequestration ranges from 1% to 40% (Aikawa et al. 1992; Fujioka et al. 
1994).
In the mice CM models mononuclear cell sequestration is followed by the 
development of intravascular inflammatory reactions (Grau et al. 1987; Polder et al.
1992) and haemorrhages are observed in the microvasculature of the brains but no
General introduction
sequestration of PRBCs (table 1). Therefore, these mice models are more suitable to 
investigate the inflammation theory.
Rest (1982) was one of the first to describe ECM in mice. Subsequently, other 
investigators developed CM models with other parasites and mouse strains. The two 
most studied ECM models in mice (P. berghei K173 / C57Bl mice and P. berghei 
ANKA / CBA mice, table 1) are characterized by sequestration and adherence of 
mononuclear cells, often containing malaria pigment or phagocytosed erythrocytes, 
that interact with and migrate between the endothelial cells of post-capillary venules, 
causing widespread petechial haemorrhages (Rest 1983; Polder et al. 1992). 
Infection of C57Bl mice with P. berghei K173 parasites induces ECM in 95% of the 
mice, while 80% of the P. berghei ANKA infected CBA mice develop ECM. 
Recently, Dennison et al. (1993) and Kaul et al. (1994) described a murine model 
for sequestration of parasitized erythrocytes in postcapillary venules of the brain. 
Dennison et al. (1993) injected mice with a mixture of P. chabaudi chabaudi and P. 
berghei ANKA parasites. While P. c. chabaudi normally adhere to vascular lining 
cells in liver and spleen, but not in the brain (Cox, 1988), sequestration and 
adherence to brain capillary lining cells was found in the mixed infection. Dennison 
et al. (1993) suggest that cytoadherence in cerebral vessels of P. c. chabaudi in 
mixed infections, is due to “hijacking” of receptors otherwise adhered to by 
leukocytes in infections with P. berghei ANKA alone. Sequestration of PRBCs was 
also found in Swiss mice infected with P. yoelii 17XL (Kaul et al. 1994). However, 
neither haemorrhages nor involvement of monocytes or macrophages were found in 
the brains.
1.4.2 Pathogenesis o f  experimental cerebral malaria
In mice, it is assumed that sequestration of mononuclear cells is followed by the 
development of intravascular inflammatory reactions, endothelial cell damage and 
finally petechiae, in the brains (Grau et al. 1987; Polder et al. 1992) and in the 
retina (Ma et al. 1996). Elimination of macrophages prevented the development of 
experimental cerebral malaria in the P. berghei K173 model (figure 1; Curfs et al.
1993).
An interesting phenomenon parallel in both rodent ECM and human CM is the 
enhanced expression of adhesion molecules on endothelial cells which are involved 
in sequestration and adherence. Endothelial ICAM-1 can serve as a receptor for
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PfEMP1 expressed on P. falciparum-infected erythrocytes in humans (Ockenhouse et 
al. 1991) and for CD11a (leukocyte function antigen 1, LFA1) expressed on 
leukocytes in both mice and humans (Grau et a l. 1991).
Malaria may be a compartmentalised inflammation reaction: the malaria parasites 
live and multiply in the blood circulation and may concequently activate T cells and 
mononuclear phagocytes and their production of bioactive substances such as 
cytokines, reactive oxygen and nitrogen intermediates. These bioactive substances 
can activate the endothelial lining to upregulate adhesion molecules resulting in 
margination of inflammatory cells and through localized reactivity damage the 
endothelial lining.
The importance of specific inflammatory cells, their interaction with PRBC and the 
endothelial lining and the release of inflammatory mediators varies among the 
available experimental CM models.
1.4.2.1 T cells
Evidence for a role of T cells in the pathogenesis of rodent ECM came from 
experiments by Wright et al. (1968, 1971) who showed that neonatal thymectomy 
(hamsters) and treatment with anti-T-cell serum prevented the development of ECM 
in hamsters and rats. Grau et al. (1986) described an important role for CD4+, but 
not CD8+ T cells in the development of ECM in P. berghei ANKA infected CBA/Ca 
mice. Imai et al. (1994), working with WM/Ms rats infected with P. berghei NK65 
parasites, observed that depletion of CD8 T cells, but not CD4 T cells prevented 
ECM. In our model, C57BL mice infected with P. berghei K173 parasites, Curfs et 
al. (1989) confirmed a role of T cells in the development of ECM by showing that 
nude mice, thymectomized mice and mice treated with anti-T-cell serum were 
protected against ECM (figure 1). The ligand of T cells, LFA-1 (leucocyte function 
antigen-1) can bind to ICAM-1 what is expressed on endothelial cells.
1.4.2.2 Tumour Necrosis Factor a
Development of ECM closely associates with high serum concentrations of both, 
immunoreactive TN Fa as measured by an ELISA, (Clark et al. 1990b) and bioactive 
TN Fa as measured by a bio assay (Grau et al. 1987). In addition, in P. berghei 
ANKA infected CBA mice having a high concentration of bioactive TNFa , ECM
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could be prevented by treatment with anti-TNFa antibodies (Grau et al. 1987; 
figure1), and transgenic mice expressing high levels of soluble fusion protein TNFa- 
Receptor-P55 (s-TNFaR-P55), a receptor for free TNFa, are markedly protected 
against development of CM (Garcia et al. 1995). Administration of high doses of 
recombinant TNFa to normal CBA/Ca mice (Grau et al. 1987) reproduced ECM and 
to P. berghei infected mice enhanced ECM (Curfs et al. 1993).
In P. falciparum  malaria a high concentration of immunoreactive TN Fa is associated 
with disease severity and in some studies with CM (Grau et al. 1989; Kwiatkowski et 
al. 1990). On the other hand, elevated concentrations of s-TNFaR-P55 and soluble 
TNFa receptor P75 (s-TNFa R-P75) were observed in the sera of such patients (Kern 
et al. 1992; Molyneux et al. 1993; Deloron et al. 1994). Moreover, treatment of 
patients with an anti-TNFa mAb reduced fever but did not cure CM (Kwiatkowski et 
al. 1993; van Hensbroek et al. 1996a).
1.4.2.3 Blood-brain-barrier
In the mouse model, ECM is associated with leukocyte adherence to the microvascular 
endothelium, oedema and petechiae in the brains. Using vascular or parenchymal 
localization of Evans blue or Monastral Blue as indicators of the integrity of the blood- 
brain-barrier (BBB), Thumwood et al. (1988) and Neill & Hunt (1992) described an 
increase in the vascular permeability at a late stage of the development of ECM in P. 
berghei ANKA infected CBA and DBA mice.
Sequestration and adherence of P. falciparum  infected erythrocytes in the cerebral 
vasculature (WHO, 1990) may disturb the permeability of the BBB (Das et al. 1991; 
Patnaik et al. 1994), permitting the entry of epileptogenic factors into the brain 
parenchyma which may be resposible for malaria specific epileptogenic seizures 
observed in patients with CM (Waruiri et al. 1996).
1.4.2.4 Reactive Oxygen Intermediates
Endothelial cells (EC) are targets for interaction with neutrophils, monocytes and 
platelets and even PRBCs which are able to release and/or generate a variety of 
bioactive and noxious agents locally. These agents can cause membrane pertubation, 
leading to cell injury with subsequent loss of endothelial function.
One group of agents, known as reactive oxygen intermediates (hydrogen peroxide, 
superoxide anion, hydroxyl anion), are produced primarily by activated neutrophils
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and are known to cause EC injury and damage (Halliwell, 1989; Varani et al. 1989; 
Ward & Varani, 1990; Ward, 1991). Oxidant-induced injury to the endothelium may 
play an important role in the pathophysiology of ECM. Activation of phagocytes 
sticking to the surface of the cerebral vasculature as observed in the mouse model 
(Rest,1982; Polder et al. 1983; Grau et al. 1986) can cause oxidative damage to the 
endothelium and disturbance of the BBB. Increased production of reactive oxygen 
intermediates (ROI) has been described during Plasmodium chabaudi, P  vinckei and P. 
berghei infection (Stocker et al. 1984; Clark et al. 1987; Prasad et al. 1990) and 
independent of ECM. Under these conditions treatment with ROI scavengers enhanced 
parasitemia (Clark et al. 1987). However, Thumwood et al. (1989) showed that the 
antioxidants butylated hydroxyanisole (BHA) and the combination superoxide 
dismutase and catalase can prevent ECM in P. berghei ANKA-infected A/J mice. 
Moreover, a BHA diet prevented disturbance of the permeability of the BBB.
1.4 .3  Characteristics o f  the Plasmodium berghei K173 cerebral malaria model
According to table 1 and the high percentage of mice developing ECM after 
infection as compared to the P. berghei ANKA/CBA mouse model it appears that 
C57Bl mice infected with Plasmodium berghei K173 is a useful model to study the 
role of inflammation parameters in ECM. During the second week after a blood- 
induced infection with 1 0  parasitised red blood cells (PRBCs) the majority of 
animals (95%) develop cerebral malaria (Curfs et al. 1992). After 9 - 10 days at 
end-stage disease, these mice become progressively inert with a ruffled fur, humped 
back and locomotor disturbances, and show a dramatic decrease of their body 
temperature to values below 30° C usually within a period of 24 hours, and die 
shortly thereafter (Curfs et al. 1989). Histopathological examination of the brains of 
these mice, either post mortem or in the period of a rapidly decreasing body 
temperature, reveals a high frequency of perivascular edema, intravascular 
accumulations of mononuclear cells adhering to endothelial cells and haemorrhages. 
The topographic distribution of the petechiae in the brains coincides with that of 
major cerebral arteries and veins (Polder et al. 1983; Curfs et al. 1992; Polder et al. 
1992).
Mice that survive this critical period (about 5%) exhibit only a limited and transient 
decrease of their body temperature and die in the third week after infection or later
20
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with high parasitemia, anaemia and frequently secondary infections without any 
cerebral pathology.
Because the progressive decrease in body temperature and death during the second 
week strongly correlated with haemorrhages in the brains after infection with P. 
berghei K173 (Curfs et al. 1989), the low body temperature and death during the 
second week of infection are useful surrogate markers for the development of 
cerebral haemorrhages.
1.5 OUTLINE OF THIS THESIS
The aim of the present study was to further elucidate the role of T cells, ROI and 
TNFa in the pathogenesis of ECM in C57Bl/6J and C57Bl/10 mice infected with P. 
berghei K173 parasites. To examine the role of T cells, ROI and TN Fa, in the 
pathogenesis of murine ECM intervention studies were carried out with depletion of 
specific T cells or using inhibitors of the inflammation mediators mentioned during 
various stages of infection.
T cells:
To elucidate the role of T cells in the pathogenesis of ECM, P. berghei K173 infected 
C57Bl mice were treated with anti-CD4 and/or anti-CD8 antibodies during infection 
and at end stage disease (chapter 2). Convulsions induced by folic-acid treatment were 
used as a marker for increased permeability of the BBB in end-stage disease mice. 
Mice, having an increased permeability of the BBB, were treated with anti-CD4 or 
anti-CD8 antibodies (chapter 3) and recovery from ECM and restoration of function of 
the BBB were determined.
ROI:
We analysed the effect of treatment with several antioxidants: apocynin, desferal-Zn, 
DMSO and ethanol. In addition SOD transgenic mice, producing high concentrations 
of SOD, a scavenger of ROI, were infected and observed for ECM (chapter 4). In 
chapter 5, we studied the effect on parasitemia and development of ECM of 
treatment with the ROI inducing drugs, artemether and alloxan that are also fast
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acting anti-malarials on. The effect of treatment was also determined at a very late 
stage of the development of ECM.
TNFa:
Intervention studies with anti-TNFa antibodies (chapter 6) were carried out because 
of the differences between the effect of anti-TNF antibody treatment in the ECM 
mouse model of Grau et al. (1987) and in humans with CM (Kwiatkowski et al. 1993; 
van Hensbroek et al. 1996a). In chapter 7, the role of TNFa was further investigated 
by administration of low doses rec-h-TNFa monomer given as a bolus or by 
sustained release during infection. The effect of monomeric rec-h-hTNFa treatment 
on parasitemia and on the development and outcome of ECM was examinated. 
Stabilised rec-h-TNFa trimers, which structure is very important for its action 
(Smith & Baglioni 1987; Van Ostade et al. 1994), were prepared by a chemical 
reaction from rec-h-TNFa monomers. Chapter 8 describes the analysis of the 
therapeutic potential of stabilised rec-h-TNFa trimers during development of ECM.
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Figure 1: Schematic representation of the possible involvement of cells, cytokines 
and their receptors (e.g.) TN Fa and sTNFa R, and unknown reactions (black box) 
after signal transduction in the pathogenesis of experimental cerebral malaria.
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ABSTRACT
The role of T-cells in development of experimental cerebral malaria was analysed in 
C57B1/6J and C57Bl/10 mice infected with Plasmodium berghei K173 or Plasmodium 
berghei ANKA by treatment with anti-CD4 or anti-CD8 MAbs. Mice were protected 
against experimental cerebral malaria (ECM) when anti-CD4 or anti-CD8 MAbs were 
injected before or during infection. Even in mice in end stage disease i.e. with a body- 
temperature below 35.5°C, treatment with anti-CD4 or anti-CD8 antibodies or the 
combination protected against ECM whereas chloroquine treatment was completely 
ineffective in inhibiting further development of the cerebral syndrome.
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INTRODUCTION
There are a number of rodent models available for the study of the pathogenesis of 
experimental cerebral malaria. In these studies mice (Rest, 1982, Grau et al. 1986, 
Thumwood et al. 1988, Curfs et al. 1989), rats (Wright et al. 1971) and hamsters 
(Rest & Wright, 1979) were used in combination with different strains of P.berghei 
parasites e.g. ANKA (Grau et al. 1986) or K173 (Curfs et al. 1989).
In all these models an immunopathological reaction is considered to be involved in the 
development of the syndrome. Studies in rodent models showed sequestration and 
adherence of white blood cells to the endothelial lining of post-capillary venules in the 
brains in association with development of petechiae (Rest et al. 1982, Polder et al. 
1992). In the model described by Grau et al. (1986) (P. berghei ANKA, CBA/Ca 
mice), CD4+ T-cells play an important role since depletion of CD4+ T-cells prevents 
and transfer of CD4+ T-cells from mice developing cerebral malaria enhances 
development of the cerebral syndrome. In addition, depletion of CD8+ T-cells did not 
prevent cerebral malaria. In mice with Murine Acquired Immunodeficiency Syndrome 
(MAIDS), which is characterized by abnormal functioning of CD4+ T-cells the level 
of protection against murine ECM is significantly increased and related to duration of 
the viral infection and, hence, with the severity of CD4 T-cell immunodeficiency 
(Eckwalanga et al, 1994). In the model using WM/Ms rats and P. berghei NK65 
parasites (Imai et al, 1994) cerebral malaria is prevented by CD8+ T-cell depletion, 
but not by CD4 T-cell depletion. In our model (P. berghei K173, C57Bl mice) Curfs 
et al. (1989) confirm a role of T-cells in the development of experimental cerebral 
malaria since nude mice, thymectomized mice and mice treated with an anti-T-cell 
serum were protected against cerebral malaria.
Here, we describe the results of treatment with anti-CD4 and anti-CD8 antibodies in 
P. berghei ANKA and K173 infected C57Bl mice. The results show that treatment 
with anti-CD4 or anti-CD8 antibodies can prevent development of experimental 
cerebral malaria. Moreover, even when performed shortly before expected death, i.e. 
in end stage disease when body-temperature has decreased to 35.5°C or lower, 
depletion of CD4 or CD8 T-cells effectively prevented further development of the 
cerebral syndrome.
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MATERIALS AND METHODS
Mice: C57Black/6J or C57Black/10 mice, aged 6-10 weeks, were obtained from speci­
fic pathogen free colonies maintained at the Central Animal Facility of the University 
of Nijmegen. All mice were housed in plastic cages and received water and standard 
RMH food (Hope Farms, Woerden, The Netherlands) ad libitum.
Parasite: Plasmodium berghei K173 and Plasmodium berghei ANKA were maintained 
by weekly tranfer of parasitized erythrocytes (PE) from infected into naive mice. 
Experimental mice were infected intraperitoneally with 10 PE from blood of infected 
donor animals of the same strain.
P. berghei ANKA (originally obtained from Dr. B. Mons, Laboratory of Parasitology, 
University of Leiden, The Netherlands) is a gametocyte-producing strain which is 
passaged through Anopheles gambiae mosquitoes after 4 weekly blood passages. For 
this purpose mosquitoes are allowed to feed on mice 3 days after infection with 10 
parasites. Blood-fed mosquitoes receive an additional blood-meal containing normal 
erythrocytes 5 days later and are allowed to infect mice 14 days later.
Parasitaemia: thin blood films were made from tail-blood, stained with May- 
Grunwald and Giemsa's solutions, and the proportion of red blood cells infected with 
the parasite was determined.
Detection of cerebral malaria: approximately 95% of C57Bl mice infected with 103 
P. berghei K173 (Curfs et al. 1992) or P.berghei ANKA parasites die early in the 
second week after infection. Approximately one day before death a progressive hypo­
thermia develops which is strongly correlated with development of haemorrhages in 
the brains as observed by histology (Curfs et al, 1989). Mice that show a transient 
hypothermia (in the majority of cases >32°C) survive this critical period but die in the 
third week or later after infection without any noticeable cerebral pathology.
Body tem perature: Body temperature was measured with a digital thermometer 
(Technoterm 1200) introduced into the rectum and read after 10 seconds.
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Histology: Mice were killed by an overdose of aether and their brains were collected 
or they were collected post mortem. Brain tissue was fixed in Carnoy's fluid for 4 
hours. Paraffin sections (5mm) were stained with PAS/Hematoxilin or Goldner's 
trichroom stain. Sections were scored for the presence of petechiae.
In-vivo CD4+ or CD8+ T-cell depletion: Rat monoclonal anti-CD4 and anti-CD8 
antibodies were produced by respectively hybridoma YTS 191.1.2, ECACC no 
87072282 and YTS 169.4.2.1, ECACC no 87072283. Both MAbs are of the IgG2b 
isotype. Pristane primed nude mice were injected i.p. with 3.106 hybridoma cells and 
the ascites produced was collected. After ammonium sulfate (45%) precipitation and 
dialysis against H O , the solution was freeze-dried and stored at 4°C until used. Ali­
quots were solubilized in sterile, pyrogen-free saline and used immediately. Normal 
and thymectomized mice were treated once or twice (4 days apart) by i.p. injection of
0.3 mg of either anti-CD4 or anti-CD8 MAb. Treatment with an irrelevant isotype 
matched, ammonium sulfate precipitated rat MAb was used in comparison to treatment 
with normal rat serum as another control. Both control treatments did not prevent 
development of ECM and did not affect parasitaemia. Therefore, both control 
treatments were used in the CD4+/CD8+ T-cell depletion experiments. The efficacy of 
T-cell depletion was determined in peripheral leucocytes isolated by watershock- 
treated peripheral blood, or in ACT-treated spleen cell suspensions from samples 
collected 3 days after treatment with the anti-T-cell MAbs (Hudson & Hay, 1989). 
Analysis of CD4+/CD8+ T-cell depletion immediately after injection of the MAbs was 
complicated by the presence of the injected MAb coating the CD4+/CD8+ T-cells in 
the cell suspensions, a problem that was absent when the analysis was performed 3 
days after the last anti-T-cell treatment. Cell suspensions were incubated in PBS 
containing 10% FCS, 0.05% sodium azide and 0.05 mg/ml of the anti-CD4 or anti- 
CD8 MAbs for 30 minutes at 4°C followed by a 30 minutes incubation of a 50 times 
diluted FITC-labelled rabbit anti-rat Ig (Dako) in PBS containing 40% mouse serum 
and 0.05% sodium azide. After washing with PBS +  0.05% sodium azide fluorescen- 
se was read microscopically.
From the peripheral blood and the spleen respectively 80% and 92% of CD4+ and 
62% and 79% of CD8+ T-cells were depleted. Treatment with either anti-CD4 or anti- 
CD8 MAbs did not change significantly the proportion of B-cells (data not shown).
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Protection against cerebral malaria was independent of iv. or ip. injection of the anti- 
T-cell MAbs (data not shown), and ip. injections were used for all experiments.
Thymectomy: thymectomy (Tx) was performed on mice anaesthetized with chloral- 
hydrate (4.5% solution; 10 ml per gram body weight). Mice were allowed to recover 
from surgery for a period of 2 weeks before they were used in experiments.
Statistical analysis: For statistical analysis the student's t-test (comparison of 2 
groups) and the Kruskal-Wallis test (comparison of more than 2 groups) were used. P  
values <0.05 were considered significant.
RESULTS
The effect of treatment with anti-CD4 or anti-CD8 MAbs on development of 
experimental cerebral malaria was analysed in thymectomised and intact C57Bl/6J and 
C57Bl/10 mice being infected with P. berghei ANKA or P. berghei K173 parasites. 
Figure 1 shows that treatment with anti-CD4 or anti-CD8 MAbs protected against 
ECM, irrespective of thymectomy in both C57Bl/6J or C57Bl/10 mice infected with 
either P. berghei K 173 or P. berghei ANKA parasites.
Parasitaemia in control mice that die of ECM was approximately 5-10% with a 
reduction of the haematocrit by approximately 20%. Neither thymectomy, nor 
treatment with anti-CD4 or anti-CD8 MAbs significantly changed parasitaemia and 
haematocrit during infection as compared to controls. All treated mice that did not die 
of cerebral malaria developed the same severe anaemia in the course of the infection 
(data not shown). Treatment with either an isotype-matched rat MAb or normal rat 
serum as a control for depletion of CD4+ or CD8+ T-cells by specific rat MAbs, had 
no effect on development of ECM (table 1) and did not change parasitaemia.
The data in table 1 show that treatment with anti-CD4 or anti-CD8 MAbs 2 days 
before and 2 days after infection protected respectively 80% and 92% of the mice 
whereas 12% of the control mice were protected. Moreover, T-cell depletion during 
infection and even when performed on day 8 i.e. shortly before expected death as 
observed in non-depleted controls, effectively prevented development of the fatal 
syndrome (table 1).
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Protection against ECM (%)
Controls
anti-CD4
treated
anti-CD8
treated
1 0 0
T 19/20
■ 7/7 •  6 / 6  
 ^ 1 1 / 1 2
1 6/7
75 x  6 / 8  a  3 / 4  
"  8 / 1 1
■ 3/4
50 •  3/6
25 ■ 5/20
0
' 1/10 -  2/23 
0/9 *  1/16
Tx intact Tx intact Tx intact
Figure 1: Protection against cerebral malaria in thymectomized (Tx) versus intact mice and in 
relation to treatment with anti-CD4 or anti-CD8 MAbs two days before and two days after 
infection. C57B1/6J infected with P.berghei K173 (▼) or with ANKA (• ) ;  C57B1/10 infected 
with P.berghei K173 (■). The number of mice protected against ECM versus the total 
number of infected mice is indicated for each experimental group.
The effect on body-temperature of treatment with anti-CD4 or anti-CD8 MAbs two 
days before and two days after infection with P. berghei K173 in C57B1/6J mice was 
analysed in eight independent experiments. The results of one representative experi­
ment are depicted in figure 2. Body-temperature of untreated infected mice 
dramatically decreased after 9 days of infection. Anti-CD4 or anti-CD8 treated mice 
showed a limited decrease of their body-temperature which stabilized. The same effect 
on body-temperature was found when treatment with anti-CD4 or anti-CD8 MAbs was 
given as a single treatment up to day 8 of infection (results not shown).
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Table 1: Effect of treatment with anti-CD4 or anti-CD8 MAbs before and during 
infection with P. berghei K173 parasites on development of cerebral malaria in C57B1 
mice.
Treatment Day(s) of Mice protected against ECM/
treatment* treated mice
n
Control 9/78° (12%)
IgG2b-controls# Day -2/2 0/5 (0%)
Day 9 1/7 (14%)
Anti-CD4: Day -2/2 39/49' (80%)
Day 4 3/3 (100%)
Day 6 3/3 (100%)
Day 8 7/8 (88%)
Day 8 + 10 5/5 (100%)
Anti-CD8: Day -2/2 33/36' (92%)
Day 4 3/3 (100%)
Day 6 2/3 (66%)
Day 8 5/8 (63%)
Day 8 + 10 5/5 (100%)
* in relation to infection at day 0
o summerized data from P. berghei K173 or P. berghei ANKA infected mice (see figure 
1)
# Isotype matched irrelevant MAb as a control of MAb anti-CD4 or anti-CD8 treatment
Anti-CD8 treatment 2 days before and 2 days after infection prevented development of 
ECM as effective as CD4+ T-cell depletion (table 1) and no significant difference in 
body-temperature during infection of the anti-CD4 and anti-CD8 treated mice was 
found too (figure 2).
To further determine the latest possible moment for effective anti-CD4 or anti-CD8 
treatment in the course of infection, mice were selected with a body-temperature
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between 35.5 and 30°C. If left untreated such infected mice die within 24 hours as 
shown in figure 2. The results in table 2 show that mice with such a hypothermia could 
be protected against fatal cerebral malaria by treatment with anti-CD4 and/or anti-CD8 
antibodies, whereas chloroquine treatment could not save any of these mice. No 
relation could be found between body-temperature on the moment of anti-T-cell 
treatment (30 - 35.5°C) and protection against fatal cerebral malaria (data not shown). 
Anti-CD4 or anti-CD8 treatment of mice with a body-temperature below 30°C never 
prevented death. Treatment with anti-CD4+ or anti-CD8+ MAbs in mice with end 
stage disease did not save all mice from the cerebral syndrome (table 2). These last 
two observations are probably due to petechiae that already developed before treatment 
(Polder et al. 1988).
Depletions that prevented further development of the cerebral syndrome also resulted 
in a subsequent increase of the body-temperature (table 2). Overall in 93% (27/29) of 
the anti-T-cell treated mice body-temperature increased within 24 hours and prevented 
further development of the cerebral syndrome.
Figure 2: The effect on body-temperature of treatment with anti-CD4 or anti-CD8 MAbs 2 
days before and 2 days after P. berghei K173 infection in C57B1/6J mice. ( • )  Control mice, 
(Q) anti-CD4 treated mice, ( ) anti-CD8 treated mice; (n=5).
39
Chapter 2
Table 2: Effect of treatment with anti-CD4 and/or anti-CD8 MAbs or chloroquine on 
development of cerebral malaria in C57B1/6J mice infected with P.berghei K173 
parasites.
Treatment ECM protected/total increased T C**
/toi:al
Saline 2/52 (4%) 1/2 (50%)
Chloroquine0 0/10 (0%) NS°°
anti-CD4 12/17 (71%) 11/12 (92%)
anti-CD8 10/20 (50%) 9/10 (90%)
anti-CD4 + anti-CD8 7/8 (88%) 7/7 (100%)
* Treatment was given when the body-temperature was between 35.5 and 30.0°C.
** Mice with a statistically significant increase of their body-temperature at 24 hours after 
treatment*
0 Chloroquine treatment: 0.8 mg i.p. mouse/daily.
00 NS = no survivors
DISCUSSION
These studies demonstrate the importance of CD4+ and CD8+ T-cells in the 
pathogenesis of murine cerebral malaria (ECM), and this was independent of the use 
of C57B1/6J or C57B1/10 mice, or infection with P. berghei K173 or P. berghei 
ANKA parasites. Thymectomized mice were used to prevent the infux of new T-cells 
after treatment with anti-T-cell MAbs, but no significant difference was found when 
data were compared to intact mice. Treatment with anti-T-cell MAbs did not 
completely eliminate all CD4+ or all CD8+ T-cells. Together these observations 
suggest that complete absence of CD4 or CD8 T-cells is not necessary to prevent 
development of murine ECM. Anti-CD4+ or anti-CD8+ T-cell treatment had no effect 
on parasitaemia and development of anemia confirming the observations made by Grau 
et al. (1986) in another murine P. berghei ECM model and by Imai & Kamiyama 
(1994) in a rat P. berghei NK 65 ECM model.
The observation that both anti-CD4 and anti-CD8 T-cell depletion can prevent 
ECM, is in contrast to observations made previously by Grau et al. (1986) who 
described a role for CD4 but not CD8 T-cells in development of ECM in P. berghei 
ANKA infected CBA mice. In contrast, Waki et al. (1992) and Imai & Kamiyama
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(1994) found a role for CD8+ but not CD4+ T-cells in preventing either early 
mortality or ECM respectively in P. berghei NK65 infected rodents. A role for both 
CD4 and CD8 T-cells in development of ECM in P. berghei ANKA infected mice 
was noted by Weidanz and collaborators using various types of knock-out mice 
(personal communication). Hancock et al (1994) found that treatment with anti-CD4 
antibodies not only depletes CD4-positive T-cells but also CD4-positive mononuclear 
cells, but their possible role in ECM remains to be determined.
In contrast to our results Grau et al (1986) found that CD8+ T-cell depletion did not 
prevent development of ECM in P. berghei ANKA infected CBA mice. This apparent 
discrepancy may relate to different mouse strains used and/or a difference in the strain 
of P. berghei ANKA.
Anti-CD4 or anti-CD8 T-cell treatment was effective even in mice with end stage 
disease (body-temperature between 35,5 and 300C). Histological analysis of brains of 
mice developing the cerebral syndrome showed that white blood cells adhere to the 
endothelial lining (Curfs et al. 1989, Polder et al. 1992) suggesting that these CD4+ 
and CD8 T-cells are involved in disturbance of the endothelial lining and thereby in 
the functioning of the blood-brain barrier.
Disturbance of the blood-brain barrier in mice developing ECM was also observed by 
Thumwood et al. (1988) and Neil & Hunt (1992). They described leakage of Evans 
blue from the vasculature into brain parenchyma. In addition, P. berghei K173 
infected mice with end stage disease are sensitive to development of folic acid induced 
convulsions, while control mice are not. Treatment with anti-CD4+ or anti-CD8+ 
MAbs not only prevents ECM but successfully treated mice also recover from their 
sensitivity to folic acid induced convulsions within 4 hours after MAb treatment 
(Hermsen et al., unpublished observations). In human cerebral malaria convulsions are 
common (Waruiru et al. 1996) raising the question whether in human CM adherence 
of sequestered infected red blood cells and possibly the presence of leukocytes (Polder, 
1989, Porta et al. 1993, Eling & Kremsner, 1994, Patnaik et al. 1994, Eling & 
Sauerwein, 1995) are involved in excessive activation of endothelial cells and 
subsequent disturbance of the function of the blood-brain barrier.
Chloroquine treatment could not save mice in end-stage disease while anti-CD4 or 
anti-CD8 treatment was still effective. This may be explained by the fact that chloroqu- 
ine like most other anti-malarial drugs need more than one day to suppress
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parasitaemia effectively, whereas most of the mice in end-stage disease die within one 
day.
Our data are compatible with the hypothesis that a localized inflammatory reaction 
involving both CD4 and CD8 T-cells disturbs and damages the endothelial lining of 
the blood-brain barrier eventually leading to petechiae. Our data suggest that both 
CD4 and CD8 T-cells are involved in stimulation of a downstream process of the 
development of the petechiae.
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ABSTRACT
Experimental cerebral malaria (ECM) can be induced in C57B1 mice by infection with 
Plasmodium berghei K173 parasites. Behavioral changes shortly before they die of 
ECM may reflect disturbance of the integrity of the blood-brain-barrier (BBB). Folic 
acid elicits strong convulsive activity if the permeability of the BBB is increased. 
Administration of folic acid to mice during development of ECM induced convulsions. 
Interventions known to prevent fatal outcome from ECM, such as splenectomy or 
treatment with anti-CD4 or anti-CD8 MAbs also prevented sensitivity to folic acid- 
induced convulsions. In addition, infected mice with ECM and sensitive to folic acid- 
induced convulsions, recovered from this sensitivity alter treatment with anti-T cell 
antibodies within 4 hours. These data suggest that disturbance of the permeability of 
the BBB can be reversed and depends on the involvement of T cells.
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INTRODUCTION
C57B1 mice infected with Plasmodium berghei K173 parasites die of experimental 
cerebral malaria (ECM) [1], Mice that develop ECM exhibit behavioral changes 
during the last 24 hours of life that reflect convulsive activity [2], In this model, ECM 
is associated with leukocyte adherence to the microvascular endothelium, edema, and 
petechiae in the brain [3, 4], Using Evans blue or Monastral Blue as indicators of the 
integrity of the blood-brain-barrier (BBB), Thumwood [5] and Neill and 
colleagues[6,7] reported increased vascular permeability in mice that developed ECM 
(P. berghei ANKA-infected CBA mice), but not in mice without cerebral malaria 
(CBA mice infected with P. berghei K173 parasites) exept at a very late stage of the 
disease [7],
Convulsions are common in childhood malaria and are associated with severity of 
disease and mortality [8], Recent observations show that childhood convulsions are 
particularly associated with malaria, but not necessarily in combination with fever, 
suggesting that Plasmodium falciparum  parasites have epileptogenic properties [10], 
Sequestration and adherence of P. falciparum-infected erythrocytes in the cerebral 
vasculature [9] may disturb the permeability of the BBB [11, 12], permitting the entry 
of epileptogenic factors into the brain parenchyma,
Hommes et al, [13] demonstrated that strong, rapidly lethal convulsions could be 
evoked in rats by injection of folic acid if the BBB was disturbed, This technique of 
provoking strong epileptic activity by folic acid treatment if the permeability of the 
BBB was increased was applied in our model of ECM,
In this study, we assessed the effect of folic acid treatment on mice with ECM and of 
interventions with anti-CD4 and anti-Cd8 monoclonal antibodies (MAbs),
MATERIALS AND METHODS
Mice: female C57Bl/6J mice, ages 6-10 weeks, were obtained from specific pathogen­
free colonies maintained at the Central Animal Facility, University of Nijmegen. All 
mice were housed in plastic cages and received water and standard RMH food (Hope 
Farms, Woerden, Netherlands) ad libitum,
Parasite: P. berghei K173 (originally obtained from W, Kretschmar, Tübingen, 
Germany) has been maintained by weekly transfer of parasitized erythrocytes (PE)
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from infected into naive mice for >30 years. Experimental mice were infected intra- 
peritoneally (ip) with 10 PE from blood of infected donors.
Parasitaemia: thin blood films were made from tail-blood stained with May-Grunwald and 
Giemsa solutions, and the proportion of parasitized red blood cells was determined.
Detection ECM: ECM was detected as described by Curfs et al. [3]. In brief, 95 % of C57Bl 
mice infected with 10 P. berghei K173 parasites die early in the second week after infection. 
One day before death a progressive hypothermia develops that is strongly correlated with 
development of hemorrhages in the brains as observed by histology [1]. The parasitaemia in 
mice that die of ECM is between 5%-10%, and such mice have a 20% reductionin 
haematocrit. Mice that show a transient hypothermia (in most cases >32°C) survive this criti­
cal period but die in the third week or later after infection with signs of severe anemia and a 
parasitaemia of 20%-40% but without any detectable cerebral pathology as determined by 
light microscopy.
End-stage disease: mice infected with P. berghei K173 parasites exhibit a rapidly decreasing 
body temperature and usually die within 24 hours [1] about day 8/9 after infection. Mice are 
considered to be in end-stage disease when their body temperature drops to < 35.5°C.
Body temperature: body temperature was measured by a digital thermometer (Technoterm 
1200, Thermotex, The Hague, Netherlands) introduced into the rectum and read after 10 
seconds.
Splenectomy: mice were anesthetized, the splenic pedicles were ligated, and the spleen was 
removed. Mice were infected with P. berghei K173 parasites 7 days after splenectomy.
Anti-CD4 or anti-CD8 Mab treatment: Mice were treated with anti-CD4 or anti-CD8 MAbs 
[14]. In brief, rat anti-CD4 or anti-CD8 MAbs were produced by hybridoma YTS 191.1.2 
and YTS 169.4.2.1, respectively. Mice received 0.3 mg of the MAb ip 2 days before and 2 
days after infection. From the peripheral blood and the spleen, respectively 80% and 92% 
of CD4 and 62% and 79% of CD8 T cells were depleted 3 days after treatment.
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Convulsions: mice received 0.2 ml of a folic acid solution (25mg/ml) intravenously. 
The folic acid (Genfarma, Maarsen, Netherlands) was dissolved in saline and adjusted 
to pH 7 with 1 M NaOH. Mice were observed after injection of 5 mg of folic acid for 
90 minutes. During this period sensitive mice developed generalized convulsions and 
died.
Phenobarbitone (0.75 mg/mouse ip) dissolved in saline and adjusted to pH 7 with 1 M 
HCl was used as an anticonvulsant and injected 10 minutes before folic acid.
Statistical analysis: all data are expressed as mean ± SD. Student's t-test was used for 
statistical analysis. P  < .05 was considered significant.
RESULTS 
Induction of convulsions by folic acid in P. berghei-infected mice
Convulsions after folic acid administration were not observed in normal C57Bl mice. 
In the absence of folic acid treatment, P. berghei-infected mice did not show obvious 
convulsions. C57Bl mice infected with 10 P. berghei K173 PE developed convulsions 
after injection of 5 mg of folic acid/mouse at day 8 or 9 after infection, depending on 
body temperature. There was a significant difference (P < .05) in mean body 
temperatures of infected mice that developed (32.1 + 2.8°C) or did not develop 
convulsions (36.3 + 2.1°C) after folic acid treatment. Of 28 infected mice, 26 (93%) 
mice with body temperature < 35.5°C and 2 of 12 (16.7%) mice with a temperature 
>35.5°C  developed generalized convulsions (P < .05). The proportion of mice that 
developed convulsions decreased when < 5  mg folic acid was injected in infected mice 
with body temperatures <35.5°C  (data not shown). Thus, in the standard test to 
determine sensitivity to induction of folic acid-dependent convulsions, mice with body 
temperatures < 35.5°C were given 5 mg folic acid i.v.
Pretreatment of infected mice with a body temperature <35.5°C with the anti­
convulsant phenobarbitone neither affected parasitaemia nor prevented ECM (n=7), 
but it protected all mice (n=8) against development of convulsions induced by a 
subsequent injection of folic acid.
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Sensitivity to folic acid-induced convulsions in splenectomized or anti-T cell- 
treated infected mice.
Splenectomized mice and mice depleted of CD4 or CD8 T cells before infection were 
protected against development of ECM and against folic acid-induced convulsions to a 
varying degree (table 1), whereas controls developed convulsions and ECM.
Table 1: Effect of splenectomy (day -1) or anti-CD4 or anti-CD8 T cell treatment (days - 
2 and 2) on prevention of ECM and of convulsions induced by folic acid treatment in P. 
berghei infected mice.
Treatment Number of mice protec­ Number of mice*
ted against ECM/ without convulsions/
total number total number
Control 
Splenectomy 
Anti-CD4 (Day -2/2) 
Anti-CD8 (Day -2/2)
0/5 (0%)
3/3 (100%)'
5/6 (83%)'
3/4 (75%)'
0/8 (0 %) 
17/28 (61%) 
9/9 (100%) 
10/15 (67%)
*: In infected mice with a body temperature between 30° and 35.5°C convulsions were 
scored after administration of 5 mg folic acid i.v.
t: Only small numbers of mice were used as controls, because protection against ECM 
by these treatments was shown before [1, 14],
When infected mice with body temperatures of 30-35.5°C were treated with folic acid 
4 or 24 hours after treatment with anti-T cell MAbs a considerable proportion were 
protected against development of convulsions, whereas all untreated infected mice 
developed convulsions after folic acid injection (table 2). There was no significant 
difference in the proportion of mice protected against convulsions when folic acid was 
given 4 or 24 hours after the anti-T cell treatment.
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Table 2: Effect of treatment with anti-CD4 or anti-CD8 MAbs of P. berghei K173 infected 
mice with a body temperature between 30° and 35.5°C on development of folic acid 
induced convulsions.
Treatment with:
Time of Anti-CD4* Anti-CD8* Saline
administration
of folic acid after 
anti-T cell treatment
No convulsions / 
folic acid treated
No convulsions / 
folic acid treated
No convulsions / 
folic acid treated
mice mice mice
4 h
24 h
5/9 (56%) 
5/9 (56%)
11/18 (61%) 
4/8 (50%)
0/5 (0%) 
0/8 (0 %)
*: 0.3 mg/0.2 ml anti-CD4 or anti-CD8 mAb was injected i.p. once.
DISCUSSION
C57Bl mice infected with P. berghei K173 develop ECM characterized by leukocyte 
adherence to the vascular endothelial lining, edema, and petechiae in the brain [1] 
suggesting a progressive loss of BBB integrity. These results show that mice during 
development of ECM become sensitive to the induction of convulsions by folic acid 
treatment and that protection against ECM by splenectomy or anti-T cell treatment, 
also protects against development of convulsions after folic acid treatment. Moreover, 
when mice in end-stage disease are treated with anti-CD4 or anti-CD8 MAbs, the 
evolution of ECM is disrupted [14] and they recover within 4 h from sensitivity to 
folic acid- induced convulsions.
In another experimental murine model of ECM [2] convulsions occured in end-stage 
disease. In our model, behavioral changes (progressively inert with ruffled fur, 
humped back, and locomotor disturbances) were not explicit enough for further 
analysis. Therefore, we injected folic acid, which induces convulsions if the BBB is 
damaged [13], to analyze the hypothesis that during development of ECM the 
permeability of the BBB is increased and causes all or part of the accompanying 
behavioral changes observed. Only infected mice developing ECM were sensitive to
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folic acid could be prevented by treatment with the anti-convulsant phenobarbitone, 
suggesting that the permeability of the BBB is increased during development of ECM. 
Thumwood et al. [5] and Neill & Hunt [6] also found an increased permeability for 
Evans blue or Monastral blue of the BBB in late stage ECM development in P. berghei 
ANKA-infected mice. Neill et al. [7] observed an increased permeability only in 
terminally ill CBA or DBA mice infected with P. berghei K173 parasites that did not 
develop cerebral symptoms. The absence of ECM in their experiments may relate to 
their use of DBA or CBA mice (we used C57Bl/6J mice) or to the number of parasites 
used for infection (10/mouse in their model vs. 10 in ours). Our previous experi­
ments showed that the proportion of mice that develop ECM decreases as more parasi­
tes are used to infect mice [3], which may explain why Neill and colleages [6, 7] 
observed neither ECM nor increased permeability until the mice are terminally ill. 
Although ECM cannot readily be compared with P. falciparum-induced childhood 
malaria, CM it is of interest that Waruiru et al. [10] describe malaria-specific 
convulsions in P. falciparum- infected children.
Previous work showed that splenectomy [1] or treatment with either anti-CD4 or anti- 
CD8 T cell MAbs [14] prevented development of ECM in P. berghei K173-infected 
mice. A close correlation between sensitivity to folic acid-induced convulsions and 
development of ECM is supported by the observation that prevention of ECM by 
splenectomy or anti-T cell treatment also prevented sensitivity to induction of convulsi­
ons by folic acid (table 1). These data support and complement the observation of Neill 
& Hunt [15] who prevented an increase in the permeability of the BBB by treatment 
with dexamethasone, which in our model successfully prevents ECM when given prior 
to day 5 of infection [1]. Treatment with anti-CD4 or anti-CD8 MAbs in our model 
prevented ECM [14] and prevented development of convulsions after folic acid 
treatment 4 or 24 hours later (table 2).
Why treatment with anti-T cell MAbs is not 100% successful remains to be 
determined. In some mice with body temperature "35.5°C  anti-T cell treatment may 
be ineffective because of preexisting fatal petechiae as observed by light and electron 
microscopy [1, 4]. This may also explain why recovery from sensitivity to folic acid- 
induced convulsions was not always successful and did not increase when folic acid 
treatment was delayed to 24 hours after anti-T cell treatment.
In summary, our results suggest that mice developing ECM suffer from an increasing 
permeability of the BBB that may further lead to petechiae. CD4 and CD8 T cells are
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involved in the increase of permeability, probably by triggering reactions that are more 
directly involved in damage.
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ABSTRACT
C57B1 mice infected with Plasmodium berghei K173 parasites develop experimental 
cerebral malaria (ECM). TNFa is considered to play an important role in the 
pathogenesis by damaging the endothelial lining causing haemorrhages. A role for a 
TNFa dependent induction of reactive oxygen intermediates (ROI) in L929 cell 
killing was analysed by the addition of antioxidants. TN Fa mediated lysis of L929 
cells was inhibited in a dose dependent way in the presence of the antioxidants 
apocynin, desferal-Zn (DFO-Zn), ethanol or dimethyl sulfoxide (DMSO). Addition 
of catalase or sodium oxide dismutase (SOD) was ineffective. Treatment of P. berghei 
infected mice by sustained release of ethanol or DMSO starting one day before 
infection or by repeated injections of DMSO starting on day 8 after infection 
protected mice against ECM. However, treatment of mice in end-stage disease (body 
temperature "35.5°C ) did not. Mice treated with DMSO did not develop convulsions 
after injection of folic acid indicating that the permeability of the blood-brain-barrier 
remained intact. Treatment with ethanol or DMSO before infection significantly 
inhibited parasitaemia but this inhibition did not explain protection against ECM. 
Mice treated with apocynin or DFO-Zn or SOD transgenic mice were not protected 
against ECM. These data indicate that ROI are involved in the pathogenesis of 
ECM, and that certain antioxidants can protect against ECM while others do not.
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INTRODUCTION
Development of (experimental) cerebral malaria ((E)CM) is associated with high 
plasma concentrations of tumour necrosis factor-a (TNFa). Likewise in CBA mice 
infected with P. berghei ANKA, development of ECM is associated with high 
concentrations of biologically active TNFa which can be prevented by treatment 
with anti-TNFa antibodies (Grau et al. 1987). TNFa is cytotoxic (Matthews & 
Watkins, 1978) and can stimulate upregulation of the expression of adhesion 
receptors (Vlassara et al. 1989; Mackay et al. 1993). Ockenhouse et al. (1992) 
reported that circulating TNFa and interferon-gamma, being elevated during P. 
falciparum  infections, systematically activate postcapillary venular endothelial cells. 
Furthermore, the activated endothelial cells not only bind neutrophils (Varani et al. 
1989; Ward & Varani 1990), monocytes (Carlos et al. 1991) and platelets (Fry et al. 
1980) but also P. falciparum  infected red blood cells (Aikawa 1988; Ockenhouse et al.
1991). The interactions with adherent neutrophils and monocytes cause local release of 
bioactive and noxious agents (Golenser et al. 1992; Chiu et al. 1997) notably cytokines 
(and more TNFa) and ROI (hydrogen peroxide, superoxide anions and hydroxyl 
anions). This can cause membrane perturbation, cell injury and loss of endothelial 
integrity (Bjork et al. 1980; Varani et al. 1989; Ward & Varani 1990; Ward, 1991; 
Sulkowska & Sulkowski 1997). Thumwood et al. (1989) found that treatment with 
antioxidants (butylated hydroxyanisole; BHA) or the combination of superoxide 
dismutase and catalase coupled to polyethylene glycol) prevented ECM in 45-60% of 
Plasmodium berghei ANKA infected AJ or CBA/H mice. In addition, mice on a diet 
containing BHA did not exhibit an increase in the permeability of the blood-brain- 
barrier (BBB) in the course of infection. Thus, oxidant-induced injury of the vascular 
endothelial lining, particularly in the brain, may play an important role in the 
pathophysiology of ECM (for review see Postma et al. 1996). Parallely, TNFa 
mediated cytotoxicity in vitro is inhibited in the presence of the antioxidants BHA 
and 4-hydroxymethyl-2,6-di-t-butylphenol (Brekke et al. 1992) also implicating 
reactive oxygen intermediates (ROI) in this damage.
This study analysed the role of several antioxidants on TNFa induced cytotoxicity in 
the L929 in vitro, as well as the capacity of these antioxidants to prevent ECM in P. 
berghei infected C57Bl mice.
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MATERIALS AND METHODS
Mice: female C57B1/6J mice, aged 6-10 weeks, were obtained from specific pathogen 
free colonies maintained at the Central Animal Facility, University of Nijmegen. All 
mice were housed in plastic cages and received water and standard RMH food (Hope 
Farms, Woerden, The Netherlands) ad libitum.
Parasite: P. berghei K173 (originally obtained from W. Kretschmar, Tübingen, 
Germany) has been maintained by weekly transfer of parasitized erythrocytes (PE) 
from infected into naive mice > 30  years. Experimental mice were infected intra- 
peritoneally (i.p.) with 103 PE from blood of infected donors.
Parasitaemia: thin blood films were made from tail blood on days 8, 9 and 10 after 
infection. They were stained with May-Grünwald and Giemsa solutions and the 
proportion of parasitized red blood cells was determined.
Detection of ECM: ECM was detected as described by Curfs et al. (1992). In brief, 
95% of C57Bl mice infected with 103 P. berghei K173 parasites die early in the second 
week after infection. One day before death a progressive hypothermia develops that is 
strongly correlated with development of haemorrhages in the brain as observed by 
histology (Curfs et al. 1989). The parasitaemia in mice that die of ECM is between 5­
10%, and such mice have a 20% reduction in haematocrit. Mice that show a transient 
hypothermia (in most cases >32°C) survive this critical period but die in the third 
week or later after infection with signs of severe anaemia, a parasitaemia of 20%-40% 
but without detectable cerebral pathology as determined by histology.
End-stage disease: mice infected with P. berghei K173 parasites exhibit a rapidly 
decreasing body temperature, and usually die within 24 hours (Curfs et al. 1989), 8 or 
9 days after infection. Mice are considered to enter end-stage disease when their body 
temperature drops to "  35.5°C (Hermsen et al. 1998).
Body tem perature: measured with a digital thermometer (Technoterm 1200, 
Thermotex, The Hague, Netherlands) introduced into the rectum and read after 10 
seconds.
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Tum our Necrosis F actora  (TNFa): recombinant-murine-TNFa (rec-m-TNFa) was 
generously donated by Dr. G. Adolf, Ernst-Boehringer Institut, Vienna, Austria. The 
specific activity was 1.2 .10 U of TNFa/mg in a TNFa dependent cytotoxicity assay 
using murine LM cells. The endotoxin content was <51 pg/ml.
L929 cell lysis assay: the TN Fa bioassay was performed as described by Aggarwal 
(1985) with minor modifications. Briefly, rec-mTNFa was added to 1 0  L929 cells per 
well in the presence or absence of a concentration range of antioxidants and cultured in 
RPMI 1640 DM (Gibco, Life Technologies, 31870-025) containing 10% foetal calf 
serum (FCS; Integro, Zaandam, The Netherlands) and 8 mg/ml emetine (Sigma) and 
5% C O  in air at a 90% relative humidity at 37°C for 20 h. A TNF-mediated 
cytopathic effect on L929 cells was measured by adding to each well 20 zl EZ4U 
solution (Biomedica, Austria) which is taken up only by live, intact cells and converted 
from a yellow tetrazolium-compound to a red formazan-derivative. After 2 hrs 
incubation at 37°C the optical density was measured in an ELISA reader at 450 nm 
with 620 nm as a reference (Titertek Multiskan MCC/340; ICN, Zoetermeer, The 
Netherlands). The detection limit of the L929 bioassay was 0.5 pg rec-mTNFa/ml.
Apocynin: 4-hydroxy-3-methoxy-acetophenone, acetovanillone 98%, (Jansen 
Chimica, Belgium) was dissolved in 96% ethanol. Saline was used for further dilutions 
and injection. The stock solution was diluted in normal drinking water for treatment 
per os. Osmotic pumps (Alzet 2001, pumping rate 1 zl/hour, 7 days, or Alzet 2002, 
pumping rate 0.5 zl/hour, 14 days) were filled with a solution of apocynin (range 50 - 
200 mM) dissolved in 96% ethanol and implanted i.p. in mice under ether anaesthesia. 
Osmotic pumps filled with 96% ethanol were implanted i.p. as controls. Apocynin 
inhibits production of hydrogen peroxide and superoxide anion (Hart & Simmons,
1992).
Catalase: ( Sigma, C6665, 1540 Units/mg solid) was dissolved in RPMI 1640 DM 
containing 10% FCS. Concentrations used in the L929 cell assay: 15 - 30,000 
Units/ml.
Desferal-Zn (DFO-Zn): was prepared by mixing 110 mM desferal (DFO, Ciba-Geigy 
AG, Bazel, Swiss) and 110 mM ZnSO4.7HO (Merck, Germany; in aqua dest). Alzet
59
Chapter 4
2002 mini-osmotic pumps, pumping rate 0.5 ul/hour for 14 days, were filled with 
DFO-Zn solution and implanted i.p. in mice under ether anaesthesia. Mini-osmotic 
pumps filled with saline were used as controls. DFO-Zn is an inhibitor of the 
production of hydroxyl radicals (Ophir et al. 1994).
Dimethyl sulfoxide (DMSO): (Merck, Germany) was either diluted in saline and 
injected i.p. or mini-osmotic pumps were filled with DMSO and implanted i.p. DMSO 
is an inhibitor of the production of superoxide anions and hydroxyl radicals 
(Grankvist, 1981; Miller & Raleigh, 1983).
Ethanol: (Merck, Germany) 100% was diluted in saline and injected i.p. or mini- 
osmotic pumps were filled with ethanol and implanted i.p. Ethanol, a hydroxyl radical 
scavenger (Kumagai et al. 1991) was used in a concentration range of 0.5 - 3% in 
the L929 cell assay.
SOD-transgenic mice: carry the human CuZn-superoxide dismutase gene (SOD-1). 
Mice with the following genetic background were used: F2 = F1(J C57Bl/6J, DBA) x 
F1(N Balb/C, C57Bl/6J). In addition, mice homozygous for TgHS-69 or TgHS-51 and 
control F2 mice were included in the experiments (Tg=Transgenic; HS=Human 
Cu/Zn SOD-1; respectively 69 and 51=Human Cu/Zn SOD-1 gene integrated at 
different sites in the mouse genome; Shanley et al. 1992).
Superoxide dismutase: (Sigma, S2515, EC 1.15.1.1., 2000 Units/mg solid) was 
diluted in RPMI containing 10%FCS. Concentrations used in the L929 cell assay: 2 - 
4.000 Units/ml.
Folic acid induced convulsions: infected mice that develop ECM and have a body 
temperature "  35.5°C show generalised convulsions upon i.v. injection of 5 mg folic 
acid (Genfarma, Maarsen, Netherlands), in 0.2 ml saline, adjusted to pH 7 with 1 M 
NaOH (Hermsen et al. 1998). Mice were observed for the development of convulsions 
after injection of folic acid for a period of 90 minutes.
Statistical analysis: all data are expressed as mean ± SD. Student's t-test was used for 
statistical analysis. P < 0 .0 5  was considered significant.
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RESULTS
Effect of antioxidants on rec-m-TNFa dependent cytotoxicity in vitro 
Tumour necrosis factor-a (TNFa) is cytotoxic for L929 cells in a concentration 
dependent manner (Aggarwal 1985; starting points in fig. 1a,b,c). The presence of 
either apocynin, desferal-Zn (DFO-Zn) or dimethyl sulfoxide (DMSO) during 
incubation of L929 cells with rec-m-TNFa, inhibited TNFa-dependent cytotoxicity in 
a concentration dependent way (fig. 1a,b,c). Similar data were obtained with ethanol 
in a dose range 0.5 - 3% (data not shown). The presence of catalase or sodium oxide 
dismutase (SOD) in the L929 test system had no effect on TNFa-mediated cytotoxicity 
(data not shown).
Effect of antioxidants on the development of Plasmodium berghei K173 induced 
experimental cerebral m alaria (ECM)
The effect of several different regimens of apocynin treatment on ECM was analysed. 
Apocynin was administered either via the drinking water (range 8 - 600 mg/L starting 
one day before infection, or orally (by gastric tube, 1 mg in 0.2 ml saline) on day 8, or 
intravenously (0.25 mg in 0.2 ml saline/mouse) on days 7-11 after infection and none 
of these treatments protected against ECM (data not shown). Apocynin, dissolved in 
ethanol and administered via osmotic pumps (range 50 - 200 mM; release rate 1 
zl/hour) implanted intra-peritoneally (i.p.) one day before infection also did not protect 
against ECM (table 1). Finally, i.p. injection of 0.25 mg apocynin in ethanol 96% on 
day 7 (n=3), day 8 (n=3), day 9 (n=3) or day 10 (n=3) after infection did not 
protect against ECM. Sustained release of 96% ethanol alone from 1 day before 
infection onwards, which was originally included as a solvent control in the apocynin 
studies, protected against ECM (table 1), but injection (i.p.) of 0.5 ml 10% ethanol on 
day 8 (n=3) or on day 9 (n=3) after infection did not protect.
Desferal-Zn (55, 110 or 220 mM), administered by sustained release from mini- 
osmotic pumps implanted i.p. one day before infection or on day 6 after infection, did 
not protect against ECM (table 1).
DMSO (100%) delivered via mini-osmotic pumps implanted one day before infection 
protected mice against ECM (table 1), but implantation 6 days after infection (n=6) 
did not protect. In addition, 4 out of 6 (67%) mice were protected against ECM by i.p. 
injection of 0.2 ml of 0.25% DMSO in saline on 3 consecutive days starting 8
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Figure 1: Effect of increasing concentrations of apocynin, desferal-Zn (DFO-Zn) or DMSO 
on the TNFa dependent lysis of L929 cells. •  = no rec-m-TNFa, 0 = 5  pg/ml rec-m- 
TNFa, □  = 20 pg/ml rec-m-TNFa, V = 80 pg/ml rec-m-TNFa. Data are presented as the 
mean ± SD of triplicate determinations.
*: P=  < 0.05 as compared to TNFa control.
Reduction of the optical density reflects lysis of L929 cells.
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days after infection, when mice had a normal body temperature, but no protection was 
observed when DMSO was administered to mice in end-stage disease (body 
temperature "  35.5°C; days 9 and 10 after infection, n=6).
Effect of antioxidant treatm ent on parasitaemia
Treatment with DMSO or ethanol 96% via mini-osmotic pumps implanted one day 
before infection significantly inhibited parasitaemia as compared to their infected 
controls while sustained release of apocynin in ethanol or DFO-Zn from 1 day before 
infection onwards did not (table 1). Further analysis showed that the inhibition of 
parasitaemia by DMSO or ethanol occured independent of protection against ECM.
Sensitivity of DMSO treated, infected mice to folic acid-induced convulsions
Mice in the course of development of ECM, particularly in end stage disease develop 
convulsions upon folic acid treatment which is indicative of an increased permeability 
of the BBB (Hermsen et al. 1998). Table 2 shows that all infected mice treated with 
DMSO released from implanted mini-osmotic pumps from 1 day before infection 
onwards and were protected against ECM (78%, table 1) did not develop sensitivity to 
the epileptogenic activity of folic acid treatment during the whole infection period.
Table 2: Effect of DMSO treatment by sustained release from mini-osmotic pumps 
implanted i.p. in mice one day before infection with 103 Plasmodium berghei K173 
parasites on folic acid induced convulsions.
Treated* with Number of mice developing
5 mg folic acid convulsions/
total number
Saline/no 8/8
Day 9 after infection 0/3
Day 15 after infection 0/3
Day 20 after infection 0/3
*: only mice with a body temperature between 35.5° and 30°C received folic acid.
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Table 1: Effect of treatment with apocynin, desferal-Zn, ethanol or dimethyl sulfoxide (DMSO) on parasitaemia and development 
of experimental cerebral malaria in C57B1/6J mice infected with Plasmodium berghei K173 parasites.
Treatment Mode of treatment ECM Parasitaemia at day 8 post infection
protected/total
n/n % controls treated mice treated mice
CM protected CM unprotected
Saline
No treatment 
Mini-osm. pump; day -1 
i.p. injection; day 8,9 and 10
1/32
2/10
1/10
3
20
10
Apocynin/
ethanol
Mini-osm. pump; day -1 11/56 20 22.9 ± 14.9 
(n=17)
14.3 ± 8.1
(n=56)
N.D. N.D.
Ethanol Mini-osm. pump; day -1 5/9 56* 20.2 ± 10.8 
(n = ll)
5.1 ± 3.0+ 
(n=9)
±
(n=5)
±
(n=4)
Desferal-Zn Mini-osm. pump; day -1 4/24 17 ±
(n=6)
±
(n=24)
N.D. N.D.
DMSO Mini-osmotic pump; day -1 28/36 78* ±
(n= 18)
±
(n=36)
±
(n=28)
±
(n=8)
DMSO i.p. injection; day 8, 9 and 10 4/6 67* N.D. N.D.
*: P < 0.05 as compared to mice with saline containing mini-osmotic pumps implanted on day -1.
■f: P<0.05 as compared to parasitaemia of their controls.
ECM development in SOD-transgenic mice infected with Plasmodium berghei 
K173.
Homozygous SOD-transgenic TgHS-69 or TgHS-51 mice infected with P. berghei 
K173 developed ECM after infection just as their control F2 littermates (table 3). 
Furthermore, no significant difference was found between the parasitaemias observed 
in P. berghei infected homozygous TgHS-69 or TgHS-51 mice and their controls (data 
not shown).
Table 3: Development of experimental cerebral malaria in SOD transgenic (TgHS-69 and 
TgHS-51), control F2 and control C57B1/6J mice infected with 103 Plasmodium berghei 
K173 parasites.
Mice ECM protected/total
n/n %
SOD-TgHS-69 0/15 0
SOD-TgHS-51 0/5 0
Control F2 1/24 4
Control Black/6J 0/6 0
DISCUSSION
C57B1 mice infected with P. berghei K173 develop ECM characterized by leukocyte 
adherence to the vascular endothelial lining, edema, and petechiae in the brain (Curfs 
et al. 1989). Local production of TNFa and/or ROI by the adherent leukocytes can 
cause cell injury and loss of endothelial integrity (Bjork et al. 1980; Varani et al. 
1989; Ward & Varani 1990; Ward, 1991; Sulkowska & Sulkowski 1997).
This study shows that TNFa dependent lysis of L929 cells in vitro can be inhibited 
by a number of antioxidants that either inhibit the production of (apocynin, DFO-Zn 
and DMSO) or scavenge (ethanol) produced reactive oxygen intermediates (ROI).
In the L929 cytotoxicity assay binding of TN Fa to its membrane receptors triggers 
internal production of ROI which can lead to cell-lysis (Beyaert & Fiers, 1994). 
Whereas, presence of apocynin, DFO-Zn, DMSO or ethanol prevented TNFa 
dependent cell lysis, presence of catalase or SOD did not protect. Probably in
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contrast to apocynin, DFO-Zn, DMSO and ethanol, catalase and SOD cannot cross 
the cell membrane and, therefore cannot exert an effect on internally produced ROI. 
TNFa plays an important role in the pathogenesis of ECM in the P. berghei-AN K A  
model (Grau et al. 1987) and treatment with rec-h-TNFa during infection 
immediately provokes an ECM like syndrome (Curfs et al. 1993). Therefore the 
possibility that a TNFa dependent production of ROI is involved in the damage of 
endothelial cells during the development of ECM was investigated.
ROI secreted by activated macrophages can damage endothelial cells (DelMaestro, 
1982, Wei et al. 1985) and adherent macrophages are observed in the brain 
pathology of all ECM models described so far (Polder et al. 1983, Grau et al. 1986; 
Curfs et al. 1992). Furthermore, extensively triggered endothelial cells can produce 
an overshoot of ROI, that are harmful for these cells (Beyaert & Fiers, 1994). 
Finally, Thumwood et al. (1989) observed that treatment with butylated 
hydroxyanisole, a free radical scavenger, or treatment with the combination of 
catalase and SOD coupled to polyethylene glycol protected a proportion of A/J and 
CBA/H mice infected with P. berghei ANKA against ECM. These observations 
argue for a role of ROI in the pathogenesis of ECM.
Our data on the effect on antioxidants only partly confirm this hypothesis. 
Administration of ethanol, a hydroxyl radical scavenger (Kumagai et al. 1991) and 
DMSO, an inhibitor of the production of superoxide anions and hydroxyl radicals 
(Grankvist, 1981; Miller & Raleigh, 1983) protected mice against ECM, whereas 
apocynin and DFO-Zn did not protect.
DMSO and ethanol treatment administered before infection inhibited parasitaemia, 
but this was not specific for the mice which were protected against ECM. A 
comparable observation was made in the same model after treatment of infected mice 
with rec-h-TNFa (Postma et al. 1998) and also in the P. berghei ANKA mouse 
model when mice were treated with the antioxidant BHA (Thumwood et al. 1989). 
Previous observations in our model (Curfs et al. 1992) showed that ECM developed 
equally well when mice were infected with a range of 10-10,000 parasites which 
results in a three days delay in the course of the parasitaemia. The inhibition 
observed after antioxidant treatment is within this range. Thus, ROI probably 
interferes with parasite proliferation but their role in development of ECM is 
mediated through other mechanisms of action.
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In addition, it is important to note that the antioxidants DMSO and ethanol were only 
effective when present during infection and did not protect mice in end-stage disease 
(body temperature "35.5°C ). Thumwood et al. (1989) succeeded in protecting mice 
against ECM with the combination catalase and SOD coupled to polyethylene glycol 
or BHA also by treatment during infection. The observation that DMSO treatment 
also prevented the development of convulsions after administration of folic acid is in 
agreement with the observation of Thumwood et al. (1989) that damage of the BBB 
scored by uptake of Evans blue or radiolabeled erythrocytes was prevented by BHA 
treatment. Thus, according to these data ROI are involved in the pathogenesis of 
ECM but a direct link between ROI and the development of haemorrhages has not 
been established. The results may suggest that ROI are involved in modulation of the 
immune response to the parasite contributing to the development of ECM and that 
antioxidant treatment can prevent this. Depletion of either CD4 or CD8 cells protects 
against ECM (Hermsen et al. 1997), but DMSO treatment did not change numbers 
of these cells in the spleen or in the peripheral blood as compared to infected 
controls on day 8 after infection (unpublished data).
Administration of ethanol prevented mice against ECM while apocynin dissolved in 
ethanol did not (table 1). Recently, Norton et al. (1998) descibed that ethanol can 
also act as an inducer of ROI. This could explain the failure of the combination of 
apocynin and ethanol to protect against ECM. In addition, recent observations in our 
model showed that treatment with an inducer of ROI, alloxan, could protect mice in 
end stage disease against ECM (Hermsen et al. Alloxan protects Plasmodium  
berghei infected mice in end-stage disease against experimental cerebral malaria. 
submitted).
Antioxidants may also inhibit NFkB preventing upregulation of adhesion molecules 
(Weber et al. 1994), but a possible role in ECM remains to be determined.
Results obtained with apocynin and DFO-Zn do not support a role for ROI in ECM 
and the reason is not clear. Apocynin inhibits production of hydrogen peroxide and 
superoxide anion (Hart & Simmons, 1992) and inhibits ROI production by activated 
mononuclear cells in vitro (Beukelkamp et al. 1995). In addition, 0.06 mM apocynin 
administered in the drinking water reduced joint swelling in collagen induced 
arthritis in rats (Hart et al. 1990). On the other hand, peroxidase deficient cells such 
as lymphocytes and mature macrophages (Welch et al. 1980), which are involved in 
pathology of ECM, are insensitive to apocynin (Hart et al. 1992).
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DFO-Zn is an inhibitor of the production of hydroxyl radicals (Ophir et al. 1994) 
and its failure to protect against ECM might relate to the use of an insufficient 
regimen. Our sustained release system was limited to a maximal daily dose of 2 
mg/day/animal. Golenser et al. (1997) observed reduction in parasite proliferation 
and protection against ECM in mice that received a polymeric implant containing 
140 mg DFO subcutaneously on day 6 postinfection. In addition, protection against 
ischemia due to reperfusion injury in the rat retina was obtained with 7.5 mg injected 
5 minutes before reperfusion (Ophir et al. 1994).
SOD-transgenic mice, with a 2.3 to 6 fold elevated intracellular SOD activity in 
various tissues including erythocytes (Shanley et al. 1992), were not protected 
against ECM. Despite increased SOD concentrations in erythrocytes parasitaemia 
was the same as in infected controls. Thumwood et al. (1989) reported protection 
when mice were treated with a mixture of SOD and catalase coupled to polyethylene 
glycol, but the mechanism e.g. prolonged circulation or cell uptake, was not 
established. One possible explanation for the lack of effect in SOD-trangenic mice is 
that an increment in SOD alone is not sufficient (Golenser et al. 1998).
In summary, the data indicate that ROI are involved in the pathogenesis of ECM. 
ROI generated during infection contribute to the development of immunopathological 
reactions leading to ECM rather than causing heamorrhages.
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ABSTRACT
C57B1 mice infected with 103 Plasmodium berghei K173 parasites develop 
experimental cerebral malaria (ECM). Mice in end-stage disease, with a body 
temperature "35.5°C , which is associated with an increased permeability of the blood- 
brain-barrier, were treated with the rapidly acting antimalarials alloxan or artemether. 
Treatment with alloxan protected all mice in end-stage disease against ECM while 
none of the artemether-treated mice were protected. Treatment with alloxan resulted in 
a 6 fold reduction in parasitaemia at 2 hours after treatment while reduction of 
parasitaemia after artemether treatment was observed after one day. Pretreatment with 
a mixture of the anti-oxidants: desferal and apocynin reduced the alloxan dependent 
protection against ECM but not the antiparasitic activity. These results indicate that 
alloxan-induced hydroxyl radicals prevent lethality by ECM and that this activity is 
independent of its parasiticidal action.
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INTRODUCTION
C57Bl mice infected with Plasmodium berghei K173 parasites develop experimental 
cerebral malaria (ECM)[1]. One day before death (approximately at day 9) a 
progressive hypothermia develops which strongly correlates with an increased 
permeability of the blood-brain-barrier (BBB) [2] and development of haemorrhages in 
the brains [1]. ECM is associated with leukocyte adherence to the microvascular 
endothelium, edema and petechiae in the brains [3, 4].
Mice in end-stage ECM can be protected by treatment with anti-CD4 or anti-CD8 
mAbs [5] or anti-LFA1 [6] suggesting that lymphocytes and more specifically those 
adhering to brain vascular endothelial cells are involved in the pathogenesis of 
petechiae. A current hypothesis is that adherent immunocompetent cells [4] locally 
stimulated by parasites or their products are involved in destabilization of the BBB. 
Since elimination of parasites by fast acting antimalarials may protect against fatal 
ECM, the effects of treatment with alloxan or artemether was analysed on parasitaemia 
and late stage ECM. Alloxan is an inducer of hydroxyl radicals [7] and a rapidly 
acting antiparasitic drug which has been shown to reduce parasitaemia and cure P. 
vinckei-infected mice [8]. Artemether acts not as fast as alloxan but clears parasitaemia 
faster than chloroquine [9]. Treatment with chloroquine could not prevent ECM in 
mice with end-stage disease [5]. The antiparasitic activity of artemether is most likely 
caused by free-radical damage of parasite membrane systems [9]. Radical production 
can be inhibited by desferal which is an iron chelator blocking radical formation by the 
iron-catalyzed Haber-Weiss reaction [8, 10] and also an antiparasitic drug [11, 12, 13]. 
Apocynin is another anti-oxidant that can block an oxidative burst [14] and treatment 
with apocynin inhibits joint swelling in collagen induced arthritis in rats [15]. A 
mixture of desferal and apocynin was administered before treatment with alloxan to 
analyse the possibility that the alloxan mediated effect on parasitaemia and protection 
against ECM is mediated by the induction of hydroxyl radicals.
MATERIALS AND METHODS
Mice: female C57Bl/6J mice, ages 6-10 weeks, were obtained from specific pathogen­
free colonies maintained at the Central Animal Facility, University of Nijmegen. All
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mice were housed in plastic cages and received water and standard RMH food (Hope 
Farms, Woerden, The Netherlands) ad  libitum.
Parasite: P. berghei K173 (originally obtained from W. Kretschmar, Tübingen, 
Germany) has been maintained by weekly transfer of parasitized erythrocytes (PE) 
from infected into naive mice > 3 0  years. Experimental mice were infected intra- 
peritoneally (i.p.) with 1 0  PE from blood of infected donors.
Parasitaemia: thin blood films made from tail-blood on days 8, 9 and 10 after 
infection. They were stained with May-Grünwald and Giemsa solutions and the 
proportion of parasitized red blood cells was determined.
Detection of ECM: ECM was detected as described by [3]. In brief, 95% of C57Bl 
mice infected with 10 P. berghei K173 parasites die early in the second week after 
infection. One day before death a progressive hypothermia develops that is strongly 
correlated with development of haemorrhages in the brains as observed by histology 
[1]. The parasitaemia in mice that die of ECM is between 5-10%, and such mice have 
a 20% reduction in haematocrit. Mice that show a transient hypothermia (in most cases 
>32°C ) survive this critical period but die in the third week or later after infection 
with signs of severe anemia, a parasitaemia of 20%-40% but without detectable cere­
bral pathology as determined by histology.
End-stage disease: mice infected with P. berghei K173 parasites exhibit a rapidly 
decreasing body temperature, and usually die within 24 hours [1] about 8 or 9 days 
after infection. Mice are considered to be in end-stage disease when their body 
temperature drops to "  35.5°C [2].
Body temperature: was measured with a digital thermometer (Technoterm 1200, 
Thermotex, The Hague, Netherlands) introduced into the rectum and read after 10 
seconds.
Heamatocrit: measured in heparinized 10 z l Drummond® capillaries (Drummond 
scientific company, Pennsylvania, USA) after centrifugation for 5 minutes in a 
Hawksley® haematocrit centrifuge.
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Glucose levels: was measured with the digital one touch glucose meter (Lifescan, 
Beerse, Belgium). Glucose concentrations are expressed as mmol/L.
Artemether: 12-P-methyldihydro-quinghaosu, 100 mg/ml, (arteminh, Euro-vina, 
Geel, Belgium) was diluted in arachis oil and injected intraperitoneally.
Alloxan: alloxan monohydrate (Sigma A7413) was dissolved in saline and injected 
intra-peritoneally. To prevent damage to the pancreatic beta-cells 0.05 mg D- 
glucose/0.2 ml saline was injected i.p. 15 minutes before the injection of alloxan [16].
Desferal/Apocynin: desferal (Ciba, Arnhem, Netherlands) was dissolved in distilled 
* 0  to 220 mM and 1:1 diluted with 2 times concentrated phosphate buffered saline 
(PBS).
Apocynin (Acetovanillone, 98%, Jansen Chimica, Belgium) was dissolved in 96% 
ethanol and further diluted in PBS. Equal volumes of desferal and apocynin were 
mixed and 0.2 ml/mouse was injected i.p. 10 minutes before alloxan treatment. Thus, 
mice received 125 mg/kg desferal and 12.5 mg/kg apocynin. In a dose finding study of 
desferal it was observed that higher concentrations were toxic (data not shown).
Statistical analysis: all data are expressed as mean ± SD. For statistical analysis the 
Student's V-test was used. P  values < 0 .05  were considered to be significant.
RESULTS
When Plasmodium berghei infected mice were treated with alloxan (250 mg/kg) on 
day 8 after infection, 4/5 mice were protected against experimental cerebral malaria 
(ECM; table 1). The therapeutic range of alloxan is rather narrow since 500 or 150 
mg/kg or less showed no effect. Further analysis showed that all mice in end-stage 
disease (n=8; body temperature "35.5°C) were protected after treatment with 250 
mg/kg alloxan (table 2), while only 42% of the mice at earlier stages of development 
of ECM (body temperature >35.5°C ) were protected. No protection against ECM 
was observed after single treatment with artemether (5 mg/kg - 20 mg/kg) 8 days after
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infection (table 2) nor after treatment with 10 mg/kg given on days 8 and 9 (data not 
shown).
Table 1: Effect of alloxan on protection against development of Plasmodium 
berghei induced experimental cerebral malaria (ECM) in C57B1/6J mice.
Dose* Number of mice protected against ECM /
(mg/kg) total number of alloxan treated mice
500 0/5
250 4/5
150 0/5
75 0/5
Treatment with alloxan on day 8 after infection.
To determine whether the capacity of alloxan to induce hydroxyl radicals played a role 
in its protective effect, a mixture of the anti-oxidants desferal and apocynin 
(DFO/Apo) was administered 10 minutes before injection of alloxan. Treatment of 
infected mice with DFO/Apo alone did not protect against ECM (table 2). Treatment 
with DFO/Apo before alloxan reversed protection in mice in end-stage disease (from 
100 to 47%) as compared to alloxan alone. DFO/Apo pretreatment did not affect the 
outcome of mice at earlier stages of development of ECM (table 2).
Figure 1 shows the effect of treatment with alloxan (250 mg/kg) or artemether (20 
mg/kg) on parasitaemia. Reduction of the parasitaemia and of the number of viable 
parasites as judged from pycnosis of parasites in bloodsmears was already significant 2 
hours after treatment with alloxan, but only 24 hours after artemether treatment. 
Pretreatment with DFO/Apo did not affect the antiparasitic activity of alloxan (fig. 1). 
Furthermore, parasitaemia was not different in mice that were protected or not against 
ECM after treatment with DFO/Apo and alloxan (fig. 1).
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Table 2: Effect of alloxan or artemether on protection against development of Plasmodium 
berghei induced experimental cerebral malaria (ECM) in C57B1/6J mice.
Treatment* Dose Pretreatment+ Number of mice protected against ECM
(mg/kg) / total number
Body temperature
early ECM end-stage ECM
(>35.5°C) (<35.5°C)
Alloxan 250 Saline 3/7 8/8
Alloxan 250 DFO/Apo 2/4 7/15+
- - DFO/Apo 0/4 0/10
Artemether 5 None 0/4 0/4
10 None 0/9 0/13
20 None None 0/6
Saline 0/4 0/18
Saline/oil 0/1 0/2
*: Administration on day 8 after infection.
■f: Pretreatment was carried out 10 minutes before treatment with alloxan
=(=: P < .05 as compared to alloxan treated mice with end-stage disease (body temperature
Clark & Hunt [8] observed hemolysis 2 hours after alloxan injection in P. vinckei 
infected mice which was not confined to parasitized erythrocytes. In our study alloxan 
treated mice have a significantly lower haematocrit level (43% ± 2; n = 5) as compared 
to sham-treated infected mice (48% ± 1; n=5; P < 0 .05 ) 2 hours after treatment. 
Treatment with DFO/Apo before alloxan prevented the alloxan dependent decrease 
(Ht= 48% ± 1; 2 hours after treatment; n = 5) but a possible to protection against 
ECM could not be determined because of the small numbers of mice involved. 
D-glucose was administered to mice 15 minutes before alloxan to prevent 
hypoglycaemia as a result from P pancreatic cell damage [16, 8]. The glucose 
concentration (7.4 ± 1.2, n = 5 , 120 min.; 6.3 ± 0.3, n = 5 , 7 days after alloxan 
treatment) were not significantly different from those of sham-treated infected (6.8 ±
0.8, n = 4) and uninfected controls (7.1 ± 0.4, n=5).
<35.5°C)
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Figure 1: Parasitaemia (mean and SD) after treatment with alloxan or artemether on day 8 
after infection of C57B1/6J mice with 103 Plasmodium berghei K173 parasites. • = Alloxan 
treated mice, 250 mg/kg, n=6; =Artemether treated mice, 20 mg/kg, n=6; _=  
Alloxan+DFO/Apo treated mice which are protected against ECM, n=5; ▼ = 
Alloxan+DFO/Apo treated mice which are not protected against ECM, n=4.
*: p < 0.05 as compared with parasitaemia at day 8 after infection and before drug treatment.
DISCUSSION
This study shows that mice can be protected against ECM by treatment with alloxan 
which is particularly effective in end-stage disease (body temperature is "35.5°C). 
Treatment with artemether late in the infection did not protect against ECM in our 
studies whereas treatment (5 mg/kg daily for three days) starting 5 or 6 days after 
infection protected P. berghei ANKA infected mice against ECM [17]. This difference 
in effectivity of artemether treatment may be explained by the earlier and longer time 
period of the antiparasitic treatment before ECM occurs in the study of Prada et al. 
[17] as compared to our study.
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The ECM protective effect of alloxan could be mediated through one or more of its 
activities: a strong and rapid antiparasitic activity [8, 18], the capacity to generate 
hydroxyl radicals [7] or the capacity to lyse erythrocytes [8].
Alloxan treatment caused a 6-fold reduction of the parasitaemia 2 hours later, whereas 
reduction of parasitaemia by treatment with artemether only became apparent 24 hours 
later. Our data also show, however, that the antiparasitic activity of alloxan and 
protection against ECM are not directly linked. Alloxan treatment strongly reduced 
parasitaemia both in ECM protected and non-protected mice and did not prevent 
recrudescences one week after alloxan treatment. Finally, neutralization of the ECM 
protective effect of alloxan treatment by pretreatment with the anti-oxidants DFO and 
apocynin did not abolish the antiparasitic activity of alloxan. These results may 
indicate that apart from its antiparasitic activity, other activities of alloxan are involved 
in protection against ECM. The assumption that rapid parasite clearance by alloxan is 
not the critical factor in protection against ECM may be supported by results described 
by Hensbroek van et al. [19] who observed that although P. falciparum  parasites 
(sequestered in brain microvasculature) in children with cerebral malaria were cleared 
from the circulation significantly faster by artemether than by quinine, the fatality rate 
was similar for both drugs.
The observation that pretreatment with DFO and apocynin can abolish the alloxan 
dependent protection against ECM points to a role of the generation of hydroxyl 
radicals by alloxan. Generation of ROI, measured as hydrogen peroxide, in relation to 
antiparasitic treatment has been described by Prada et al. [17] though a causative 
relation was not described. Sensitivity of the parasite to ROI mediated damage has 
been shown before [20, 21] and possibly explains the antiparasitic activity of alloxan 
and artemether [8, 9].
In addition to parasite killing alloxan also caused lysis of uninfected erythrocytes 
confirming observations of Clark et al. [8] in P. vinckei infected mice. In addition, this 
haemolysis could be prevented by pretreatment with anti-oxidantia. Thus, hydroxyl 
radicals generated by alloxan are probably involved in erythrolysis. Treatment with 
DFO/Apo before alloxan prevented lysis of uninfected erythrocytes but not killing of 
parasites. This may indicate that the antioxidant effect of DFO/Apo on alloxan induced 
ROI is incomplete and that parasites are more sensitive to the effect of ROI than 
erythrocytes. The capacity of the hydrophilic DFO to enter
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parasitized red blood cells is rather low [22, 23, 24]. Inhibition of the antiparasitic 
effect of alloxan by pretreatment with 200 mg/kg of DFO was observed by Clark et a l. 
[8] in P. vinckei infections in CBA/CaH mice, but this regime was too toxic in our P. 
berghei model, where only 125 mg/kg could be administered maximally.
The observation that alloxan causes damage of pancreatic P cells and diabetes [25] and 
lyses of erythrocytes and killing of parasites might indicate that alloxan also affects 
other as yet undefined cells (e.g. T cells) and that such cells or their products play a 
role in development of ECM. Mice infected with P. berghei K173 parasites exhibit a 
rapidly decreasing body temperature and usually die within 24 hours [1] and light- and 
electronmicroscopical analysis show an increasing adherence of white blood cells to 
the brain vascular endothelium [4]. Possibly, alloxan interferes with the activity of 
these adhering cells preventing damage to the endothelial lining. Previous work has 
shown that depletion of CD4 or CD8 T-cells in end-stage disease mice can protect 
against ECM [5], however, an effect of alloxan on T-cell activity has not been 
described.
Artemether treatment did not protect against ECM, despite its capacity to generate free 
radicals [9, 26, 27]. Our studies suggest that artemether treatment did not generate 
enough or the right type of free radicals or to the appropriate cells in time to be 
effective against the rapidly evolving ECM. Thus, artemether treatment still requires 
24 hours to show a substantial effect on parasites and if this is indicative for effects on 
other cells that play a role in development of ECM the artemether dependent induction 
of ROI might be too slow to be effective in the protection against ECM. Alloxan 
treatment protected against ECM more efficiently when given to mice in end stage 
disease ("35.5°C) than at an earlier stage (> 35 .5°C ; table 2). This may reflect a 
narrow timewindow for effective treatment with alloxan. Such a timewindow has been 
described for treatment of sepsis in which administration of anti-TNF is likely to 
provide the most benefit in patients with severe sepsis or early shock, but not those 
with refractory shock [28].
In summary, these results show that alloxan treatment protects P. berghei-infected 
mice in end-stage disease, i.e. when the permeability of the blood-brain-barrier is 
already disturbed, against fatal ECM. The capacity of alloxan to generate hydroxyl 
radicals, rather than its fast acting antiparasitic activity is probably involved in the 
mechanism of protection.
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ABSTRACT
Administation of neutralizing anti-TNFa antibodies did not prevent Plasmodium  
berghei induced cerebral malaria (ECM) in C57B1/6 mice, when given at different 
dosages and time intervals. Elevated concentrations of immunoreactive TNFa were 
found in the circulation but no bioactive TNFa could be detected in mice developing 
ECM. Furthermore, elevated TNFa receptor concentrations were measured in the 
plasma of mice developing ECM. Plasma of these mice neutralized bioactive recombi- 
nant-mouse TNFa indicating that a part of the plasma TNFa-receptors were not 
complexed with TNFa. The apparent absence of free TNFa probably explains why 
treatment with antibodies against TNFa failed to prevent development of ECM.
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INTRODUCTION
Experimental cerebral malaria (ECM) can be induced in CBA mice by experimental 
infection with Plasmodium berghei ANKA (reviewed Eling & Sauerwein 1995). 
Development of ECM is closely associated with high serum concentrations of 
immunoreactive Tumor Necrosis Factora (TNFa), measured by ELISA, (Clark et al. 
1990) and of bioactive TNFa, measured by bio-assay, (Grau et al. 1987, Neill & Hunt
1995). In mice with high concentrations of bioactive TNFa ECM can be prevented by 
treatment with anti-TNFa antibodies (Grau et al. 1987), and transgenic mice expres­
sing high levels of soluble fusion protein TNFaR-P55 are markedly protected against 
CM (Garcia et al. 1995).
In human P. falciparum  malaria high concentrations of immunoreactive TNFa have 
been associated with both disease severity and cerebral malaria (Grau et a l . 1989, 
Kwiatkowski et al. 1990). Recent studies have shown that children homozygous for the 
TNF2 allele, a variant of the TNFa gene promotor region, which corresponds to a 
high production capacity of TNFa, have a higher risk for CM (McGuire et al. 1994). 
However, in other studies the relation between plasma concentrations of immunore- 
active TNFa and clinical outcome was unclear (Shaffer et al. 1991; Yamada-Tanaka et 
al. 1995). Whilst a number of studies (Kern et al. 1992, Molyneux et al. 1993 and 
Kossodo, Houba & Grau 1995) have detected high levels of immunoreactive TNFa in 
the plasma of patients with complicated P. falciparum  malaria, very low 
concentrations of bioactive TNFa have been reported. Strongly elevated concentrations 
of soluble TNFa receptors P55 (s-TNFaR-P55) and P75 (s-TNFaR-P75) have also 
been observed in the sera of such patients (Kern et al. 1992; Molyneux et al. 1993; 
Deloron et al. 1994). Importantly treatment with anti-TNFa MAbs did not cure 
cerebral malaria in children (Kwiatkowski et al. 1993).
It can be concluded from both murine and human studies that bioactive TNFa is the 
important denominator for success of anti-TNFa antibody treatment rather than immu- 
noreactive TNFa. We have studied the effect of anti-TNFa antibodies, that neutralize 
bioactive TNFa, on the development of Plasmodium berghei K173 induced cerebral 
malaria in C57Bl mice. The results have been related to concentrations of immunore­
active and bioactive TNFa and of soluble TNFa receptors.
87
Chapter 6
MATERIALS AND METHODS
Mice: Female C57Bl/6J mice, aged 6-10 weeks, were obtained from specific pathogen 
free colonies maintained at the Central Animal Facility of the University of Nijmegen. 
All mice were housed in plastic cages and received water and standard RMH food 
(Hope Farms, Woerden, The Netherlands) ad  libitum.
Parasite: Plasmodium berghei K173 was maintained by weekly transfer of parasitized 
erythrocytes (PE) from infected into naive mice. Experimental mice were infected 
intraperitoneally with 10 PE from blood of infected donor animals of the same strain 
and sex.
Parasitaemia: Thin blood films were made from tail-blood, stained with May-Grun- 
wald and Giemsa's solutions, and the proportion of parasitized red blood cells was 
determined.
Detection of experimental cerebral malaria: The detection of ECM was performed 
as described by Curfs et al. (1992). Briefly, 95% of C57Bl mice infected with 1 0  P. 
berghei K173 parasites die early in the second week after infection. One day before 
death a progressive hypothermia develops which is strongly correlated with develop­
ment of haemorrhages in the brain as observed by histology (Curfs et al. 1989). The 
parasitaemia in mice that die from ECM is between 5 and 10%, and such mice have a 
20% reducion of the haematocrit. Mice that show a transient hypothermia (in the 
majority of cases >32°C ) survive this critical period but die in the third week or later 
after infection with severe anaemia, a parasitaemia between 20 and 40 % but without 
any noticeable cerebral pathology.
Body temperature: Body temperature was measured with a digital thermometer 
(Technoterm 1200) introduced into the rectum and read after 10 s.
Lipopolysaccharide: LPS E. coli phenol extract was obtained from Sigma (L-3129), 
dissolved in pyrogen-free saline and injected intraperitoneally. Body-temperature was 
measured and plasma collected 1.5 hours after the LPS injection when TNFa levels 
were expected to be maximal (Fong et al. 1989).
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Collection of plasma: Blood was collected in endotoxin free tubes (4°C) which contained 
endotoxin free (LAL assay) heparin (NPBI, The Netherlands). Plasma was col lected by 
centrifugation within 20 min. after bleeding and stored at -20°C.
Tumour Necrosis Factor. (TNFa): Recombinant-murine-TNF a (rec-mTNFa) was 
generously donated by Dr. G. Adolf, Ernst-Boehringer Institut, Vienna, Austria. The specific 
activity was 1.2.107U/mg in murine LM cells. The endotoxin content was <51 pg/ml.
Anti-TNFa: Neutralizing (Echternacher et al. 1990) rat anti-murine TNF a MAbs produced 
by V1Q hybridoma cells (gift of P.H. Krammer, Heidelberg, FRG) were used. Pristane 
primed nude mice were injected i.p. with 3.106 hybridoma cells and the ascites produced was 
collected. After ammoniumsulfate (45%) precipitation and dialysis against H O , the solution 
was freeze-dried and stored at 4°C until used. Aliquots were solubilized in sterile, pyrogen­
free saline and used immediately. The in-vitro neutralizing capacity was determined in a 
TNFa dependent L929 cell-lysis assay (Aggarwal, 1985). The amount of rec-mTNF athat 
caused lysis of 50% of the L929 cells as determined in a standard serial twofold dilution curve 
was defined as 1 unit of rec-mTNF a and corresponded to 100 pg/ml. The amount of anti- 
TNFa MAbs neutralizing 1 unit rec-mTNF a was defined as one neutralizing unit (nU). 
Normal rat-Ig (Sigma) was used as a control of anti-TNF a MAbs in the in-vivo studies. The 
LPS content (LAL assay) of the anti-TNF a (V1Q) MAbs solution used in-vivo was less then 
8.2 pg/ml.
Rabbit anti mouse-TNFa antibodies: A New Zealand rabbit was immunized with 50 mg rec- 
mTNF mixed with Freunds Complete AdLuvant and boosted 3 times with a four week interval 
with 25 mg rec-mTNF mixed with Freunds Incomplete Adjuvant. One week after the last 
booster, serum was collected and stored at -20°C. The antiserum was a gift from Dr.J.W.M. 
van der Meer, Department of Internal Medicine, Academic Hospi tal, NiLmegen, The 
Netherlands. The neutralizing capacity was determined in the L929 assay. Using the 
procedure as described above for anti-TNF a MAbs, one unit rabbit anti mouse-TNFa neu­
tralized 100 pg rec-mTNF a/ml.
Immunoreactive TNFa: The plasma concentration of immunoreactive TNFa was 
determined by a sandwich ELISA which recognize free unbound TNFa and TNFaR- 
TNFa complexes. An ammoniumsulfate precipitate of ascites containing anti-TNFa
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MAbs were purified by protein G (Pharmacia) affinity chromatography followed by 
dialysis. ELISA plates were coated with 100 ml of 0.01 mg anti-TNFa MAbs/ml 
phosphate buffered saline (PBS) overnight at 4°C. After washing with PBS plates were 
incubated with 250 ml 1% BSA +  0.1% Tween 20 in PBS for one hour at room 
temperature. After washing five times with PBS, 100 ml of serial dilutions of standard 
rec-mTNFa or test samples were added and incubated for 1 hour. After washing, 
plates were incubated with 100 ml rabbit anti rec-mTNFa antiserum (see below). 100 
ml of a 1:500 dilution of a swine-anti rabbit Ig horseradish peroxidase antiserum 
(Dakopatts) was added to the plates followed by 100 ml of tetramethyl benzidine 
solution (0.25 mM 3,3',5,5'-tetramethyl benzidine, 0.7 mM H2O2 in 0.1 M sodium 
acetate, pH 5.5) as the substrate. The peroxidase substrate reaction was stopped by 
adding 100 ml of 4 M H2SO4 and the optical density was determined in an ELISA 
reader at 450 nm (Titertek Multiskan MCC/340;ICN, Zoetermeer, The Netherlands). 
The detection limit was 100 pg rec-mTNFa/ml.
Bioactive TNFa: TNFa bioassay was performed as described by Aggarwal (1985) 
with minor modifications. Briefly, rec-mTNFa or test samples were added to 100,000 
L929 cells per well. The mixture was cultured in the presence of 8 mg/ml emetine 
(Sigma) and 5% C O  in air at 90% relative humidity at 37°C for 20 h. TNF-mediated 
cytopathic effects on L929 cells were measured by discarding the supernatant, washing 
the adherent cells gently and fix the remaining cells. After drying, 1% crystal violet 
(Sigma) in PBS was added and incubated for 10 min. After removing the excessive 
crystal violet acetic acid was added to dissolve the colored cells. The optical density 
was determined in an ELISA reader at 540 nm (Titertek Multiskan MCC/340;ICN, 
Zoetermeer, The Netherlands). The L929 bioassay detection limit was 50 pg rec- 
mTNFa/ml.
TNFa neutralizing assay: L929 cells were cultured as described above. To each well 
50 ml cellsuspension (2.10 cells/ml) in culture medium without fetal calf serum was 
added. After addition of rec-m-TNFa to mouse plasma (20 and 40 % in culture 
medium) 50 ml was added to the L929 cells. Serial dilutions of rec-m-TNFa in culture 
medium with 20% fetal calf serum (FCS) were taken as a standard. The TNFa 
mediated cytopathic effect on L929 cells was measured by adding 20 ml EZ4U 
substrate (Nuclilab b.v. Ede, The Netherlands) to each well and cells were incubated
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at 5% C O  in air at 90% relative humidity at 37°C for 2 h. Absorbance was 
determined at 450 nm with 620 nm as a reference on an ELISA reader (Titertek Mul- 
tiskan MCC/340;ICN, Zoetermeer, The Netherlands).
TNFa receptor P55 (TNFaR-P55) and P75 (TNFaR-P75) ELISAs: The ELISAs 
recognizing both free, unbound TNF receptors and TNFaR-TNFa complexes, were 
carried out according to the methods described by Bemelmans et al. (1994). Briefly, 
microtiter plates were coated with anti-TNFR-P55 or anti- TNFR-P75. Aspecific 
binding was blocked with 1% BSA. After washing, serum samples were added. A 
standard titration curve was made by recombinant murine TNFR-P55 of TNFR-P75. 
Subsequentely, plates were washed and incubated with biotinylated anti-TNF-receptor 
antibodies. After washings, plates were incubated with streptavidin peroxidase 
followed by enzyme reaction. The detection limit for murine sTNFR-P55 was 5 pg/ml 
and for sTNFR-P75 50 pg/ml.
Statistical analysis: For statistical analysis the student's t-test was used. P  values 
< 0 .05  were considered to be significant.
RESULTS
Immunoreactive TNFa concentrations in ECM
In the course of developing ECM, immunoreactive TNFa concentration was 
determined in plasma of P. berghei K173 infected C57Bl mice (figure 1). An increa­
sing concentration of immunoreactive TNFa was measured in plasma of mice in the 
second week after infection, whereas the immunoreactive plasma TNFa concentration 
was below the detection limit before infection.
Neutralizing effect o f anti-TNFa MAbs on LPS challenge in-vivo
Initially, the in-vivo neutralizing capacity of anti-TNFa MAbs was tested by injecting 
12,500 - 50,000 nU of anti-TNFa MAbs, intravenously in uninfected mice 3 hours 
before an intraperitoneal injection of 100 or 500 mg of LPS. LPS treatment induced a 
decrease in body-temperature , which was inhibited by treatment with anti-TNFa 
MAbs in a dose-dependent manner (R value = 0.75, p = < 0 .0 0 5 , Table 1). The body-
91
Chapter 6
temperature of mice treated with either 50,000 or 25,000 nU of anti-TNF a MAbs followed by 
injection of LPS (100 mg/mouse) was not significantly different from untreated mice. LPS 
dependent mortality after injection of 500 mg LPS/mouse (4/4 mice died) was prevented by 
pretreatment with 50,000 nU of anti-TNF a MAbs/mouse (1/4 mice died). Plasma concen­
trations of immunoreactive TNF a and bioactive TNFa were increased 90 minutes after 
injection of 100 mg LPS/mouse (Table 1). Pretreatment with 50,000 nU of anti-TNF a MAbs 
3 hours before injection of 100 mg LPS significantly reduced immunoreactive TNF a 
concentrations and reduced the bioactive TNF a concentration below the detection limit.
Figure 1: Concentration of immunoreactive TNFa in plasma of Plasmodium berghei infected 
mice (n=5); *:p<0.05 compared to day 7; data are depicted as mean + SD
Neutralizing effect of anti-TNKx MAbs on LPS challenge in P. berghei infected mice.
To confirm the neutralizing activity of anti-TNF a MAbs during malaria infection, the 
concentration of immunoreactive and bioactive TNFa was determined 90 minutes after 
injection of 100 mg LPS on day 8 after P. berghei infection. The bioactive TNF a plasma level 
in infected / LPS treated mice (Table 2) was approximately 1300 times higher in compari son 
to uninfected-LPS treated mice. Pretreatment with 50,000 nU anti-TNF a MAbs of infected / 
LPS treated animals neutralized bioactive TNFa to levels below the detection limit 
(Table 2).
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Table 1: The effect of anti-TNFa MAbs (V1Q) on a LPS mediateci decrease of thè body- 
temperature and on thè concentration immunoreactive and bioactive TNFa.
Injection of Injection of LPS 
(T = 3.0 h)
Body-temperature
(°C)
(T = 4.5 h)
TNFa
neutralizing
units
anti-TNFa
(T= Ohrs) immuno
reactive bioactive
pg/ml pg/ml
No No 37.6 ±  0.5 (n=18) <100 <50
Saline 100 mg 36.4 ±  0.2 (n=3)* 500 220
50,000 nU 100 mg 37.3 ±  0.4 (n=3) 303 <50
25,000 nU 100 mg 37.2 ±  0.3 (n=3) nd nd
12,500 nU 100 mg 36.7 ±  0.4 (n=3)* nd nd
n = number of mice
* = significantly different as compared to untreated mice 
nd = not done
Table 2: Effect of anti-TNFa MAbs (V1Q) on the concentration of immunoreactive and 
bioactive TNFa in LPS treated P. berghei infected mice.
P. berghei infected mice 8 days after infection
anti-TNFa LPS Immunoreactive TNFa Bioactive TNFa
(T= Oh) (T= 3 h) (T= 4.5 h) (T= 4.5 h)
mg/mouse pg/ml pg/ml
No No 292 ±  180* nd
Saline 100 265,000# 294,000#
50,000 nU 100 5,00 O' < 50#
* n=5
nd = not done
# pool (n=5)
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Effect of anti-TNFa treatment on the development of ECM
Mice were treated with anti-TNFa MAbs before or in the course of development of 
ECM. Individual groups of mice received a single dose of anti-TNFa MAbs. In a 
second experiment infected mice received three times anti-TNFa MAbs 2 days apart 
(Table 3). The results show that almost all mice treated with anti-TNFa MAbs develo­
ped ECM as did untreated or saline treated controls. Similarly, mice treated with 
polyvalent rabbit anti-mouse recombinant TNFa antibodies also developed ECM 
(Table 3).
Table 3: Effect of anti-TNFa MAbs and polyvalent anti-TNFa treatment on the develop-
ment of cerebral malaria in P. berghei infected mice.
Anti-TNFa treatment Number of ECM protec­
ted mice / number of 
treated mice
Days after infection Treatment nU
- 1 anti-TNFa MAbs 17,000 0/2
2,4,6 tf 50,000/day 0/6
3 tf 17,000 0/2
5 tf 43,000 0/2
6 tf 50,000 0/5
7
7
7
tf
tf
tf
17.000
50.000
100.000
2/7
0/10
0/3
8 tf 100,000 1/3
9 tf 100,000 0/12
7 R-M-TNFa* 50,000 0/7
2,4,6 saline 0/7
7 tf 0/15
8 tf 1/2
9 tf 0/7
Controls No 2/52
* Polyvalent rabbit-anti-mouse rec TNFa antibodies
** Neutralizing Units (determined in the L929 cell-lysis assay)
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TNFa receptors during development of ECM.
Measurement of the concentration bioactive TNFa in the course of the infection 
showed high concentrations of immunoreactive TNFa (Figure 1), concentrations of 
bioactive TNFa below 50 pg/ml (Table 4).
Table 4: Concentration of bioactive TNFa and soluble TNFa receptors during develop­
ment of cerebral malaria
Plasma samples of Bioactive Soluble TNFa-receptors
normal and infected mice TNFa
pg/ml s-TNFa-P55 s-TNFa-P75
ng/ml ng/ml
Normal mice < 50 0.04-0.1* 3-6*
Exp 1:
day 7s < 50 0.57° 34.7°
day 10s < 50 0.79° 97.4°
Exp 2:
day 10s < 50 0.54 + 0.2400 108.5 ±  42.5-
O O
$: after infection 
*: range 
°: pool (n=3)
00: individual samples (n=9)
Plasma concentrations of soluble TNFa receptors P55 and P75 were 10 and 20 times 
higher at day 10 after infection compared to control mice (Table 4). Furthermore, 
plasma of mice collected on day 10 after infection, inhibited significantly the 
cytopathic effect of rec-m-TNFa in the L929 cell-lysis assay in a dose-dependent 
manner (Figure 2) as compared to plasma of normal mice. The assay was carried out 
in 2 individual experiments, one with 10% and one with 20% plasma of day 10 after 
infection.
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Figure 2: Neutralization of bioactive recombinant-mouse TNFa induced L929 cell lysis by 
plasma from normal mice (Q =  10%, # = 2 0 % , n=5) or plasma from mice of day 10 after 
infection with 103 Plasmodium berghei K173 parasites ( =10%, B=20% , n=9). A dose 
dependent lysis of L929 cells by rec-m-TNFa was taken as a control (+  = 10% fetal calf 
serum (FCS), +=20%  FCS); *:p<0.05 compared to plasma from normal mice; data are 
depicted as mean + SD.
DISCUSSION
Our principle finding is that the administration of either anti-TNFa MAbs or polyva­
lent rabbit anti-TNFa antibodies could not prevent development of P. berghei K173 
induced cerebral malaria in C57Bl mice. Furthermore no bioactive TNFa could be 
detected in plasma of mice developing ECM. Anti-TNFa antibodies were ineffective 
when given at different dosages and time intervals despite proven neutralization of 
bioactive TNFa (Table 3). These anti-TNFa antibodies effectively neutralized LPS 
induced bioactive TNFa and prevented LPS dependent decrease of body-temperature 
and mortality (Table 1,2). Moreover, anti-TNFa MAbs treatment reduced the plasma
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concentration of bioactive TNFa to <  50 pg/ml, even when the plasma concentration 
of bioactive TNFa in P. berghei infected mice treated with LPS was a 1300-fold 
higher as compared to non-infected mice. The reduction of immunoreactive TNFa in 
anti-TNFa / LPS treated normal mice was about 50% (Table 1), while a 50-fold 
reduction was obtained in anti-TNFa / LPS treated and P. berghei infected mice 
(Table 2). In both instances bioactive TNFa was not detectable, which indicates that 
immunoreactive TNFa is complexed to anti-TNFa antibodies. A possible explanation 
of the difference in reduction of bioactive TNFa in anti-TNFa / LPS treated normal 
mice compared with anti-TNFa / LPS treated and P. berghei infected mice could be 
that the TNFa - anti-TNFa complex circulates longer in normal mice as compared to 
infected mice. A longer circulation period of the TNFaa / anti-TNFa complex is also 
found in P. falciparum  infected children treated with anti-TNFa MAbs (Kwiatkowski 
et al. 1993).
Our results are in contrast with those obtained by Grau et al. (1987) in P. berghei 
ANKA infected CBA/Ca mice, but in agreement with studies in P.falciparum  infected 
children (Kwiatkowski et al. 1993, van Hensbroek et al. 1996). Another discrepancy 
between our results and those of Grau et a l. (1987) is the absence of bioactive TNFa 
in plasma of our P. berghei infected C57Bl mice that develop the cerebral syndrome 
(Table 4). These differences may be due to the different combinations of mouse (resp. 
CBA/Ca vs. C57Bl mice) and parasite strains used (resp. ANKA parasites vs. K173 
parasites).
The absence of bioactive TNFa despite high concentrations of immunoreactive TNFa 
is similar to data obtained from P. falciparum  in humans (Kern et al. 1992; Kwiat­
kowski et al. 1993; Molineux et al. 1993). This finding could be explained by the 
presence of excess soluble TNFa receptors in the plasma (Kern et al. 1992; Molyneux 
et al. 1993; Deloron et al. 1994; Kremsner et al. 1995). This is in line with the 
observation of Garcia et a l . (1995) showing that in contrast to normal infected mice, 
transgenic mice, expressing high levels of soluble TNFaR-P55 fusion protein, are 
markedly protected against development of a P. berghei ANKA induced ECM.
Our studies show increased concentrations of soluble TNFa receptors (Table 4). Not 
all TNFa-receptors are complexed with TNFa as plasma taken on day 10 after 
infection is still able to neutralize bioactive rec-mTNFa (Figure 2).
Kwiatkowski et al. (1993) observed a reduction of fever after treatment with anti- 
TNFa MAbs in Gambian children suffering from P. falciparum  induced CM. In our
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mouse model we observe an increase in body-temperature to peak values of 39°C 
around day 8/9 after infection, which is just before body-temperature rapidly decreases 
during development of the cerebral malaria syndrome (Curfs et al. 1989). Treatment 
with either anti-TNFa MAbs or polyvalent rabbit anti-TNFa antibodies on different 
days during infection (day 2 to day 8) with different doses (2.104 to 1 .1 0  nU) did not 
prevent this increase in body-temperature.
In summary, the results suggest that in P. berghei K173 infected mice plasma levels of 
soluble TNFa receptors increase as a response to produced bioactive TNFa. Fur­
thermore, soluble TNFa receptors can neutralize bioactive TNFa and the resulting 
bio-inactive complex can be measured as an increasing concentration of immunoreacti- 
ve TNFa during infection. Not all TNFa receptors are complexed. The apparent 
absence of free TNFa probably explains why treatment with a MAbs against native 
TNFa or polyclonal antibodies against rec-mTNFa failed to prevent development of 
ECM in this model.
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ABSTRACT
The present study shows that treatment with recombinant human tumour necrosis 
factor-a (rec-h-TNFa) can suppress parasitaemia and prevents development of 
cerebral malaria (ECM) in P. berghei K173 infected mice. Mice received rec-h- 
TNFa treatment either by subcutaneous injection of free or liposome-encapsulated 
rec-h-TNFa or sustained intraperitoneal administration of rec-h-TNFa given via 
mini-osmotic pumps. Low dose treatment with a subcutaneous bolus injection of rec- 
h-TNFa protected against ECM when treatment was started at day 5 or 6 after 
infection. The same protective efficacy was obtained either by subcutaneous injection 
of liposome-encapsulated rec-h-TNFa or by sustained release from osmotic pumps, 
but in the latter case a 10-fold lower daily dose of rec-h-TNFa was sufficient. 
Treatment with rec-h-TNFa substantially suppressed parasitaemia in ECM-protected 
mice, but not in mice developing ECM. Thus, the rec-h-TNFa mediated suppression 
of parasitaemia is directly or indirectly involved in protection against ECM. 
Sustained delivery of rec-h-TNFa through osmotic pumps, but not by subcutaneous 
injection of liposome-encapsulated rec-h-TNFa, resulted in increased concentrations 
of soluble mouse TNF receptor R75 (sTNFR75) in plasma at day 9 after infection 
when non-treated mice die of ECM. Thus, protection against ECM is not directly 
correlated with the sTNFR75 concentrations at day 9 after infection.
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INTRODUCTION
Tumour necrosis factora (TNFa) plays a dual role in malaria, being involved both in 
the control of parasitaemia (Taverne et al. 1994; Kremsner et al. 1995; Jacobs et al.
1996) and in the development of malaria-pathology, like cerebral malaria (ECM) 
(Grau et al. 1989; McGuire et al. 1994). Administration of high doses of rec-h- 
TNFa to P. berghei K173 infected mice induced pathology in the brains that 
resembled the pathology found in the brains of non-treated mice dying of ECM 
(Curfs et al. 1993). However, a preliminary observation in this model showed that 
low dose rec-h-TNFa treatment protected against ECM, which merits further 
attention. A possible mechanism involved in the rec-h-TNFa mediated protection 
against ECM is the production of soluble TNF receptors (sTNFRs) (Engelmann, 
Novick & Wallach, 1990). STNFRs are derived from proteolytic cleavage of the 
cellular receptors TNFR55 and TNFR75. They competitively inhibit interaction of 
TNFa with the membrane-bound receptor (Lesslauer et al. 1991) and thus provide a 
possible mechanism for regulating the availability of TNFa. In another observation, 
repeated administration of rec-h-TNFa resulted in the development of tolerance to 
the lethal effects of TNFa (Takahashi, Brouckaert & Fiers, 1995). Sustained release 
(from osmotic pumps or liposomes) of small amounts of rec-h-TNFa might prevent 
development of the cerebral syndrome e.g. through induction of refractoriness of 
TNFa sensitive cells to subsequent stimuli (Alexander et al. 1991). The successful 
use of liposomes as carrier systems for sustained release of encapsulated agents in 
general (Kadir, Zuidema & Crommelin, 1993) and in the treatment of malaria 
(Peeters et al. 1989) has been described before.
The aim of the present study was to analyse the effect of treatment with low doses of 
rec-h-TNFa on the protection against the development of ECM in P. berghei K173 
infected mice. Sustained release of rec-h-TNFa from intraperitoneally (i.p.) 
implanted mini-osmotic pumps is compared with a subcutaneous (s.c.) injection of 
free or liposome-encapsulated rec-h-TNFa. The protective effect of rec-h-TNFa 
treatment on ECM is analysed in relation to its effect on parasitaemia and on the 
production of soluble TNF receptors (sTNFR55 and sTNFR75).
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MATERIALS AND METHODS
Materials: Highly purified rec-h-TNFa from Escheria coli (Wang et al. 1985) with 
a biological activity of 2.5 1 0  U/mg (Creasey et al. 1987) was a kind gift of Chiron 
Corporation (Emeryville, California USA). Egg phosphatidylcholine (EPC) and egg 
phosphatidylglycerol (EPG) were donated by Lipoid (Ludwigshafen, Germany). All 
other reagents used were of analytical grade.
Preparation o f liposomes: A mixture of EPC and EPG (9:1, molar ratio) was 
dissolved in ethanol and evaporated to dryness in a rotary evaporator under reduced 
pressure at 35° C. After drying the lipid film with nitrogen for at least 20 min, the 
lipid film was hydrated with the rec-h-TNFa solution (100 zg  rec-h-TNFa/ml in 20 
mM Hepes, 149 mM NaCl, pH 7.4, at a lipid concentration of 40 mM). The 
resulting liposome dispersion (MLVs) was centrifuged three times (275000 g  for 30­
60 min at 4° C) to remove the non-liposomal rec-h-TNFa (Beckmann Optima™ LE- 
80K, Beckman Instruments, Palo Alto, CA).
Empty or buffer-loaded liposomes were prepared in the same way, but hydrated with 
Hepes buffer only (20 mM Hepes, 149 mM NaCl, pH 7.4). Liposome dispersions 
were used within 1 week after preparation; they were stored in the refrigerator (4- 
6°C).
Liposome characterisation: Lipid phosphate was determined by the method of 
Rouser, Flusher & Yamamoto (1970).
Approximately 2% bioactive rec-h-TNFa appeared to be encapsulated as determined 
in the WEHI cytotoxicity assay after solubilisation of the liposomes (see below).
The liposomes used in the experimental studies were non-sized.
Determination of bioactive TNFa: The bioactivity of rec-h-TNFa, free or 
liposome-associated (expressed as dose of free rec-h-TNFa in the aqueous phase of 
the liposomes), was determined using the WEHI cytotoxicity assay essentially 
according to the method described previously (Espevik & Nissen-Meyer, 1986). 
WEHI 164 clone 13 mouse fibrosarcoma cells were cultured in Iscove's Modified 
Dulbecco's Medium with glutamine (IMDM; Gibco Life Technologies, Breda, The 
Netherlands) supplemented with 10% foetal bovine serum (FBS; Integro, Zaandam,
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The Netherlands), penicillin (100 IU/ml), streptomycin (100 zg/ml) and amphotericin B 
(0.25 zg/ml) at 37°C in a humidified atmosphere containing 5% CO2. One day before
testing, WEHI cells were transferred to new flasks and grown overnight. The next day cells 
were collected to a final concentration of 0.5 10 cells/ml medium of which 50 zl was 
pipetted into 96 wells microtiter plates (Falcon, Micronic, Lelystad, The Netherlands). 
Following incubation for 3 to 5 hours at 37°C and 5% CO , 50 zl of standard or test sample 
was added. A standard curve (up to 20000 pg/ml) was made from rec-h-TNFa (Boehringer 
Ingelheim, Germany) with an originally defined biological activity of 6 10 7 U/mg in a 
murine LM bioassay according to WHO standards. Serial dilutions of free TNF a in medium 
were added directly to the cells. In case of liposome-encapsulated rec-h-TNFa, liposomes 
were disrupted with 10% Triton X-100 in Hepes buffer (20 mM Hepes, 149 mM NaCl, 0.5 
% bovine serum albumin, pH 7.4) in a volume ratio of 1:1. No effect of Triton X-100 was 
observed in the bioactivity assay of rec-h-TNFa with a sample dilution of 30000 times. 
After incubation for 18 hours at 37°C and 5% CO 2 the viable cells were quantitated using 
the XTT assay (Scudiero et al. 1988). Briefly, 100 zl of N-methyldibenzopyrazine methyl 
sulfate (0.4 mg/ml in phosphate buffered saline) from Sigma ( Bornem, Belgium) was added 
to 5 ml of sodium 3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6- 
nitro)benzene sulfonic acid hydrate (XTT, Sigma, Bornem, Belgium) and 1 mg/ml RPMI 
1640 (Gibco, Life Technologies, Breda, The Netherlands). Fifty microliters of the XTT 
labelling mixture was added to the wells and incubated for 90 min at 37°C and 5% CO . 
The absorbance was measured using a Biorad Novapath microplate reader (Bio-Rad 
Laboratories, Veenendaal, The Netherlands) at a wavelength of 495 nm (reference 
wavelength: 655 nm). The WEHI cytotoxicity assay lower detection limit was 
approximately 80 pg rec-h-TNF a/ml.
In the above WEHI cytotoxicity assay, the specific biological activity (U/mg) of rec-h- 
TNFa used for the experiments was about 8-10 times higher than for the standard rec-h- 
TNFa (Boehringer Ingelheim, Germany).
Mice: Female C57Bl/6J mice, 6 to 10 weeks old, were obtained from a specific pathogen 
free colony maintained at the Central Animal Facility of the University of NiLmegen. All 
mice were housed in plastic cages and received water and standard RMH food (Hope 
Farms, Woerden, The Netherlands) ad libitum.
Parasite and development of cerebral malaria Mice were infected with the murine 
parasite Plasmodium berghei K173. The parasite was maintained by weekly transfer of
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parasitised erythrocytes from infected into naive mice. About 95% of C57Bl/6J mice 
i.p. infected with 10 parasitised erythrocytes die early in the second week after 
infection (day 9-12) due to the development of ECM as described by Curfs et al. 
(1992). One day before death a progressive hypothermia develops which is strongly 
correlated with development of haemorrhages in the brain as observed by histology 
(Polder et al. 1992). Mice that survive this critical period only show a limited, 
transient hypothermia and the majority dies in the third week or later after infection 
with severe anaemia and a parasitaemia of 20-40%, but without any noticeable 
cerebral pathology. Day of death after infection was used as the parameter for ECM 
or protection against ECM in the experiments described in this paper.
Experimental design: For each experiment mice received 1 0  parasitised 
erythrocytes i.p. on day 0. At day 5, 6, 7 or 8 after infection, mice were treated with 
a single s.c. injection of either free rec-h-TNFa or liposome-associated rec-h-TNFa. 
Sustained delivery of rec-h-TNFa through i.p. implanted mini-osmotic pumps (Alzet 
model 2001; release rate 1 ml/hour for 7 days, Alza, Palo Alto, CA) was started at 
day 5 or 7 after infection. Prior to injection, appropriate dilutions were prepared 
using Hepes buffer (20 mM Hepes, 149 mM NaCl, pH 7.4) containing 1% mouse 
plasma.
The effect of treatment on parasitaemia (% infected erythrocytes) at day 8 after 
infection was studied from thin blood films made from tail-blood and stained with 
May-Grunwald and Giemsa’s solutions. A considerable variation is observed in 
parasitaemia at day 8 after infection among independent infected control groups 
(average parasitaemia +  s.d.: 20 +  15%; 21 experiments and 3-5 mice per 
experimental group). Therefore, within each experiment the average parasitaemia in 
non-treated mice was determined and the parasitaemia of each individual mouse from 
either a control or a treatment group was divided by this average. These ratios were 
used to compare and summarise the results of independent repeat experiments.
The effect of treatment on the development of ECM was studied by monitoring 
survival of mice. Death of mice within two weeks after infection was used to identify 
ECM-death (Curfs et al. 1992). Persistent, recurrent parasitaemia and survival for 
more than 2 weeks after infection indicated protection against ECM.
TNF receptor R55 and R75 (TNFR55 and TNFR75) ELISAs: Mice treated with 
rec-h-TNFa and non-treated mice were sacrificed at day 9 after infection to study the
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effect of treatment on the plasma concentrations of soluble mouse TNF receptors. 
Blood was collected in endotoxin free tubes (4°C) which contained endotoxin free 
(LAL assay) heparin (NPBI, Emmer Compascuum, The Netherlands). Plasma was 
collected by centrifugation within 2 h after bleeding and stored at -20°C.
The ELISAs recognising both free and complexed TNF receptors, were carried out 
with the materials and according to the methods described by Bemelmans et a l . 
(1994). Briefly, microtiter plates were coated with anti-TNFR55 or anti-TNFR75 
monoclonal antibody. Aspecific binding was blocked with 1 % BSA. After washing, 
mouse plasma samples were added. A standard curve was made using recombinant 
murine TNFR55 and TNFR75 protein. Subsequently, plates were washed and 
incubated with biotinylated anti-TNF receptor antibodies. After washing, plates were 
incubated with streptavidin peroxidase followed by an enzyme reaction providing a 
coloured reaction product. The lower detection limit for murine soluble TNFR55 
was 20 pg/ml and for soluble TNFR75 was 500 pg/ml.
Statistical analysis: The effect of treatment on parasitaemia was analysed by one­
way ANOVA. The effect of treatment on survival was analysed by the Chi-Square 
test. Differences were considered significant at a level a =0 .05 .
RESULTS 
Subcutaneous injection of free rec-h-TNFa in P. berghei infected mice
Mice received a single s.c. injection of free rec-h-TNFa at day 5, 6, 7 or 8 after 
infection and protection against ECM was monitored (Fig. 1). Approximately 50­
90% of the mice were protected against ECM when treatment was started at day 5 
after infection (0.5-5 zg  rec-h-TNFa). The protective efficacy against ECM 
depended on the day of treatment (day 5-8, p < 0 .0001; summarised data of all 
doses) and decreased when treatment was started later in infection. Protection against 
ECM was independent of the dose of rec-h-TNFa in the studied dose range 0.5-5 zg  
rec-h-TNFa (summarised data of treatment of days 5-7). Administration of 10 zg  
rec-h-TNFa was toxic (death within 24 h after injection) at day 5 for 7 out of 10
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Figure 1: The effect of treatment with free rec-h-TNFa during infection on protection 
against ECM. Mice received a single subcutaneous injection of rec-h-TNFa (0.5-10 fxg 
rec-h-TNFa) at day 5, 6, 7 or 8 after infection with 103 P. berghei parasites and survival 
for more than 2 weeks after infection was used as a marker for protection against ECM.
The percentage of mice protected against ECM is plotted against the day of treatment and 
the dose of rec-h-TNFa. Above each bar, the number of mice protected against ECM 
divided by the number of treated mice is indicated
mice, while all mice died within 24 h when injected at day 8. No toxic effects were 
observed after injection of 5 zg  rec-h-TNFa at day 8 after infection.
The parasitaemia data are expressed as the ratio of the parasitaemia of a certain 
mouse divided by the mean parasitaemia of the infected but otherwise non-treated 
mice in the same experiment. Calculation of this ratio permitted to summarise the 
results of independent repeat experiments. The effect of rec-h-TNFa treatment on 
parasitaemia was similar when treatment was started at day 5, 6 or 7 and in the dose­
range of 0.5-5 zg  rec-h-TNFa (Fig. 2). Therefore, statistical analysis was performed 
on the summarised data. Treatment with rec-h-TNFa significantly (p<0.0001  
compared to non-treated mice) suppressed parasitaemia independent of the day of 
treatment (day 5-7; summarised data of doses ranging from 0.5-5 zg  rec-h-TNFa) 
and independent of dose of rec-h-TNFa (0.5-5 zg rec-h-TNFa; summarised data of 
treatment on days 5-7) (Table 1). The effect of rec-h-TNFa treatment on 
parasitaemia was also studied in relation to protection against ECM; parasitaemia 
was significantly suppressed in ECM-protected mice but not in mice developing 
ECM (p < 0 .0001 , Table 1).
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Figure 2: The effect of treatment with rec-h-TNFa during infection on parasitaemia. Mice 
received a single subcutaneous injection of rec-h-TNFa (0.5-5 fig rec-h-TNFa) at day 5, 6 
or 7 after infection with 103 P. berghei parasites. The average parasitaemia at day 8 after 
infection was determined in each control group and the parasitaemia of each individual 
mouse was divided by the average of the corresponding control group. The ratio is plotted 
against the dose of rec-h-TNFa for each mouse. When treatment has no effect on 
parasitaemia the ratio scatters around 1, while ratios < 1 indicate that parasitaemia is 
suppressed.
Table 1: Effect of treatment with a subcutaneous bolus injection of rec-h-TNFa on 
parasitaemia in relation to development of cerebral malaria in /5, berghei infected mice.
Treatment+ Ratio parasitaemia at day 8/ mean parasitaemia non-treated mice*
All mice Mice with ECM Mice without ECM
no treatment 1 ±  0.6 (n=87) 1 ±  0.6 (n=87) (n=0)
rec-h-TNFa 0.6** + 0.6 (n = 101) 0.9 ±  0.6 (n=48) 0.4*** ±  0.4 (n=53)
+Mice received a subcutaneous injection of rec-h-TNFa (0.5-5 fig) at day 5, 6 or 7 after 
infection with 103 parasites and the effect on parasitaemia at day 8 after infection was studied in 
relation to protection against cerebral malaria.
*The average parasitaemia at day 8 after infection was determined in each control group and the 
parasitaemia of each individual mouse was divided by the average of the corresponding control 
group. This permitted to summarise results of independent repeat experiments. Values represent 
averages ±  s.d. of the combined data of different doses (0.5-5 ¿tg rec-h-TNRx) and days of 
treatment (day 5, 6 or 7).
** p <0.0001 as compared to non-treated mice.
#p <  0.0001 as compared to mice developing ECM in the same treatment group.
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Sustained release of rec-h-TNFa in P. berghei infected mice
Sustained release of low doses of 0.05-0.15 zg  rec-h-TNFa/day, from i.p. implanted 
osmotic pumps (release rate 1 ml/hour during 7 days) starting at day 5 after infection 
protected 65-100% of the mice against the development of ECM (Table 2). The 
protective efficacy against ECM was independent of dose in the dose range studied. 
The summarised data of mice receiving saline containing pumps exhibit protection 
against ECM in 5 out of 16 mice. This was an unexpectedly high protection rate 
when considering the outcome of earlier work (unpublished data). For unknown 
reasons in one of the four independent experiments 3 out of 3 mice treated with the 
saline containing pumps were protected against ECM. Despite this, protection 
against ECM was significantly (p < 0 .0 1 ) higher by sustained release of rec-h-TNFa 
(0.05-0.15 zg  rec-h-TNFa/day) as compared to saline treated controls.
Treatment with rec-h-TNFa via osmotic pumps (0.05-0.15 zg  rec-h-TNFa/day) 
starting at day 5 after infection significantly (p < 0.001) suppressed parasitaemia 
(average +  s.d.: 0.4 +  0.3; n = 14) (data not shown).
When sustained release of rec-h-TNFa started at day 7 after infection, no effect was 
observed on parasitaemia and mice were not protected against ECM (data not 
shown).
Table 2: Effect of sustained release of rec-h-TNFa from intraperitoneally implanted 
osmotic pumps on protection against cerebral malaria.
Treatment+ Number of ECM protected mice /
number of treated mice
no treatment 2/86 (2%)
pump:
saline 5/16 (31%)
0.05 fig rec-h-TNFa/day 13/20 (65%)
0.10 fig rec-h-TNFa/day 4/4 (100%)
0.15 fig rec-h-TNFa/day 8/9 (89%)
+ The pumps were implanted at day 5 after infection with 103 P. berghei parasites and 
released 1 ml/hour during 7 days. Controls received either pumps containing saline or 
no treatment at all.
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S.c. injection of liposomal rec-h-TNFa in P. berghei infected mice
Subcutaneous injection of rec-h-TNFa encapsulated into fluid type (EPC:EPG) 
liposomes was used as another approach for sustained release of rec-h-TNFa.
The dose range of 0.5-5 zg  of bioactive rec-h-TNFa as used for free rec-h-TNFa 
was also used for the liposomal rec-h-TNFa preparation. Protection against ECM 
was dose-dependent (0.5-5 zg  liposomal rec-h-TNFa, p < 0 .001; summarised data of 
treatment on days 5-7) and increased to 100% protection when 5 zg  liposomal rec-h- 
TNFa was injected at day 5 or 6 after infection (Fig. 3). The protective efficacy of 
liposomal rec-h-TNFa against ECM also depended on the day of treatment (day 5-8, 
p < 0.0001; summarised data of all doses) and decreased when treatment was started 
later in infection, similar to the results obtained with free rec-h-TNFa (cf Fig. 1 and 
Fig. 3). Injection of liposomal rec-h-TNFa at day 8 was completely ineffective, but 
also non-toxic.
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Figure 3: The effect of treatment with liposomal rec-h-TNFa during infection on protection against 
ECM. Mice received a single subcutaneous injection of liposomal rec-h-TNFa (0.5-5 fig bioactive 
rec-h-TNFa) at day 5, 6, 7 or 8 after infection with 103 P. berghei parasites and survival for more 
than 2 weeks after infection was used as a parameter for protection against ECM. The percentage of 
mice protected against ECM is plotted against the day of treatment and the dose of rec-h-TNFa 
administered. Above each bar, the number of mice protected against ECM divided by the 
number of treated mice is indicated.
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The effect of treatment with liposomal rec-h-TNFa on parasitaemia as compared 
with non-treated mice did not reach significance (p = 0.06), which is probably linked 
to the remarkably high parasitaemia of a few mice treated with 2 zg  liposomal rec-h- 
TNFa (Fig. 4 and Table 3). On the other hand, parasitaemia was significantly 
(p < 0.001) suppressed in ECM-protected mice as compared to non-treated mice or 
mice developing ECM (Table 3).
Subcutaneous injection of empty, buffer-loaded liposomes at day 5, 6 or 7 after 
infection did not protect against ECM (data not shown) and did not affect 
parasitaemia (Table 3).
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Figure 4: The effect of treatment with liposomal rec-h-TNFa during infection on 
parasitaemia. Mice received a single subcutaneous injection of liposomal rec-h-TNFa (1-5 
fig rec-h-TNFa) at day 5, 6 or 7 after infection with 103 P. berghei parasites. The average 
parasitaemia at day 8 after infection was determined in each control group and the 
parasitaemia of each individual mouse was divided by the average of the corresponding 
control group. The ratio is plotted against the dose of rec-h-TNFa for each mouse. When 
treatment has no effect on parasitaemia the ratio scatters around 1, while ratios < 1 indicate 
that parasitaemia is suppressed.
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Effect o f sustained treatment with rec-h-TNFa on sTNFRs in plasma
The effect of treatment by sustained release of rec-h-TNFa on the concentrations of 
sTNFRs in plasma was determined at day 9 after infection when non-treated mice 
normally die of ECM.
Groups of mice received protective doses of 0.5 zg  rec-h-TNFa/day (mini-osmotic 
pump) or 2 zg  liposomal rec-h-TNFa s.c. at day 5 after infection. The 
concentrations of soluble mouse TNFR55 and TNFR75 in rec-h-TNFa treated and 
non-treated mice are depicted in Table 4. No differences were observed in the 
concentration of soluble mouse TNFR55 at day 9 after infection in plasma samples 
of non-treated and rec-h-TNFa treated mice. In contrast, soluble mouse TNFR75 
concentrations were increased significantly (p < 0 .05 ) at day 9 after infection when 
rec-h-TNFa was released from osmotic pumps, but not when rec-h-TNFa containing 
liposomes were administered s.c. at day 5.
Table 3: Effect of treatment with a subcutaneous injection of liposomal rec-h-TNFa on 
parasitaemia in relation to development of cerebral malaria in /5, berghei infected mice.
Treatment Ratio parasitaemia at day 8 / mean parasitaemia non-treated mice*
All mice Mice with ECM Mice without ECM
No treatment 1.0 ±  0.6 (n=86) 1.0 ±  0.6 (n=86) (n=0)
Empty
liposomes
0.8 ±  0.3 (n= 15) 0.8 ±  0.3 (n= 15) (n=0)
Liposomal
rec-h-TNFa
0.8 ±  1.0 (n=82) 1.5* ±  1.3 (n=23) 0.5** ±  0.6 (n=59)
+Mice received a subcutaneous injection of empty liposomes or liposome-encapsulated 
rec-h-TNFa (1-5 ¡xg rec-h-TNFa) at day 5, 6 or 7 after infection with 103 parasites and 
the effect on parasitaemia at day 8 after infection was studied in relation to protection 
against cerebral malaria.
::The average parasitaemia at day 8 after infection was determined in each control group 
and the parasitaemia of each individual mouse was divided by the average of the 
corresponding control group. The ratios were used for further analysis. Values represent 
averages + s.d. of the combined data of different doses (1-5 fxg rec-h-TNFa) and days of 
treatment (day 5, 6 or 7).
* p< 0 .01  as compared to non-treated mice, #p < 0.0001 as compared to mice developing 
ECM in the same treatment group.
113
Chapter 7
Table 4: Effect of sustained rec-h-TNFa treatment starting at day 5 after infection on the 
concentrations of soluble mouse TNF receptor in plasma at day 9 after infection in P. 
berghei infected mice.
Treatment+ Soluble mouse TNF receptor in plasma
(ng/ml)
STNFR55 STNFR75
no treatment 0.3 ±  0.2 (n=5) 50 + 9 (n=5)
rec-h-TNFa infusion 
(0.5 /¿g/day)
< 0 .2  (n=3) 84* + 13 (n=3)
liposome-encapsulated rec-h-TNFa
(2 /xg)
0.3 ±  0.1 (n=5) 54 + 13 (n=5)
+Mice received rec-h-TNFa either from i.p. implanted mini-osmotic pumps (release rate 
1 ml/h, 0.5 fig rec-h-TNFa/day for 7 days) or from a single s.c. injection of 2 ¡xg 
liposome-encapsulated rec-h-TNFa at day 5 after infection with 103 parasites. A third 
group of mice did not receive rec-h-TNFa treatment. Groups of mice were sacrificed at 
day 9 after injection and plasma was collected for analysis by specific ELISAs. Values 
represent averages + standard deviation.
* p < 0.05 as compared with non-treated mice.
DISCUSSION
The most important observation of this study is that low dose treatment with rec-h- 
TNFa protected against ECM and suppressed parasitaemia when treatment was 
started at day 5 or 6 after infection. The rec-h-TNFa mediated protection against 
ECM gradually disappeared when treatment was postponed to day 7 or 8 after 
infection. The same protective efficacy was obtained by either s.c. injection of free 
or liposome-encapsulated rec-h-TNFa or i.p. infusion, but it should be noted that a 
10 times lower daily dose of rec-h-TNFa was sufficient when continuously released 
from an i.p. implanted osmotic pump. Sustained release of rec-h-TNFa probably 
results in prolonged therapeutic concentrations of rec-h-TNFa in the circulation. It 
has been demonstrated that rec-h-TNFa is rapidly cleared from the circulation after
i.v. injection into mice with an initial half-life less than 20 min and a subsequent 
slower b-phase (Ferraiolo et al. 1988). The sustained effect of rec-h-TNFa released 
from osmotic pumps is also shown by the higher plasma concentrations of sTNFR75 
as compared with non-treated or liposomal rec-h-TNFa treated mice (Table 4). 
Bolus injection of rec-h-TNFa resulted in increased levels of sTNFR75 4 h after
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injection, returning to levels seen in the infected controls within 24 h after injection 
(unpublished observations).
The observation that doses needed for protection against ECM by treatment with 
liposome-encapsulated rec-h-TNFa were as high as for free rec-h-TNFa (Fig. 1 and 
3) and the observation that sTNFR75 was not increased by this treatment (Table 4), 
suggest that the s.c. liposomal depot released protective amounts of rec-h-TNFa only 
for a limited period of time.
The mortality observed after s.c. injection of 10 zg  rec-h-TNFa at day 5 or 8 
probably reflects the role of TNFa in malaria-pathology as has been described 
before (Curfs et al. 1993) and limits the dose that can be administered by s.c. bolus 
injection.
A significant suppression of parasitaemia by rec-h-TNFa treatment was observed in 
ECM-protected mice (Table 1 and 3). Under the experimental conditions used, the 
reduction of parasitaemia was independent of day of treatment or treatment regimen. 
Suppression of parasitaemia by administration of rec-h-TNFa to mice has been 
observed before (Stevenson & Ghadirian, 1989). TNFa alone does not inhibit 
parasite-growth in vitro  (Taverne et al. 1987) and activated macrophages and 
neutrophils are probably involved in TNFa mediated parasite-killing (Kumaratilake, 
Ferrante & Rzepczyk, 1990; Taverne et al. 1994). In addition, TNFa affects 
erythropoiesis, which may also play a role in suppression of parasitaemia (Johnson et 
al. 1989; Moldawer et al. 1989).
The observation that parasitaemia was suppressed in ECM-protected mice, but not in 
mice developing ECM (Table 1 and 3), suggests that the effect of rec-h-TNFa on 
parasitaemia plays a role in rec-h-TNFa mediated protection against ECM. It should 
be noted that almost all mice infected with parasites in a range of 10 to 10000, 
develop ECM despite a widely varying parasitaemia after infection (Curfs et al. 
1993). Moreover, parasitaemia in non-treated mice varies extensively before the 
mice die of ECM. Therefore, the course of an untreated infection is probably not a 
critical factor in development of ECM in P. berghei infected mice. Thus, the change 
in parasitaemia by treatment with rec-h-TNFa may interfere with the development of 
ECM. On the other hand, the effect of rec-h-TNFa on parasitaemia may be an 
associated but not causally related factor in protection against ECM.
Possible other mechanisms involved in the rec-h-TNFa mediated protection are the 
stimulation of the production of sTNFRs and the induction of tolerance or
115
Chapter 7
refractoriness of TNFa sensitive cells. Elevated concentrations of sTNFRs have been 
observed during malaria infection in humans (Deloron et al. 1994) and in the murine 
model used in the present study (Hermsen et al. 1997). STNFRs are probably 
increased as a response to endogenous TNFa production. They can inhibit TNFa 
interaction with membrane-bound receptors (Lesslauer et al. 1991) and high levels of 
sTNFR55 were shown to protect against ECM (Garcia et al. 1995). Our study did 
not reveal an increase in the plasma concentration of sTNFR55 in relation to 
sustained treatment with rec-h-TNFa. The increase in sTNFR75 at day 9 after 
infection is only observed in mice receiving rec-h-TNFa from osmotic pumps, not in 
mice receiving rec-h-TNFa from a s.c. liposomal depot, while both treatment 
regimens protected against ECM (Table 4). This suggests that the increase in 
sTNFR75 is not linked to protection against ECM. However, only one time point 
was measured and that may not be the critical point to observe functional changes in 
sTNFR75 involved in the protection against ECM.
Another mechanism involved in rec-h-TNFa mediated protection against ECM may 
be the induction of refractoriness of tolerance of TNFa sensitive cells. Several 
studies demonstrated that pre-treatment with TNFa induces refractoriness and 
therefore tolerance to its pathological effects (Fraker et al. 1988; Takahashi et al. 
1995). Tolerance persists for several days and might be a “natural” regulatory 
mechanism to control toxicity of this cytokine (Takahashi, Brouckaert & Fiers, 
1993). Our data do not permit to decide whether treatment with rec-h-TNFa induces 
refractoriness and therefore prevents development of ECM.
In summary, low dose treatment with rec-h-TNFa at day 5 or 6 after infection 
protects against ECM in P. berghei K173 infected mice. The effect of rec-h-TNFa 
treatment on suppression of parasitaemia may play a role. No indications were found 
that treatment with rec-h-TNFa protects through triggering of production of 
sTNFRs. The mechanism by which rec-h-TNFa prevents the development of ECM 
remains to be elucidated.
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ABSTRACT
The introduction of reactive thiol groups in recombinant human tumour necrosis 
factor-a (rec-h-TNFa) by the reagent succinimidyl-S-acetylthioacetate resulted in the 
formation of a chemically stabilised rec-h-TNFa trimer (rec-h-TNFa-AT, SDS- 
PAGE analysis). Rec-h-TNFa-AT showed a slightly reduced in vitro bioactivity, but 
a substantially enhanced protective efficacy against development of murine cerebral 
malaria (CM) after intravenous injection as compared with non-modified rec-h- 
TNFa. Administration of thiolated rec-h-TNFa with protected thiol groups (rec-h- 
TNFa-ATA, no stabilised trimers in vitro) exhibited the same protective efficacy 
against CM while in vitro bioactivity was reduced. Parasitaemia was significantly 
suppressed in CM-protected mice, but not in treated mice developing CM. Protection 
against CM was not related to enhanced plasma concentrations of soluble TNF 
receptor R55 and R75 directly after injection, nor prior to the development of CM in 
non-treated mice. The present study demonstrates that chemical stabilisation of rec- 
h-TNFa trimers increases its potential (therapeutic and protective) in vivo.
INTRODUCTION
Tumour necrosis factor-a (TNFa) is a pleiotropic cytokine primarily produced by 
stimulated macrophages and a major mediator of the inflammatory and cellular 
immune response. Although TNFa was originally identified by its antitumour 
properties and cytotoxicity to some transformed cell lines [1], it has also been 
implicated in the pathophysiology of septic shock, cachexia, certain inflammatory 
diseases (e.g. rheumatoid arthritis) and infections, like malaria [2-4]. Recent studies 
demonstrated that treatment with low doses of recombinant human TNFa (rec-h- 
TNFa) inhibited parasite proliferation and prevented the development of cerebral 
malaria (CM) in P. berghei K173 infected mice (unpublished observations). 
Momomeric rec-h-TNFa is a non-glycosylated polypeptide of 157 amino acids with 
a molecular mass of 17 kD [5]. Studies from analytical ultracentrifugation [6-8], 
cross-linking [9-12], gel filtration chromatography [13, 14] and X-ray-scattering [15] 
showed that rec-h-TNFa was present as a trimer in solution. X-ray crystallographic 
studies of rec-h-TNFa revealed that rec-h-TNFa forms a compact, bell-shaped 
homotrimer [16, 17]. The effects of both rec-h-TNFa and rec-h-TNFP are mediated 
by two receptors with a distinct molecular weight, TNFR55 and TNFR75 [18]. 
Studies with TNFR55 provided evidence that each rec-h-TNFa trimer can interact 
with three receptor molecules [19, 20]. Additional mutational analysis studies with 
rec-h-TNFa suggest that each trimer has three receptor interaction sites located in 
the intersubunit grooves near the base of the trimer and that integrity of the trimeric 
structure is essential for rec-h-TNFa activity [21, 22].
These studies clearly demonstrate that the trimeric structure of rec-h-TNFa is very 
important for its action. However, rec-h-TNFa oligomers (dimers and trimers) have 
been shown to be unstable at low concentrations or upon incubation in buffer 
resulting in the formation of inactive monomers and polymers [12, 14, 23, 24]. This 
suggests that when rec-h-TNFa is applied as a therapeutic agent, bioactive rec-h- 
TNFa may only be present at or near the site of administration [24]. Stabilisation of 
rec-h-TNFa trimers by chemical cross-linking prevents the dissociation into inactive 
monomers and may therefore enhance the therapeutic potential of rec-h-TNFa due to 
higher and longer-circulating concentrations of bioactive rec-h-TNFa with an 
enhanced access to deeper body compartments. Stabilised rec-h-TNFa trimers were 
prepared by reaction of the protein with the reagent succinimidyl-S-acetylthioacetate 
(SATA). Reactive thiol groups are introduced in the protein at the site of primary
amino groups [25], which can lead to formation of disulphide bridges between 
adjacent rec-h-TNFa monomers.
The aim of this study was to analyse the therapeutic potential of covalently stabilised 
rec-h-TNFa trimers in P. berghei K173 induced CM in mice. The effect on 
parasitaemia and development of CM was monitored after intravenous injection and 
compared with non-modified rec-h-TNFa. The protective effect of rec-h-TNFa 
treatment on CM was analysed in relation to its effect on the production of soluble 
TNF receptors (sTNFR55 and sTNFR75).
MATERIALS AND METHODS
Materials: Rec-h-TNFa (4 mg/ml in 10 mM sodium phosphate pH 7, 200 mM 
NaCl) (E .coli-derived) [26] with a specific activity of 5 .1 0  U/mg (bioassay: murine 
LM cells) was a gift from Dr. G.R. Adolf (Boehringer Ingelheim, Vienna, Austria). 
N-succinimidyl S-acetylthioacetate (SATA) was purchased from Pierce (Rockford, 
USA). All other reagents used were of analytical grade.
Thiolation of rec-h-TNFa by the SATA-reaction: Basically, the procedure to 
thiolate proteins with SATA as described by Duncan et al. [25] was used. Rec-h- 
TNFa (4 mg/ml in 10 mM sodium phosphate pH 7, 200 mM NaCl) was applied on a 
Sephadex G-25M column (PD-10 column, Pharmacia, Uppsala, Sweden) and eluted 
with Hepes buffer (10 mM Hepes, 135 mM NaCl, 1 mM EDTA, pH 7.5). The 
eluted rec-h-TNFa solution was concentrated using microsep filters with a 
molecular weight cut-off of 10kD (Pall Filtron, Breda, The Netherlands) at 4°C to 
approximately 2 mg/ml before reaction with SATA. SATA was dissolved in 
dimethylformamide (DMF) and mixed with the rec-h-TNFa solution in a volume 
ratio of DM F:buffer=1:100 and a molar ratio of SATA:rec-h-TNFa = 8:1. The 
mixture was incubated at room temperature under continuous rotation for at least 20 
min to allow formation of rec-h-TNFa with protected thiol groups (rec-h-TNFa- 
ATA). After incubation, the unreacted SATA was separated from rec-h-TNFa-ATA  
on a PD-10 column. The protein fraction in the eluate was detected by monitoring 
the absorption at 280 nm, collected and stored at -20°C (maximally 3 weeks). Rec-h- 
TNFa-ATA was de-acetylated by adding a freshly prepared hydroxylamine-HCl 
solution (0.5 M Hydroxylamine-HCl, 0.5 M Hepes, 25 mM EDTA, pH 7.5). The 
mixture was incubated for 60 min at room temperature under continuous rotation at a
volume ratio of rec-h-TNFa-ATA:hydroxylamine = l0 : l ,  yielding rec-h-TNFa with 
reactive thiol groups (rec-h-TNFa-AT). This product was used in all studies.
Protein determination: To determine the concentration of rec-h-TNFa and rec-h- 
TNFa-ATA the method described by Wessel and Flugge [2T] was used. However, 
the amount of rec-h-TNFa-AT could not be determined by the same method due to 
interference of hydroxylamine with the analysis. Therefore, the amount of protein in 
the rec-h-TNFa-AT solutions was estimated from the amount of rec-h-TNFa-ATA  
measured and corrected for dilution upon addition of hydroxylamine, as it is not 
likely that addition of hydroxylamine will change the amount of protein in any other 
way.
Gel permeation chromatography: The molecular weights of rec-h-TNFa, rec-h- 
TNFa-ATA and rec-h-TNFa-AT were determined by gel permeation 
chromatography (GPC) with a system consisting of a Model S l0  HPLC pump 
(Waters Associates, Milford, MA, USA), a thermostated (3S0C) pre-column (Biosep 
SEC S3000 PEEK, S0 x T.S mm, Phenomenex, Torrance CA) and a TSK-GEL 
G3000SW column (TS x 300 mm, particle size l0  mm, Tosohaas, Japan). The 
system was equilibrated with l00  mM sodium sulphate/phosphate buffer, pH 6.T. 
The material was eluted with the same buffer at a flow rate of l .0  ml/min and the 
elution profile was monitored at 280 nm with a UV-detector (Model 486, Waters 
Associates, Milford, MA, USA). The system was calibrated with mixtures of 
standards of known molecular weight (dextran blue 2,000,000, ovalbumin 43,000, 
and ribonuclease A l3,T000; thyroglobulin 669,000, lactoglobulin l8 ,400, and 
insulin 6,000; immunoglobulin G lS0,000, chymotrypsin 2S,000, bovine serum 
albumin 6T,000, and myoglobin lT,200).
SDS polyacrylamide gel electroforesis (SDS-PAGE): SDS-PAGE analysis of rec-h- 
TNFa, rec-h-TNFa-ATA and rec-h-TNFa-AT was performed in a modified 
Laemmli system [28] using a horizontal 8-l8% gradient gel (ExelGel®, Pharmacia, 
Uppsala, Sweden) and gels were silver stained. Gels were run with non-reduced and 
reduced (0 .l M DTT and l0% iodocetamide) samples. Molecular weight markers 
(Bio-Rad Laboratories, Veenendaal, The Netherlands) were used with a molecular 
mass ranging from l4  to 200 kD.
In vitro bioactivity: The biological activity of rec-h-TNFa, rec-h-TNFa-ATA and 
rec-h-TNFa-AT was determined in the WEHI cytotoxicity assay essentially 
according to the method described previously [29], WEHI 164 clone 13 mouse 
fibrosarcoma cells were cultured in Iscove's Modified Dulbecco's Medium with 
glutamine (IMDM; Gibco Life Technologies, Breda, The Netherlands) supplemented 
with 10% foetal bovine serum (FBS; Integro, Zaandam, The Netherlands), penicillin 
(100 IU/ml), streptomycin (100 zg/m l) and amphotericin B (0.25 zg/m l) at 37°C in 
a humidified atmosphere containing 5% C 0 2. One day before testing, WEHI cells
were transferred to new flasks and grown overnight. The next day cells were 
collected to a final concentration of 0.5 10 cells/ml medium of which 50 z l was 
pipetted into 96 wells microtiter plates (Falcon, Micronic, Lelystad, The 
Netherlands). Following incubation for 3 to 5 hours at 37°C and 5% C O , 50 z l of 
standard or test sample was added. A standard curve (10 to 20,000 pg/ml) was made 
from rec-h-TNFa (Boehringer Ingelheim, Germany) with an originally defined 
biological activity of 6 10 U/mg in a murine LM bioassay according to W H 0  
standards. Serial dilutions of samples in medium were added directly to the cells. 
After incubation for 18 hours at 37°C and 5% C O  the viable cells were quantitated 
using the XTT assay [30]. Briefly, 100 z l of N-methyldibenzopyrazine methyl 
sulfate (0.4 mg/ml PBS) from Sigma (Bornem, Belgium) was added to 5 ml of 
sodium 3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) 
benzene sulfonic acid hydrate (XTT, Sigma, Bornem, Belgium) with a concentration 
of 1 mg/ml RPMI 1640 (Gibco Life Technologies, Breda, The Netherlands). Fifty 
microliter of the XTT labelling mixture was added to the wells and incubated for 90 
min at 37°C and 5% C O . The absorbance was measured using a Biorad Novapath™ 
microplate reader (Bio-Rad Laboratories, Veenendaal, The Netherlands) at a 
wavelength of 495 nm (reference wavelength: 655 nm). The WEHI cytotoxicity 
assay lower detection limit was approximately 80 pg rec-h-TNFa/ml.
In the above WEHI cytotoxicity assay the specific biological activity of rec-h-TNFa 
(U/mg) used for the experiments was about 2-4 times higher than for the standard 
rec-h-TNFa (Boehringer Ingelheim, Germany).
Mice: Female C57Bl/6J mice, 6 to 10 weeks old, were obtained from a specific 
pathogen free colony maintained at the Central Animal Facility of the University of 
Nijmegen. All mice were housed in plastic cages and received water and standard 
RMH food (Hope Farms, Woerden, The Netherlands) ad  libitum.
Parasite and development of cerebral m alaria: Mice were infected with the 
murine parasite Plasmodium berghei K173. The parasite was maintained by weekly 
transfer of parasitised erythrocytes from infected into naive mice. About 95% of 
C57B1/6J mice intraperitoneally (i.p.) infected with 103 parasitised erythrocytes die 
in the second week after infection (day 9-12) due to the development of CM [31]. 
One day before death a progressive hypothermia develops which is strongly 
correlated with development of haemorrhages in the brain as observed by histology 
[32]. Mice that survive this critical period only show a limited, transient 
hypothermia and the majority dies in the third week or later after infection with 
severe anaemia and a parasitaemia between 20 and 40%, but without any noticeable 
cerebral pathology. Time of death after infection was used as the parameter for CM 
or protection against CM in the experiments described in this paper.
Experim ental set-up: For each experiment mice received 103 parasitised 
erythrocytes i.p. on day 0. At day 5 mice were treated with a single intravenous 
(i.v.) injection of either rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT. Prior to 
injection, appropriate dilutions were prepared using Hepes buffer (10 mM Hepes, 
135 mM NaCl, 1 mM EDTA, pH 7.5) containing 1% mouse plasma. Placebo- 
treated mice received buffer only. Control mice did not receive any treatment (non­
treated mice). The effect of treatment on parasitaemia (% infected erythrocytes) at 
day 8 after infection was studied from thin blood films made from tail-blood and 
stained with May-Grunwald and Giemsa’s solutions. A considerable variation is 
observed in parasitaemia at day 8 after infection among independent infected control 
groups (average parasitaemia and standard deviation: 17 + 8%; n = 8  experiments). 
Therefore, within each experiment the average parasitaemia in non-treated mice was 
determined and the parasitaemia of each individual mouse from either a control or a 
treatment group was divided by this average. These ratios were used to compare the 
results of independent repeat experiments. The effect of treatment on the 
development of CM was studied by monitoring survival of mice. Death of mice 
within two weeks after infection was used to identify CM-death [31]. Persistent, 
recurrent parasitaemia and survival for more than 2 weeks after infection indicated 
protection against CM.
TNF receptor R55 and R75 (TNFR55 and TNFR75) ELISAs: Mice treated with 
buffer, rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT at day 5 after infection
were sacrificed at pre-defined time points after injection (t = 4 h, 24 h, T2 h or 96 
h). Blood was collected in endotoxin free tubes (4 0 C) which contained endotoxin 
free (LAL assay) heparin (NPBI, Emmer Compascuum, The Netherlands). Plasma 
was collected by centrifugation within 2 h after bleeding and stored at -200C. The 
ELISAs recognising both free and complexed TNF receptors were carried out with 
the materials and according to the methods described by Bemelmans et al. [33]. 
Briefly, microtiter plates were coated with anti-TNFRSS or anti-TNFRTS 
monoclonal antibody. Aspecific binding was blocked with l % BSA. After washing, 
mouse plasma samples were added. A standard curve was made using recombinant 
murine TNFRSS and TNFRTS protein. Subsequently, plates were washed and 
incubated with biotinylated anti-TNF receptor antibodies. After washing, plates were 
incubated with streptavidin peroxidase followed by an enzyme reaction providing a 
coloured reaction product. The detection limit for murine soluble TNFRSS was 40 
pg/ml and for soluble TNFRTS was lS60 pg/ml.
Statistical analysis: The effect of treatment on parasitaemia was analysed by the 
one-way ANOVA. The effect of treatment on survival was analysed by the Chi- 
Square test. Differences were considered significant at a level a= 0 .0S .
RESULTS 
Characterisation of rec-h-TNFa, rec-h-TNFa-ATA and rec-h-TNFa-AT by GPC 
and SDS-PAGE.
Using GPC under non-denaturing conditions, rec-h-TNFa is eluted as a single peak 
corresponding to a molecular mass of approximately 42 kD indicative of a compact 
trimer (data not shown). No other peaks were present. Chromatography of both rec- 
h-TNFa-ATA or rec-h-TNFa-AT showed a major peak corresponding to a 
molecular mass of 3T and 36 kD, respectively (dimer or compact trimer). Small 
fractions eluted with molecular mass of approximately 80 kD (multimers) and in the 
void volume (molecular weight >  S00 kD). When subjected to SDS-PAGE analysis, 
non-reduced samples of non-modified rec-h-TNFa showed a strong monomeric band 
of lT kD (Fig. lA , lane l). Rec-h-TNFa-ATA exhibited two major bands around lT 
kD (Fig. lA , lane 2), whereas rec-h-TNFa-AT showed a major band at S2 kD 
(indicative of a trimer, Fig. lA , lane 3). Reduced samples yielded a single band
corresponding to the rec-h-TNFa monomer of about 17 kD (Fig. 1B). No other 
products were observed.
Figure 1A and B: Samples of rec-h-TNFa (1), rec-h-TNFa-ATA (2) and rec-h-TNFa- 
AT (3) were analysed by SDS-PAGE in the absence (A) or presence (B) of reducing 
agents as described in the materials and methods section. Photometric scans of silver 
stained SDS-PAGE gels are presented. The major bands are indicated by arrows with 
the corresponding molecular mass.
In vitro bioactivity
The bioactivity of non-modified rec-h-TNFa, rec-h-TNFa-ATA and rec-h-TNFa- 
AT was determined in a standard WEHI cytotoxicity assay. Equal concentrations of 
protein were added to the cells. The cytotoxicity of rec-h-TNFa-ATA was about 8-9 
fold lower compared with non-modified rec-h-TNFa (Fig. 2). The cytotoxic activity 
was almost completely restored (70-90%) upon de-acetylation of rec-h-TNFa-ATA 
to rec-h-TNFa-AT. Under the experimental conditions used, hydroxylamine was not 
cytotoxic and did not change the cytotoxicity of rec-h-TNFa (data not shown).
Effect of treatment with rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT on 
CM
Intravenous injection of increasing doses of rec-h-TNFa of 2-18 mg protein 
protected up to 30% of the mice against CM (Fig. 3). No further increase was 
observed when 80 mg rec-h-TNFa was administered, and no toxicity of this dose
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Figure 2: Dose-response curves o f the cytotoxic activity of rec-h-TNFa, rec-h-TNFa- 
ATA and rec-h-TNFa-AT. Equal protein doses of rec-h-TNFa, rec-h-TNFa-ATA or 
rec-h-TNFa-AT were added to TNF-sensitive WEHI cells. Absorbance was measured 
at 490 nm and plotted against the logio of protein concentration. Samples were 
measured in triplicate and averages +  standard deviation are presented
was observed (data not shown).
Administration of either rec-h-TNFa-ATA (1-18 mg protein) or rec-h-TNFa-AT (1­
18 mg protein) showed a significantly (p< 0 .05 , Chi-Square test) enhanced 
protection against CM compared with non-modified rec-h-TNFa (Fig. 3). The 
protective efficacy increased up to 80% at doses of 9 and 18 mg protein for both rec- 
h-TNFa-ATA and rec-h-TNFa-AT. Differences in the protective effects of rec-h- 
TNFa-ATA and rec-h-TNFa-AT were not significant (summarised data of doses of 
1-18 mg protein). However, in the WEHI cytotoxicity assay equal protein 
concentrations were associated with a 8-9 fold lower bioactivity of rec-h-TNFa-ATA 
as compared to rec-h-TNFa and rec-h-TNFa-AT (Fig. 2).
A 9-fold higher dose of rec-h-TNFa-ATA (81 mg protein corresponding to 9 mg 
bioactive protein in the WEHI cytotoxicity assay) killed 13 out of 15 mice within 24 
h, which is in contrast with the observation that 80 mg of non-modified rec-h-TNFa
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Figure 3: Effect of treatment with rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT during 
infection on prevention of cerebral malaria (CM). Mice received a single intravenous injection of 
rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT at day 5 after infection with 103 P. berghei 
parasites and survival for more than two weeks after infection was used as a marker for protection 
against CM. The percentage of mice protected against CM is plotted against protein dose. Above 
each bar the number of mice protected against CM divided by the number of treated mice is 
indicated.
was not toxic to the infected mice. A comparable toxicity was observed after i.v. 
injection of 80 mg rec-h-TNFa-AT (data not shown). Injection of buffer only did not 
protect against CM (data not shown).
Effect of treatment with rec-h-TNa, rec-h-TNFa-ATA or rec-h-TNFa-AT on 
parasitaemia
The effect of treatment with rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT on 
parasitaemia at day 8 after infection is shown for rec-h-TNFa-ATA (Fig. 4A) and 
rec-h-TNFa-AT (Fig. 4B). The data are expressed as the ratio of the parasitaemia of 
a certain mouse divided by the mean parasitaemia of the infected but otherwise non­
treated mice in the same experiment. In the studied dose range, the effect treatment 
on parasitaemia was independent) of protein dose rec-h-TNFa-ATA(fig. 4A) or
Table 1: Effect of an intravenous injection of rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT
on parasitaemia in relation to development of cerebral malaria in /5, berghei infected mice.
Treatment+ Parasitaemia at day 8 after infection/mean parasitaemia of
non-treated mice in the same experiment*
All mice Mice with CM Mice without CM
No treatment 1 +  0.4 (n=27) 1 + 0.4 (n=27) (n=0)
rec-h-TNFa 
(2-18 mg)
1 ±  0.5 (n=33) 1 ±  0.5 (n=27) 0.6” + 0.2 (n =6)
rec-h-TNFa-AT A 
(1-18 mg)
0.8 ±  0.5 (n=52) 1 ±  0.6 (n=  17) 0.6 : +  0.2 (n==35)
rec-h-TNFa-AT 
(1-18 mg)
0.7' +  0.4 (n=35) 0.7 ±  0.2 (n=9) 0.6' +  0.4 (n==26)
+Mice received a single intravenous injection of non-modified rec-h-TNFa, or thiolated 
rec-h-TNFa with either protected thiol groups (rec-h-TNFa-ATA) or reactive thiol groups 
(rec-h-TNFa-AT) at day 5 after infection with 103 parasites. Doses ranged from 1-18 mg 
protein.
*The average parasitaemia at day 8 after infection was determined in each control group 
and the parasitaemia of each individual mouse was divided by the average of the 
corresponding control group. The ratios were used for further analysis. Values represent 
averages +  standard deviation of the combined data of different doses 
(1-18 mg protein). p < 0 .0 5  (ANOVA) as compared to non-treated mice, ::p < 0 .0 5  
(ANOVA) as compared to mice developing CM in the same treatment group.
rec-h-TNFa-AT (fig 4B).
The summarised parasitaemia data ( l- l8  mg protein) are shown in Table l. 
Parasitaemia was significantly (p<O.O5 as compared to non-treated mice, ANOVA) 
suppressed after treatment with rec-h-TNFa-AT, but not after administration of rec- 
h-TNFa or rec-h-TNFa-ATA (Table l). When the effect of treatment on 
parasitaemia was studied in relation to protection against CM, parasitaemia was 
significantly suppressed in CM-protected mice but not in mice developing CM in 
each treatment group (p<O.O5, ANOVA).
Injection of buffer only did not affect parasitaemia (data not shown).
Effect of treatment with rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT on 
sTNFR in plasma
The effect of treatment on changes in plasma concentrations of soluble TNFR55 and 
TNFR75 (sTNFR55 and sTNFR75) was analysed in comparison with buffer-treated 
P. berghei infected mice. Since rec-h-TNFa-ATA exhibited a 8-Q fold lower in vitro 
bioactivity than non-modified rec-h-TNFa and rec-h-TNFa-AT, the effect of both 
treatment with comparable amounts of protein (Q mg) and bioactive rec-h-TNFa- 
ATA (8l mg protein) was analysed. At all time points concentrations of sTNFR55 in 
plasma were below the detection limit (<4O pg/ml). The plasma concentration of 
sTNFR75 at different time points after treatment is shown in Table 2.
The plasma concentration of sTNFR75 remained below the detection limit in buffer- 
treated mice until day 6, and increased thereafter. Treatment with either rec-h- 
TNFa, rec-h-TNFa-ATA (Q mg protein) or rec-h-TNFa-AT significantly (p<O.O5, 
ANOVA) increased the concentration of sTNFR75 4 h after injection and a further 
significant increase was noted when 8l mg rec-h-TNFa-ATA was injected.
Analysis 24 h after injection showed that the plasma concentrations of sTNFR75 had 
returned to control values in mice treated with Q mg of rec-h-TNFa, rec-h-TNFa- 
ATA or rec-h-TNFa-AT, but concentrations were still elevated in mice treated with 
8l mg rec-h-TNFa-ATA. However, data of only two mice could be obtained as l3 
out of l5 mice had died due to toxicity of this dose of rec-h-TNFa-ATA. At day 8 
and Q after infection sTNFR75 concentrations in mice treated with either rec-h- 
TNFa, rec-h-TNFa-ATA or rec-h-TNFa-AT increased again as was observed in 
buffer-treated mice.
Plasma sTNFR75 concentrations were significantly (p<O.O5, ANOVA) enhanced at 
day 8 after infection, but did not reach significance at day Q after infection as 
compared with buffer-treated mice. Treatment with rec-h-TNFa-AT resulted in a 2­
fold increase in plasma sTNFR75 concentrations at day Q after infection compared to 
rec-h-TNFa and rec-h-TNFa-ATA, and a 3-fold increase compared to buffer-treated 
mice.
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Figure 4A and B: The effect of treatment with rec-h-TNFa-ATA or rec-h-TNFa-AT 
during infection on parasitaemia. Mice received a bolus i.v. injection of rec-h-TNFa-ATA 
(A; 1-18 /ig protein) or rec-h-TNFa-AT (B; 1-18 fig protein) at day 5 after infection with 
103 P. berghei parasites. The average parasitaemia at day 8 after infection was determined 
in each control group and the parasitaemia of each individual mouse was divided by the 
average of the corresponding control group. The ratio is plotted against the protein dose for 
each mouse. When treatment has no effect on parasitaemia the ratio scatters around 1, 
while ratios <  1 indicate that parasitaemia is suppressed.
Table 2: Effect of treatment with non-modified of rec-h-TNFa, rec-h-TNFa-ATA or rec-h-TNFa-
AT on mouse soluble TNFR75 in plasma in P. berghei infected mice.
Time after Time after Soluble mouse TNFR75 (ng/ml)
infection (days) injection (h)
Buffer rec-h-TNFa rec-h-TNFa-ATA rec-h-TNFa-ATA rec-h-TNFa-AT
9 iig protein 9 iig protein 81 iig protein8 9 iig protein
5 0 < 1.6 (n=3)
5 4 < 1.6 (n=3) 62* +  6 (n=4) 85* +  25 (n=7) 96*' +  4 (n=4) 84* +  17 (n=3)
6 24 < 1.6 (n=3) < 1.6 (n=4) < 1.6 (n=7) 136, 129' < 1.6 (n=3)
8 72 22 ±  10 (n=5) 38* +  8 (n=4) 36* +  11 (n=7) 33* +  7 (n=3)
9 96 28 +  7 (n= 3) 45 +  23 (n=4) 52 +  18 (n=7) 103 +  28 (n=3)
Mice received an intravenous injection of buffer, rec-h-TNFa, rec-h-TNFa-ATA, or rec-h-TNFa- 
AT at day 5 after
infection with 103 parasites. At pre-defined time points after injection, mice were sacrificed and 
blood samples were taken.
Plasma was stored at -20°C until analysis of soluble TNFR75. Values represent averages + 
standard deviation.
s9 fxg bioactive protein in W EHI cytotoxicity assay 
*p < 0.05 as compared to buffer-treated mice 
p <  0.05as compared to treatment with rec-h-TNFa
::13 out of 15 mice died; values represent data of the surviving mice (n= 2).
DISCUSSION
The present study demonstrates that the introduction of reactive thiol groups in rec- 
h-TNFa by the SATA-reaction results in the formation of a covalently stabilised 
trimer (rec-h-TNFa-AT) with a significantly enhanced protective efficacy against P. 
berghei induced CM. Administration of thiolated rec-h-TNFa with protected thiol 
groups (rec-h-TNFa-ATA, no stabilised trimers in vitro) exhibited similar protective 
efficacy against CM, in spite of a Q-fold reduced in vitro bioactivity.
SDS-PAGE analysis under non-reducing conditions confirmed that stabilised rec-h- 
TNFa trimers were formed upon thiolation of rec-h-TNFa (rec-h-TNFa-AT) with 
SATA (Fig. l). Stabilised trimers of thiolated rec-h-TNFa probably result from the 
formation of disulphide bridges between monomers already locked into a trimeric 
position. Monomeric rec-h-TNFa contains one terminal valine and six lysyl 
residues. It was shown before that up to l2  residues could be acetylated in the rec-h- 
TNFa trimer [34], indicating that three amino groups in the monomer were not 
available for modification e.g., because they participate in intra- and inter-subunit 
interactions [l6]. The total number of thiolated residues in rec-h-TNFa was not 
determined in the present study. The heterogeneity of bands on the SDS gel probably 
reflects differences in disulphide-bridging resulting in different molecular complexes 
[lO].
The absence of other products besides the trimer suggests that the trimer is the actual 
conformational state of rec-h-TNFa in solution and is not merely a cross-linking 
phenomenon of rec-h-TNFa monomers. Gel permeation chromatography (GPC) 
analysis of rec-h-TNFa under non-denaturing conditions revealed a single peak with 
a molecular weight of 42 kD, indicative of a dimer or compact trimer which is in 
accordance to literature [6, l l ,  24]. Under denaturing conditions (SDS-PAGE) only 
the monomeric form of rec-h-TNFa was present, demonstrating that the rec-h-TNFa 
oligomer is held together by non-covalent interactions. The presence of bioactive 
oligomers and inactive monomers and polymers of hTNFa has also been 
demonstrated in vivo and may represent a “natural” mechanism in regulating 
cytokine activity [35]. Taken together the present data suggest that the enhanced 
therapeutic potential of rec-h-TNFa-AT results from an increased availability of 
bioactive rec-h-TNFa (i.e. rec-h-TNFa trimers).
Chapter 8
Interestingly, administration of rec-h-TNFa-ATA showed the same protective 
efficacy against CM, while the majority of the protein was present as non-covalently 
bound oligomers (GPC data and Fig. 1), and in vitro bioactivity was reduced 8-9 
fold as compared with rec-h-TNFa and rec-h-TNFa-AT (Fig. 2). The latter may be 
explained by perturbation of the tertiary structure of rec-h-TNFa interfering with 
receptor binding or some post-binding events [34]. De-acetylation of rec-h-TNFa- 
ATA to rec-h-TNFa-AT restored the in vitro bioactivity probably because a 
functional, bioactive trimer is formed again after fomation of disulphide-bridges 
between the monomers in the trimer.
It is hypothesised that rec-h-TNFa-ATA is transformed into a bioactive compound in 
vivo. This hypothesis is supported by three observations. First, treatment with 80 mg 
rec-h-TNFa-ATA and rec-h-TNFa-AT, but not with rec-h-TNFa, is toxic in vivo 
whereas in vitro cytotoxicity of rec-h-TNFa-ATA was 8-9 fold lower as compared 
with rec-h-TNFa and rec-h-TNFa-AT. Secondly, the observation that the increase 
of sTNFR75 is stronger after treatment with rec-h-TNFa-ATA as compared with 
rec-h-TNFa (Table 2) is also in line with the above hypothesis. Thirdly, treatment 
with rec-h-TNFa-ATA, like rec-h-TNFa-AT, showed enhanced protection against 
CM as compared with rec-h-TNFa (Fig. 3). This leads to the assumption that rec-h- 
TNFa-ATA is de-acetylated in vivo to rec-h-TNFa-AT which may form stabilised 
trimers in vivo.
The mechanism by which treatment with rec-h-TNFa, rec-h-TNFa-ATA or rec-h- 
TNFa-AT protected against the development of CM remains to be elucidated. Our 
data suggest that reduction of parasitaemia might be a factor that plays a role, 
particularly because the reduction was observed in CM-protected mice but not in 
treated mice developing CM (Table 1). Reduction of parasitaemia by TNFa has been 
described before in the same model (unpublished observations) and in other models 
[36, 37] and is probably mediated through rec-h-TNFa activated cells (e.g. 
macrophages and neutrophils) [36, 38]. Inhibition of erythropoiesis by rec-h-TNFa 
may also play a role in suppression of parasitaemia [39, 40]. It should be noted that 
almost all mice infected with a range of 10 to 10,000 parasites develop CM despite a 
widely varying parasitaemia after infection [31] and parasitaemia in controls varies 
extensively before they die of CM. These observations suggest that the course of an 
untreated infection is not a critical factor in development of CM in P. berghei
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infected mice. Thus, other, as yet undefined processes may be involved as well in 
the rec-h-TNFa-ATA or rec-h-TNFa-AT mediated protection against CM.
Another possible factor in protection against CM could be the timely production of 
sufficient sTNFRs. STNFRs have been shown to competitively inhibit interaction of 
TNFa with membrane bound receptor [41] and transgenic mice expressing high 
levels of soluble TNFR55 were protected against CM [42]. On the other hand, an 
increase in sTNFR results in a decreased amount of receptors on the cell membrane, 
which could reduce the sensitivity of cells to TNFa. Previous observations have 
shown that TNFR75 knock out mice are protected against CM in a murine model 
[43]. Our data indicate that treatment with either rec-h-TNFa, rec-h-TNFa-ATA or 
rec-h-TNFa-AT induced the production of sTNFR75 4 h after injection, but this was 
not directly related to protection against CM (15% in rec-h-TNFa treated mice and 
80% in the rec-h-TNFa-ATA and rec-h-TNFa-AT treated groups; Fig. 3 and Table
2). The enhanced concentrations of sTNFR75 24 h after injection of 81 mg rec-h- 
TNFa-ATA may reflect prolonged circulation times of bioactive protein, and may be 
a proof of a strong compensating response of the body to an overdose of bioactive 
rec-h-TNF a-A TA.
No increase of sTNFR55 was observed in our studies, probably because peak levels 
were reached earlier in time (<  2 h after injection) and had returned to normal 
levels [44]. Interestingly, treatment with rec-h-TNFa induced the production of 
sTNFR75, whereas rec-h-TNFa binds only to mouse TNFR55 [45]. The induction 
of both sTNFRs after injection of rec-h-TNFa was observed before in non-infected 
mice, indicating that triggering of TNFR55 is sufficient to cause shedding of both 
TNFR [44].
The enhanced protection against CM by treatment with rec-h-TNFa-ATA and rec-h- 
TNFa-AT compared with rec-h-TNFa is not reflected by a difference in sTNFR75 
levels at day 8 after infection (Fig. 3 and Table 2). Mice with non-treated infections 
develop CM despite increasing concentrations of sTNFRs [46]. The observation that 
protection against CM is not correlated with sTNFR-concentrations is in agreement 
with the observation that no bioactive mTNFa was present in the plasma of non­
treated infected mice and the inability to protect against CM by treatment with anti- 
TNF antibody in this model [46]. Interestingly, sTNFR75 plasma concentrations at 
day 9 after injection were strongly enhanced after injection of rec-h-TNFa-AT. The 
enhanced plasma concentrations of sTNFR75 were not related to an enhanced
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suppression of parasitaemia (Table 1), nor an enhanced protective efficacy against 
CM as compared with rec-h-TNFa-ATA (Fig. 3). However, parasitaemia was only 
determined at day 8 after infection, one day before elevated plasma concentrations of 
sTNFR75 were observed. The mechanism behind the increase in sTNFR75 and 
potential therapeutic implications remains to be elucidated.
The mechanism(s) by which rec-h-TNFa-ATA and rec-h-TNFa-AT protect against 
CM is also not known, yet. Other processes involved may be the development of 
refractoriness or tolerance after treatment with rec-h-TNFa or stimuli that provoke 
TNFa release [47, 48, 49].
In summary, intravenous injection of covalently stabilised trimers of rec-h-TNFa 
strongly enhances the bioactivity of rec-h-TNFa in vivo. This is reflected in 
protection against CM at low doses (2-18 mg protein). Moreover, the data suggests 
that activation of protected thiol groups into reactive thiol groups by de-acetylation 
and formation of the bioactive configuration can take place in vivo. Finally, the 
effect on parasitaemia could play a role in the rec-h-TNFa mediated protection 
against CM, whereas sTNFRs are probably not involved.
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SUMMARY AND DISCUSSION
We studied the role of subsets of T cells, reactive oxygen intermediates (ROI) and 
TNFa in the pathogenesis of ECM in our P. berghei K173-mouse model.
Data from several murine models (reviewed in Chapter 1, table 1) support the 
hypothesis (Chapter 1, figu re 1) that the infection generates a localised inflammatory 
reaction activated by the parasite, resulting in damage of the endothelial lining. This 
reaction is mediated by T cells and macrophages that adhere to the endothelial cells.
The involvement of T cell subsets and TNFa has been the subject of debate over the 
last years based on results in different rodent ECM models. Grau et al. (1986) 
described protection against ECM after depletion of CD4, but not CD8 T cells, 
while Imai et al. (1994) observed protection after depletion of CD8 T cells, but not 
CD4 T cells.
With respect to the role of TNFa, it became clear that anti-TNFa treatment protected 
against death from ECM in the model of Grau et al. (1987). An important question 
was whether this was also true in our model and if so how TNFa contributed to the 
development of the haemorrhages. In view of the well documented cytolytic activity 
of TNFa the hypothesis was developed that excessive TNFa generates an excessive 
amount of ROI that damages cells. If this is the case, this might open new venues for 
prevention of ECM and therapy in end-stage disease.
Our studies surprisingly showed that depletion of CD4 and/or CD8 T cells before or 
during the infection or in the end-stage of the disease protected against ECM 
(Chapter 2 and 3). The role of CD4 T cell subset in ECM was also noted in mice 
with acquired immunodeficiency syndrome (MAIDS): protection against ECM 
increased with the severity of MAIDS and the absence of functional CD4 cells 
(Eckwalanga et al. 1994).
The finding that both depletion of CD4 and CD8 independently protected against 
ECM suggest that these T cells are involved in the stimulation of a downstream 
process in the development of the petechiae. Possible downstream mechanisms are 
excessive stimulation of endothelial receptor molecules or the release of 
(inflammatory) mediators from adherent (T cells, macrophages; Curfs et al. 1993) or 
trapped WBC activated by parasitized erythrocytes or their proteins.
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To study the possibility of a beneficial intervention late in the course of the infection, 
we looked for a stage in ECM with apparent disturbances of the blood brain barrier 
(BBB), but still permitted recovery from fatal ECM. Earlier observations showed 
that folic acid can only cross the BBB when it is damaged (e.g. by heat coagulation 
of brain tissue); under these conditions, folic acid can induce severe seizures and 
even death. Folic acid was administered to test the integrity of the BBB in the course 
of ECM. Almost all infected mice with a body temperature "35 .5  °C (defined as 
mice in end-stage disease) developed convulsions after folic acid treatment (Chapter 
3). This suggested that changes in the permeability of the BBB were demonstrable 
within one day before the mice died with extensive haemorrhages. Next, it was 
shown that depletion of CD4 and/or CD8 T cells (Chapter 3) or treatment with 
alloxan (Chapter 5) of mice in end-stage disease protected mice against fatal ECM. 
In addition, within 4 hours after anti-T cell treatment mice did not develop 
convulsions after folic acid treatment. This supported the hypothesis that at first the 
permeability of the brain vascular endothelial lining was increased by a reversible 
process and soon thereafter was disrupted causing the haemorrhages and death of the 
mice. These data are compatible with the hypothesis that a local inflammatory 
reaction mediated by adherent T cells contribute to the development of the 
haemorrhages.
TNFa and ROI are possible candidates as inflammatory mediators that can directly 
damage the endothelial lining. Administration of anti-TNFa antibodies in end-stage 
disease protected against ECM in the model of Grau et al. (1987). TNFa dependent 
cell lysis can be mediated by generation of excessive amounts of ROI and ROI can 
cause membrane pertubation, leading to cell injury with subsequent loss of 
endothelial function (Bjork et al. 1980; Varani et al. 1989; Ward & Varani 1990; 
Ward, 1991; Sulkowska & Sulkowski 1997). Thus, ROI dependent cell damage can 
be the result of TNFa dependent cell lysis.
Antioxidants included in an in vitro test for TNFa dependent lysis of L929 cells 
prevent cell lysis (Chapter 4) and confirm the hypothesis that biologically active 
TNFa exerts its lytic activity through generation of ROI. However, treatment of 
mice with inhibitors, scavengers or inducers of ROI before or during infection as 
well as in end-stage disease does not give unequivocal answers with respect to the 
role of ROI in ECM (Chapter 4  and  5). Only the ROI scavengers dimethyl sulfoxide 
(DMSO) and ethanol, but not the antioxidants apocynin and desferal-zinc (DFO-Zn),
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can protect against ECM and this is only achieved when treatment is given before or 
during infection but not in end-stage disease. In addition, alloxan, a reported inducer 
of ROI, prevents rather than induces ECM when applied in end-stage disease.
Of course, differences in pharmacokinetics of the antioxidants in vivo versus in vitro 
may explain discrepancies but it remains unclear why mice with increased SOD 
expression after transfection of the human SOD gene still develop ECM after 
infection.
Antioxidant treatment was protective when started before or in the first part of the 
infection, but showed no effect in end-stage disease. Therefore, ROI are modulators 
of the immunopathological reactions leading to ECM rather than key effector 
molecules. This is supported by the observation that treatment with the ROI-inducer 
alloxan in end-stage disease protects against rather than induces ECM and that this 
protection can be abolished by additional antioxidant (apocynin and DFO) treatment. 
Alloxan treatment also killed the majority of the parasites within 2 hours. This might 
imply that alloxan depletes the antigen that otherwise stimulates adherent 
lymphocytes and macrophages on endothelial cells in a localised inflammatory 
reaction. On the other hand, antioxidant treatment in combination with alloxan 
reduced the protective capacity of alloxan treatment, but did not prevent killing of 
the parasites. This could argue for an effect on adherent lymphocytes or 
macrophages or an additional effect of alloxan next to ROI generation. The role of 
ROI in the generation of immunopathological reactions during development of ECM 
and/or in the protection against ECM in end-stage disease is complex and needs 
further analysis.
High plasma levels of TNFa correlated with ECM as was observed by Grau and 
collaborators (1987) who showed that excessive levels of biologically active TNFa 
were present in their P. berghei-ANKA model and that treatment of severely ill mice 
with antibodies to TNFa protected against fatal ECM.
Our studies (Chapter 6) demonstrated also increased TNFa plasma concentrations in 
P. berghei-infected mice with ECM, but treatment with antibodies to TNFa did not 
protect against ECM. In addition, plasma TN Fa was not biologically active and 
associated with elevated levels of sTNFRs. Treatment with rec-h-TNFa was found to 
trigger and enhance ECM-like pathological changes (Curfs et a l . 1993). This 
suggests that circulating TNFa is not directly involved in the pathogenesis of ECM 
in our model, but does not exclude an indirect role for TNFa. Recent experiments in
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a P. berghei ANKA-mouse model showed protection against ECM in TNFR75 but 
not in TNFR55 knock-out mice and an association between ECM and endothelial cell 
upregulation of TNFR75 but not TNFR55 (Lucas et al. 1997). It also appears that 
membrane bound TNFa needs TNFR75 interaction for cell signalling and 
upregulation of ICAM-1, which in turn is a receptor for LFA1 on lymphocytes. 
Thus, membrane bound TNFa in a cell-to-cell contact rather than systemic TNFa in 
the presence of sTNFR may be the factor that contributes to endothelial damage. 
This supports the observations that membrane bound TN Fa is superior over sTNFa 
in the activation of TNFR, particularly TNFR75 of endothelial cells (Grell et a l .
1995) and that TNFa dependent cytotoxicity mediated through interaction with 
TNFR55 is 1000-fold enhanced by co-stimulation of TNFR75 (Weiss et al. 1997). 
Therefore, further studies could explore the role of various types of TNFa 
(membrane bound vs. free; human vs. mouse; native vs. recombinant) and the 
differential activation of TNFR55 and TNFR75 by TN Fa, free or membrane bound, 
in the pathogenesis of (E)CM.
Earlier observations showed that high concentrations of rec-h-TNFa (15 zg/mouse) 
enhanced the ECM syndrome, whereas smaller doses (0.5-1 zg/mouse) can protect 
(Curfs et al. 1993). We could confirm these observations in more extensive studies 
(Chapter 7). Bolus injection of free or liposome encapsulated TNFa and even 10 
times lower daily doses achieved through sustained release from mini-osmotic pumps 
were effective in the protection against ECM. Further studies with TNFa coupled to 
the outside of the liposomes showed better protection than free TNFa and this 
triggered the idea that chemical stabilisation of TNFa on the outside of liposomes 
mimicked to some extent the formation of the functionally active trimeric complex of 
TNFa (Zhang et al. 1992; Van Ostade et al. 1993). Therefore, the activity of 
thioliated rec-h-TNFa was analysed and found superior over rec-h-TNFa in the 
protection against ECM (Chapter 8). In addition, thioliation produced stable TNFa 
trimers. The data support the notion that a stable trimer in vivo is responsible for the 
biological activity of TNFa (Zhang et al. 1992; Van Ostade et al. 1994) and stable 
trimers can now be prepared to further study of the effects of TNFa.
An important question is how TNFa treatment protects against ECM. Two 
observations from our experiments are relevant. The first observation is that TNFa 
treatment was successful when given before the animals were in end-stage disease 
(Chapter 7 and  8). Possibly TNFa treatment can trigger TNFa release from TNFaR
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bearing cells (e.g. macrophages and lymphocytes) that subsequently enter a 
refractory state (Patton et al. 1987; Fraker et al. 1988; Takahashi et al. 1991). If so, 
this may implicate that this action has to take place before the cells become adherent 
and critical amounts of TNFa are released locally, or before membrane-bound 
TNFa interacts with endothelial TNFaR and activation of the endothelial cell takes 
place and the addition of more TNFa is only more harmful.
The second observation is that TNFa treatment can reduce parasitaemia in mice that 
later appear to be protected against ECM (Chapter 7 and 8). It is known that TNFa 
can suppress erythropoiesis (Roodman, 1987, Johnson et al. 1990) that may explain 
the reduction in parasitaemia. It should be noted, however, that the reduction in 
parasitaemia after TNFa treatment is limited and not as complete as observed after 
alloxan treatment (Chapter 5). The resulting parasitaemias after TNFa treatment 
remain within the range observed from individual variations within and between 
experiments. Moreover, induction of ECM is equally effective when 100 times less 
parasites are used for infection delaying parasitaemia by approximately 2 days (Curfs 
et al. 1992). May be not the parasitaemia as such, but other mechanisms changed by 
treatment with rec-h-TNFa during the ongoing infection may modulate the 
immunopathological process. Thus, in view of the multifaceted activity of TNFa the 
effect on parasitaemia may be associative and a marker that TN Fa treatment was 
effective in another process that modulates ECM.
Many animal models (Chapter 1, table 1) are used to study the pathogenesis of ECM 
but none of these models reflect exactly the human situation. Nevertheless they can 
mirror certain aspects.
There are a number of similarities comparing ECM in the P. berghei K173/C57Bl 
mouse model with human CM.
Data from P. falciparum  infected patients suggest that T cells and particularly the 
CD4 subset become sequestered in CM patients (Hviid et al. 1991; Elhassan et al. 
1994). They re-emerge rapidly after anti-malaria therapy (Hviid et al. 1997). In the 
ECM mouse model depletion of CD4 and CD8 T cells turned out to be effective in 
protection against ECM (Chapter 2 and  3). Depletion is rapidly effective in 
protection against ECM suggesting depletion of adherent T cells. Post mortem  
histopathological analysis of patients that died of CM have shown margination of
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mononuclear cells in brain microvessels in addition to, or even in the absence of 
sequestered parasitized erythrocytes (Toro & Roman, 1978; Porta et al. 1993; 
Patnaik et al. 1994).
Malaria is by far the commonest cause of seizures in children in endemic areas 
(Waruiru et al. 1996). This may be due to an increased permeability of the BBB like 
we observed in mice developing ECM (Chapter 3). Enhanced capillary permeability 
to albumin is also observed in patients suffering from severe P. falciparum  malaria 
(Areekul, 1988).
Increased TNFa plasma concentrations are observed both in human CM and in our 
ECM model. Children with CM do not recover from coma by treatment with 
neutralizing MAbs against TNFa; actually more complications are found in patients 
treated with anti-TNFa antibodies (Kwiatkowski et al. 1993; Hensbroek et al.
1996). This resembles our findings in anti-TNFa treated mice (Chapter 6). Mice 
with ECM and patients with CM have high serum levels of sTNFa receptors (ECM: 
Chapter 6, CM: Kern et al. 1992; Molineux et al. 1993; Kossodo et al. 1995), 
which are supposed to block the biological activity of the elevated serum TNFa 
(Mohler et al. 1993). Our studies show that plasma from mice in end-stage disease is 
still able to neutralize bioactive rec-m-TNFa suggesting that not all TNFa-receptors 
are complexed with TNFa.
The above described similarities suggests that the P. berghei/C57Bl mouse model is 
valuable for the analysis of the role of TNFa and T cells and the increased 
permeability of the BBB and results can be used for comparison with human CM.
In conclusion (figure 1):
Hemorrhages in the brain are the result of loss of the integrity of the microvascular 
endothelial lining possibly as a result of excessive activation of signal transduction. 
The damaging mechanisms, which are still unknown, are probably triggered by 
activation of the TNFa receptor P75 and by ICAM both induced and/or upregulated 
on activated endothelial cells. This activation may be the result of binding of 
activated T cells (CD4 or CD8) and/or white blood cells (WBC) through their 
ligands, e.g. membrane bound TNFa and/or LFA1. Adhered cells can also release 
other substances (see ?) like reactive nitrogen intermediates which could be 
deleterious.
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Upregulation of the expression of ICAM (see + ) is due to activation of TNFa 
receptors on the endothelial cell by TNFa (soluble or membrane bound).
T cells, granulocytes and macrophages are activated by parasites or their products or 
by circulating proinflammatoir cytokines during infection.
Not only T cell depletion/inactivation but depletion/inactivation of all white blood 
cells (WBC) in mice in end stage ECM can be considered for therapeutic 
intervention.
Figure 1:
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INLEIDING
Malaria tropica is nog altijd een van de belangrijkste oorzaken van ziekte en sterfte 
in de tropen. Malaria wordt veroorzaakt door een eencellige parasiet van het geslacht 
Plasmodium. Er zijn 4 typen Plasmodia die de mens kunnen besmetten, waarvan er 
drie min of meer goedaardig zijn en zelden leiden tot levensbedreigende situaties. Dit 
in tegenstelling tot Plasmodium falciparum , de veroorzaker van malaria tropica, die 
vele dodelijke slachtoffers eist. Jaarlijks maken tussen de 250 en 500 miljoen mensen 
een aanval van malaria door van wie tussen de 1 en 3 miljoen de infectie niet 
overleven. Malaria is verantwoordelijk voor een kwart van alle sterftegevallen onder 
Afrikaanse kinderen tussen 1 en 4 jaar. Oudere kinderen en volwassenen in Afrika 
krijgen nog wel klinische verschijnselen van malaria maar hebben over het algemeen 
genoeg afweer opgebouwd om niet ernstig ziek te worden. Wel heeft de malaria bij 
hen invloed op hun gezondheid, ontwikkeling en arbeidscapaciteit.
Het merendeel van de Afrikaanse kinderen krijgt gemiddeld eenmaal per jaar een 
malaria aanval. Deze presenteert zich meestal als een griepachtig beeld met koorts. 
Na het starten van een effectieve antimalariabehandeling treedt meestal snel herstel 
op. Een kleine groep (1-3%) ontwikkelt echter ernstige malaria, hetgeen gepaard kan 
gaan met convulsies (stuipen), ernstige bloedarmoede en hersenmalaria (met een diep 
coma). Hersenmalaria (cerebrale malaria) heeft een sterftekans die tussen de 10 en 
40% ligt. De oorzaak van cerebrale malaria is onbekend maar er bestaan een aantal 
hypotheses.
Voor de bestudering van cerebrale malaria zijn een aantal diermodellen beschikbaar 
(hoofdstuk 1, tabel 1). In hoofdstuk 1 wordt uitgelegd waarom de muizenstam 
C57Bl/6J en de knaagdier malariaparasiet Plasmodium berghei K173 gekozen zijn. 
In dit model ontwikkelen ongeveer 95% van de geïnfecteerde dieren experimentele 
cerebrale malaria (ECM). Een van de hypotheses stelt dat ECM ontstaat, doordat in 
de loop van de infectie, de malaria parasieten die in het vaatsysteem leven en zich 
vermenigvuldigen, een ontstekingsreactie induceren waarbij geactiveerde 
mononucleaire cellen aanhechten aan de bekleding van de vaatwand (endotheel) o.a. 
in de hersenen. Als gevolg hiervan ontstaan er ter plaatse ontstekingsreacties 
waardoor schade ontstaat aan het endotheel en ten slotte bloedingen in de hersenen. 
Uit eerder wetenschappelijk onderzoek van onze groep en anderen was gebleken dat
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verwijdering van T cellen bij malaria geïnfecteerde muizen de ontwikkeling van 
ECM voorkomt.
Een van de vragen is nu of de T cellen direct verantwoordelijk zijn voor de schade 
aan de vaatwand en zo ja  welke subset van deze T cellen en/of zijn het de door deze 
cellen geproduceerde bioactieve stoffen die bijdragen aan de ontwikkeling van ECM. 
In dit onderzoek is gekeken naar de rol van specifieke T cellen, reactieve 
zuurstofradicalen en tumor necrosis factor .  (TNFa) in de ontwikkeling van ECM.
T cellen
Resultaten van onderzoekers die de rol van T cel subsets (CD4 en CD8) bij ECM 
hebben onderzocht zijn niet eensluidend.
Om de rol van specifieke T cellen tijdens de pathogenese van ECM in ons model te 
bestuderen zijn geïnfecteerde muizen behandeld met anti-CD4 of anti-CD8 
antistoffen. Deze behandeling is er op gericht om de betreffende T cel populatie te 
verwijderen (hoofdstuk 2). Beide behandelingen gaven bescherming tegen ECM.
Dit suggereert dat deze T cellen onafhankelijk van elkaar betrokken zijn bij de 
stimulatie van ECM. Mogelijk zijn de T cellen betrokken bij verhoogde stimulatie 
van endotheel-receptormoleculen en/of de produktie en vrijmaking van 
(ontstekings)mediatoren van aangehechte cellen of vastgelopen witte bloedcellen die 
geactiveerd worden door geparasiteerde erytrocyten of hun produkten.
Intregriteit van de bloed-hersen-barrière is een belangrijke functie van de stabiliteit 
van hersenfuncties. Convulsies na behandeling met foliumzuur zijn een aanwijzing 
voor een gestoorde bloed-hersen-barrière. Alleen muizen in het eindstadium van 
ECM (met een lichaamstemperatuur < 35.5°C) reageerden met convulsies na 
foliumzuur, hetgeen de aantasting van de bloed-hersen-barrière illustreert (hoofdstuk
3). Behandeling van muizen met een lichaamstemperatuur lager dan 35.5°C met 
anti-CD4 of anti-CD8 antistoffen, gaf bescherming tegen ECM. Binnen 4 uur na de 
behandeling met deze anti-T cel sera vertoonden de muizen geen convulsies meer na 
toediening van foliumzuur, hetgeen een aanwijzing is dat de bloed-hersen-barrière 
zich heeft hersteld.
Deze resultaten ondersteunen de hypothese dat bij de ontwikkeling van ECM als 
eerste de permeabiliteit van de bloed-hersen-barrière is verhoogd, wat aanvankelijk 
reversibel is, maar snel verder ontwikkelt tot bloedingen die sterfte van de muizen 
veroorzaakt.
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Reactieve zuurstofradicalen
Geactiveerde neutrophielen en macrophagen die hechten aan het oppervlak van de 
hersenvaten, zoals in het geval van ECM al eerder was waargenomen, kunnen 
diverse bioactieve stoffen uitscheiden. Een groep van deze stoffen, de reactieve 
zuurstofradicalen, staan bekend om hun schadelijke werking op endotheelcellen. 
Deze stoffen kunnen membraanschade veroorzaken, dat kan leiden tot celschade en 
vervolgens tot een verlies van de endotheelfunctie.
In hoofdstuk 4  is geanalyseerd of antioxidantia een rol kunnen spelen in de 
bescherming tegen ECM. Omdat TN Fa cellen kan doden en mogelijk betrokken is 
bij de ontwikkeling van ECM werd via in vitro proeven aangetoond, dat lysis van 
L929 cellen, die veroorzaakt wordt door TN Fa, verhindert wordt in aanwezigheid 
van een aantal antioxidantia: apocynine, desferal-Zn, dimethyl sulfoxide (DMSO) en 
ethanol. Hiermee wordt bevestigd dat TN Fa zijn lytische activiteit kan ontlenen aan 
het generen van reactieve zuurtofradicalen. Vervolgens werden muizen die na 
infectie ECM ontwikkelen met de antioxidantia behandeld, maar de resultaten waren 
niet eenduidig. Alleen behandeling met DMSO of ethanol en dan alleen indien die 
behandeling voor de infectie was gestart, beschermde tegen ECM. Behandeling met 
apocynine of desferal-Zn voor of tijdens infectie, of bij muizen in het eindstadium 
van ECM beschermde niet.
Omdat de antioxidant behandeling alleen profylactisch beschermd, bestaat de indruk 
dat reactieve zuurstofradicalen eerder modulatoren zijn van de immunopathologische 
reactie dan essentiële effector moleculen die leiden tot celschade bij ECM.
In een andere serie experimenten werd gevonden dat muizen die een verhoogde 
productie van het enzym superoxide dismutase hebben, door de extra aanwezigheid 
van het getranfecteerde humane superoxide dismutase gen, desalniettemin niet tegen 
ECM beschermd waren. Uit de resultaten beschreven in hoofdstuk 4  komt dus geen 
eenduidige rol voor reactieve zuurstofradicalen in de pathogenese van ECM. De 
resultaten beschreven in hoofdstuk 5  bevestigen dit verder. In dit hoofdstuk is 
gekeken naar het effect van behandeling met alloxan, een inducer van reactieve 
zuurstofradicalen.
Behandeling in het eindstadium, kort voor de muizen overlijden aan ECM, 
beschermde juist in plaats dat het de ontwikkeling van ECM versnelde. Bovendien 
werd deze beschermende werking van alloxan opgeheven door voorafgaande
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behandeling met de antioxidantia apocynine en desferal. Alloxan behandeling doodt 
binnen 2 uur een groot gedeelte van de aanwezige parasieten. Hierdoor kan 
misschien de rol van de parasieten in een ontstekingreactie, waaraan lymphocyten 
en/of macrophagen deelnemen die zich gehecht hebben aan de vaatwand, beperkt 
worden. Een direct effect van alloxan op de activiteit van de ontstekingscellen 
behoort ook tot de mogelijkheden.
Een met alloxan vergelijkbaar effect werd niet gevonden na behandeling met 
artemisinine, dat zijn werking dankt aan de aanwezigheid van een peroxide brug, 
maar als antiparasitair middel veel langzamer en mogelijk te langzaam werkt.
De rol van antioxidantia in de ontwikkeling van ECM en/of in de bescherming tegen 
ECM is complex en moet nog verder onderzocht worden.
Tumor necrosis factora (TNFa)
Uit eerder onderzoek is gebleken dat de ontwikkeling van ECM geassocieerd is met 
een verhoogde concentratie TN Fa in het plasma van muizen. Grau en onderzoekers 
(1987) konden muizen beschermen tegen ECM door antistoffen in te spuiten die de 
werking van TNFa neutraliseerden (hoofdstuk 1, figuur 1). In een vervolg onderzoek 
is dit ook toegepast bij kinderen die cerebrale malaria hadden, maar met 
teleurstellende resultaten. Behandeling met anti-TNFa antistoffen kon bij deze 
kinderen de cerebrale malaria niet opheffen.
Vanwege het verschil in resultaten van de behandeling met anti-TNFa antistoffen bij 
muizen en mensen is de rol van TN Fa in de pathogenese van ECM in ons model 
geanalyseerd. Onze resultaten toonden verhoogde concentraties van immunologisch 
aantoonbaar TNFa in het plasma van P. berghei-geïnfecteerde muizen met ECM, 
maar behandeling met antistoffen werkte niet beschermend (hoofdstuk 6). Uit verder 
onderzoek bleek dat het plasma TN Fa niet biologisch actief was en associeerde met 
verhoogde concentraties circulerende TNF-receptoren. In vervolg experimenten 
werd aangetoond dat plasma van muizen, die in het eindstadium van de ziekte zitten, 
zelfs toegevoegd rec-m-TNFa kon neutraliseren. Deze resultaten geven aan dat in de 
pathogenese van ECM in ons model circulerend TN Fa niet direct verantwoordelijk 
is voor de endotheelschade en het ontstaan van de bloedingen maar sluiten niet uit 
dat er een indirecte rol zou kunnen zijn via membraan-gebonden TN Fa in cel-cel 
interacties.
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In hoofdstuk 7 is de rol van TN Fa in de ontwikkeling van ECM verder onderzocht 
door geinfecteerde muizen te behandelen met rec-h-TNFa. Eerder onderzoek liet 
zien dat behandeling met hogere doseringen rec-h-TNFa het ECM beeld versneld en 
systematisch opriep terwijl preliminaire resultaten van een voorstudie aangaven dat 
lage doses rec-h-TNFa de ontwikkeling van ECM juist kon voorkomen. Resultaten 
van onze studies lieten zien dat dit ECM beschermende effect van rec-h-TNFa 
verkregen kon worden via een bolusinjectie van vrij rec-h-TNFa of van rec-h-TNFa 
ingevangen in liposomen. Door TNFa toe te dienen via een mini-osmotische pomp 
(continue uitscheiding) kon de beschermende werking ook met een 10x lagere 
dosering nog verkregen worden. Betere resultaten werden verkregen met rec-h- 
TNFa dat chemisch aan het oppervlak van liposomen was gekoppeld (Postma et al. 
1998). Dit suggereerde dat door chemische stabilisering het rec-h-TNFa op het 
oppervlak van liposomen meer gelijkenis heeft met het actieve trimeer-complex dat 
TNFa onder natuurlijke omstandigheden in oplossing vormt.
In hoofdstuk 8  wordt beschreven dat door chemische modificatie van de monomeer 
vorm van rec-h-TNFa een stabiel trimeer gevormd kan worden. Behandeling met de 
trimeer vorm geeft een betere bescherming tegen ECM dan behandeling met de 
monomeer vorm. Behandeling met zowel de monomeer als de trimeer vorm van rec- 
h-TNFa verhoogde de plasma concentratie van de TNF receptoren, maar dit was 
niet gecorreleerd met bescherming tegen ECM. Mogelijk dat de trimeer vorm en de 
monomeer vorm in mindere mate een interactie aangaat met TN Fa receptoren op 
cellen, die dan vervolgens een refractaire fase doormaken voor verder stimulering of 
voor hernieuwde afgifte van TN Fa en daardoor niet meer deelnemen aan de 
ontwikkeling van ECM.
Vervolgonderzoek is nodig om deze hypothese uit te werken, dan wel andere 
processen op te sporen die door de behandeling met rec-h-TNFa de pathogenese van 
ECM moduleren.
Tot slot
De waarschijnlijke stand van zaken na de voltooiing van de in dit proefschrift 
beschreven experimenten is dat de beschadigingen aan het endotheel van het 
vaatsysteem in de hersenen verloopt via de (overmatige) activatie/opregulatie van de 
TNF receptoren en van ICAM op het oppervlak van deze cellen (hoofdstuk 9, figuur
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1). Deze activatie kan tot stand komen door interactie met en hechting van 
geactiveerde T (CD4 en CD8) cellen, monocyten en macrophagen via hun liganden 
(LFA1, MAC1, membraangebonden TN Fa, etc.), waarbij ook stoffen vrijgemaakt 
kunnen worden die celschade veroorzaken. De aan het endotheel gehechte cellen 
kunnen de doorstroming belemmeren en ter plaatse een interaktie aangaan met 
aanwezige parasieten, waardoor pro-inflammatoire cytokinen kunnen worden 
vrijgemaakt en het ter plaatse tot een ontstekingsreaktie kan komen, die het 
vaatwandendotheel kan beschadigen.
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FCS foetal calf serum
FITC fluorescein isothiocyanate
i.p. intraperitoneal
i.v. intravenous
ICAM intercellular adhesion molecule
IFNy interferon gamma
RPMI RPMI 1640 medium
IMDM iscove’s modified dulbeco’s medium
kD kilo Dalton
MAb monoclonal antibodies
NFMB nuclear factor kappa B
OD optical density
OH hydroxyl radical
O superoxide radical
P plasmodium
PBL peripheral blood lymphocytes
PBS phosphate buffered saline
PE parasitized erythrocyte
PÎEMP1 plasmodium falciparum erythrocyte membrane protein-1
rec-m-TNFa recombinant mouse tumor necrosis factor alpha
171
Abbreviations
rec-h-TNFa recombinant human tumor necrosis factor alpha
rec-h-TNFa-AT thioacetyl rec-h-TNFa
rec-h-TNFa-ATA acetylthioacethyl rec-h-TNFa
RNI reactive nitrogen intermediates
ROI reactive oxygen intermediates
ROS reactive oxygen species
s.c. subcutaneous
SATA N-succunimidyl-4-S-acetyl thioacetate
SOD superoxide dismutase
TNFa tumor necrosis factor alpha
TNFa-R TNFa receptor
sTNFa soluble TNFa
VCAM vascular adhesion molecule
WBC white blood cells
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